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ABSTRACT
EXPRESSION, ACTIVATION, AND REGULATION OF MATRIX 
METALLOPROTEINASE 2 (MMP-2) IN THE BOVINE CORPUS LUTEUM
by 
Bo Zhang
University of New Hampshire, May, 2002
Matrix metalloproteinases (MMPs) have been postulated to be important for 
angiogenesis and for tissue remodeling events associated with corpus luteum (CL) 
development. The MMPs are mainly regulated at three levels, transcription, activation, 
and inhibition by endogenous tissue inhibitors of metalloproteinases (TIMPs). Unlike 
most MMPs, pro-MMP-2 activation is accomplished on the cell surface rather than 
extracellularly. The objectives of the present study were to clone bovine cDNAs for 
MMP-2 and its activator, membrane type 1- (MTl-)MMP, to investigate the expression 
and localization of MMP-2, MT1-MMP, TIMP-1, and TIMP-2 in three ages of CL, and 
to explore the regulation of MMP-2 expression in luteal and endothelial cells by 
cytokines. Molecular cloning and sequence analysis demonstrated that the bovine MMP- 
2 and MTl-MMP genes are highly similar to their homologs in other species. Although 
the levels of MMP-2 and MTl-MMP transcripts were constant in the early (day 4), mid 
(day 10), and late (day 16) stage CL, active MMP-2 and MTl-MMP proteins were
xi
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significantly increased (p<0.05) from the early to the mid and late stages. In addition, the 
patterns of TIMP-2 mRNA and protein expression were similar to MMP-2 and MTl- 
MMP, being expressed at higher (p<0.05) levels in the mid and late stages than the early. 
Immunohistochemistry demonstrated that MMP-2, MTl-MMP, and TIMP-2 were 
localized in endothelial and large luteal cells. In contrast, TIMP-1 mRNA and protein 
were highly expressed in the early and mid cycle CL, but decreased in the late stage. 
TIMP-1 was detected in vascular smooth muscle cells and large luteal cells. In a luteal 
cell culture system, TNFa stimulated MMP-2 expression in a dose and time dependent 
manner. In luteal-derived endothelial cells, TNFa increased while IFNy inhibited MMP-2 
expression. In the presence of both cytokines, IFNy attenuated the stimulatory effects of 
TNFa alone, bringing MMP-2 expression down to control levels. In conclusion, the 
coordinate expression of TIMP-2, and active MMP-2 and MTl-MMP suggests that the 
MT1 -MMP/TIMP-2/pro-MMP-2 system may be spatially and temporally available for 
pro-MMP-2 activation in the bovine CL. Furthermore, cytokines regulate MMP-2 
expression in luteal and endothelial cells.
xii
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CHAPTER I
MATRIX METALLOPROTEINASES (MMPS) AND TISSUE INHIBITORS OF 
METALLOPROTEINASES (TIMPS) IN OVARIAN PHYSIOLOGY:
A LITERATURE REVIEW
I. Introduction
II. Characteristics and Properties o f Matrix Metalloproteinases (MMPs) and Tissue Inhibitors of 
Metalloproteinases (TIMPs)
III. MMPs/TIMPs in Follicular Development and Atresia
IV. MMPs/TIMPs in Ovulation
V. MMPs/TIMPs in Corpus Luteum Formation. Maintenance, and Regression
VI. MMPs/TIMPs in Ovan an Angiogenesis
VII. Perspectives
I. Introduction
The ovary, a primary female reproductive organ, has two principal functions. Ovaries release 
mature egg(s) or oocyte(s) at appropriate intervals for fertilization and successful propagation of 
the species (Findlay. 1991). In addition, they produce steroid hormones to regulate reproductive 
cy clicity, to prepare the adult female for fertilization and implantation o f the zygote, and to 
support pregnancy. The follicle and corpus luteum. two structures found in the ovary, are largely 
responsible for these functions.
Follicles consist o f an inner avascular granulosa compartment harboring the oocyte, an 
external vascularized thecal layer, and a  basement membrane in between to separate these two 
compartments. The development o f  follicles from primordial to primary, then to secondary, and
- l -
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eventually the final Graafian stages involves not only the proliferation o f granulosa and theca 
cells, but also the breakdown and resynthesis o f  extracellular matrix to accommodate the 
enlargement and maturation o f the follicle (Rodgers et al.. 1999: Rodgers et al., 2000). When 
stimulated by the preovulatory surge o f gonadotropins, the dominant Graafian follicle ruptures 
and releases the mature oocyte into the oviduct. This event requires the breakdown o f tissue 
barriers, such as the basement membrane where granulosa cells rest, the theca externa, collagen 
fibers, tunica albuginea, and a second basement membrane beneath the surface epithelium, before 
the ovarian surface is breached to release the egg (Espey. 1994a: Espey. 1994b). Following 
ovulation, fibroblasts and endothelial cells o f the thecal layer invade the granulosa layer. The 
gonadotropin surge also initiates luteinization. a process by which the remaining ruptured follicle 
is transformed into a new endocrine gland called the corpus luteum. which secretes progesterone 
to support pregnancy (Niswender and Nett. 1994). If fertilization does not occur, the CL will 
undergo a degenerative process, referred to as Iuteolysis or luteal regression, enabling a new 
reproductive cycle to commence.
All these physiological events that occur during the course o f a normal reproductive cycle 
necessitate remodeling o f the extracellular matrix (ECM). which require the participation o f four 
classes o f proteolytic enzymes: serine proteases, cysteine proteases, aspartic proteases, and 
metalloproteases. O f these, a  wealth of evidence suggests that matrix metalloproteinases (MMPs) 
and their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs). are known to 
play important roles, not only in ECM remodeling in pathological situations such as rheumatoid 
arthritis, wound healing (Ravanti and Kahari. 2000) and tumor invasion and metastasis (Kahari 
and Saanalho-Kere. 1999: Stamenkovic. 2000). but in physiological processes such as embrvo 
development, bone formation, implantation, and the ovarian events described above (Smith et al., 
1999: Vu and Werb. 2000). The present review focuses on the molecular and biochemical 
characteristics o f  MMPs and TIMPs. and their roles in follicular development, ovulation, corpus 
luteum development and regression, and angiogenesis in the ovary.
- 2 -
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
II. Characteristics and Properties of Matrix Metalloproteinases (MMPs) and Tissue 
Inhibitors o f Metalloproteinases (TIMPs)
The matrix metalloproteinases (MMPs) are a  family o f zinc and calcium dependent 
proteolytic enzymes that share a  similar protein structure and collectively are able to digest all 
known ECM macromolecules (Matrisian. 1990: Birkedal-Hansen et al., 1993). However, 
individual MMP members have distinct protein structures and different preferences for a 
particular group o f matrix proteins (Massova et al.. 1998). The MMP family members are 
products of different genes. So far. more than 25 members have been identified in this enzyme 
family (see Table 1-1). The characteristic domains o f MMPs include (see Figure 1-1): (1) the 
signal peptide domain, which directs the enzyme into the rough endoplasmic reticulum during 
synthesis: (2) the propeptide domain, which maintains enzyme latency until it is removed or 
disrupted: (3) the catalytic domain, which contains the highly conserved Zn:‘ binding region 
(HExGHxxGxxHS/T) and dictates enzyme activity: (4) the hemopexin domain, which is 
responsible for the substrate specificity' o f MMPs: and (5) a small hinge region, which acts as a 
"hub", enabling the hemopexin region to present substrate to the active core o f the catalytic 
domain. For the subfamily o f membrane-type MMPs. there is also a transmembrane domain, 
which has a membrane-spanning segment o f about 20 hydrophobic amino acids and an 
intracellular domain of approximately 24 amino acids.
1. MMP family
Based on these structural and functional features. MMP family members can be classified 
into different subfamilies (see Table 1-2): (I) collagenases, including MMP-1, MMP-8, and 
M M P-13: (2) gelatinases. including MMP-2 and MMP-9: (3) stromelysins, including 
stromelysin-l. and -2: (4) membrane-type metalloproteinases (MT-MMPs), including MT1-6 
MMP: and (5) other MMPs. which require further characterization. This last group includes
-  J  -
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MMP-19. MMP-18. and MMP-7 There are now more than twenty-five members in the MMP 
family.
(1) Collagenases Collagenases are the first enzymes to be characterized in the MMP 
family (Gross and Lapiere. 1962). Thus far. four members have been identified in this 
collagenase subfamily. They are: collagenase I (MMP-1), collagenase 2 (MMP-8), collagenase 3 
(MMP-13). and Xenopus collagenase 4 (M M P-18). These collagenases cleave the triple helix of 
type I. II. and III collagen exclusively at the Gly77;-Leu/Ileu776 peptide bond, which is located 
very close to three-quarters o f the distance from the amino terminus of the substrate molecule. 
The N-terminal V* and C-terminal '/4-length fragments that are generated then undergo 
spontaneous denaturation and become susceptible to further cleavage by other MMPs such as 
gelatinases (Miller et al.. 1976: Hasty et al.. 1987: Dioszegi et al., 1995: Mitchell et al.. 1996: 
Reboul et al.. 1996). However, each o f these collagenases has various preferences for different 
collagen types.
Although the first vertebrate collagenase activity was originally described by Gross et al.
(1962) in amphibian tissues, it took about one decade before human collagenase was purified in 
skin (Bauer et al.. 1970) and fibroblasts (Stricklin et al., 1977). The cDNA o f human collagenase 
was also cloned from fibroblasts (Goldberg et al.. 1986). This enzyme, bearing the designation 
matrix metalloproteinase-1 (MMP-1), has served as the prototype for all other interstitial 
collagenases. MMP-1 is secreted from cells as two latent forms, one with molecular weight o f  52 
kDa and the other 57 kDa. which depend on the status of the Asn-linked glycosylation (Dioszegi 
et al.. 1995). After activation, the enzyme is processed to a 42 kDa form (Table 1-2). MMP-l 
preferentially degrades type III collagen. It also cleaves type I, II, and X collagens, type I gelatin, 
the antiprotease p ran ti trypsin. and it is likely that other substrates exist for this enzyme as well 
(W elgus et al.. 198 la: Welgus et al., 198 lb). A variety of cell types, including tumor cells, 
endothelial cells, fibroblasts, keratinocytes, chondrocytes, osteoblasts, and hepocytes, have the
- 4 -
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ability to produce MMP-1. indicating the importance o f  this MMP in both pathological and 
physiological conditions (Birkedal-Hansen etal.. 1993; Birkedal-Hansen. 1995).
Collagenase-2 (MMP-8) is also called neutrophil collagenase due to its original 
identification in human neutrophils as a distinct protein (Macartney and Tschesche. 1983: Hasty- 
et al.. 1984) and gene product (Hasty et al.. 1990) from MMP-1. However, the collagenase 
activity in human neutrophil was first described in the late 1960s (Lazarus et al., 1968). One 
feature unique to MMP-8 is that this enzyme is stored in specific granules in neutrophil 
leukocytes (Murphy et al.. 1977) and released upon phagocytic stimulation (Oronsky et al., 1973). 
In addition, although the function is still unclear, there is a high level o f glycosylation in MMP-8 
(Birkedal-Hansen et al.. 1993). The reported molecular weight of MMP-8 varies depending on the 
investigators. This may be due to method of determination (purified protein vs. deduced from 
cDNA). In the purified protein, the calculated molecular weight may be affected by the level of 
glycosylation on the enzyme. In general, it is believed that the latent form o f MMP-8 is 
approximately 75 kDa. but it is usually processed during extraction protocols to about 58 kDa 
(this form still lacks catalytic activity). The active form of MMP-8 has a molecular mass of 
around 40-42 kDa. In addition to its expression in polymorphonuclear leukocytes during their 
maturation (Hasty et al.. 1987). MMP-8 is also produced in melanoma cells (Giambemardi et al.. 
1998). rheumatoid synovial fibroblasts (Hanemaaijer et al.. 1997), endothelial cells, and 
chondrocytes (Cole et al.. 1996). Furthermore, its high expression in rat postpartum uterus 
indicates that it may play a  potential role during involution of this reproductive organ (Balbin et 
al.. 1998). This enzyme displays a substrate specificity profile different from that of MMP-1 
(Hasty et al.. 1987). The preferred substrate for MMP-8 is type I collagen, not type in  collagen, 
which is digested at a higher rate by MMP-l (Hasty et al., 1987). Intriguingly, MMP-8 also 
degrades collagen type Q at a much greater (~ 150 times) rate than MMP-1 (Knauper et al., 
1997b: Jeffery. 1998). indicating that it may be involved in diseases such as rheumatoid arthritis 
and osteoarthritis, where type II collagen degradation plays a  major role. Moreover, MMP-8 is
- 5 -
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capable o f  cleaving aggrecan (Fosang et al., 1996a; Arner et al., 1997), but at sites distinct from 
the major enzyme called cartilage aggrecanase (Arner et al., 1997).
Collagenases 3. designated as MMP-13. was first sequenced from human breast tumor 
(Freije et al., 1994). The latent and active forms o f MMP-13 possess a molecular mass o f about 
52 and 42 kDa, respectively. Unlike MMP-1. which has a  low activity on type D collagen, MMP- 
13 cleaves type II collagen at a higher rate than types I and III. Similar to MMP-8, this efficient 
catalytic action o f MMP-13 on type II collagen signifies its importance in the physiology and 
pathology o f cartilage, where type II collagen is the predominant ECM protein. Additionally, 
MMP-13 displays considerably greater gelatinolytic activity than collagenolytic activity (Welgus 
et al.. 1985a; Mitchell et al.. 1996). O f particular interest MMP-13 has broad substrate 
specificity. MMP-13 also catalyzes type IV. IX. X and XIV collagens, laminin. fibrillin-1, 
fibronectin. tenascin. aggrecan. and inhibitors o f serine proteinases (Fosang et al., 1996a;
Knauper et al.. 1996a; Knauper et al.. 1997a; Ashworth et al.. 1999). Thus, in addition to its 
original localization in breast carcinomas (Freije et al.. 1994; Heppner et al., 1996; Uria et al..
1997). MMP-13 is expressed in a variety of tumor types, including chondrosarcomas (Uria et al.,
1998). melanomas (Airola et al.. 1999). and squamous cell carcinomas (Johansson et al.. 1997; 
Cazorla et al.. 1998). It is also associated with a number of diseases, where excessive collagen 
degradation has been postulated to be causative, such as periodontitis (Uitto et al., 1998), 
rheumatoid synovium (Stahle-Backdahl et al.. 1997), osteoarthritic cartilage (Mitchell et al..
1996; Shiopov et al.. 1997). and atherosclerosis (Sukhova et al.. 1999). Interestingly, this enzyme 
is also highly expressed in the uterus (Welgus et al.. 1985b), suggesting its potential roles during 
tissue remodeling of this reproductive organ.
Collagenase 4 (MMP-18) was recently identified in the African clawed toad, Xenopus laevis 
(Stolow et al.. 1996). This is also the first sequenced MMP from an amphibian. The predicted 
molecular masses o f the latent and active forms o f MMP-18 are 51 and 42 kDa, respectively 
(Stolow et al., 1996). Collagenase 4 has the ability to degrade type I collagen (Stolow et al.,
- 6 -
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1996). rat type II and human type in  collagens. a  1-antitrypsin, and a2-macroglobulin (Shi and 
Sang. 1998). M MP-18 is transiently expressed in the region o f branchial arches, thorax, and the 
dorsal anterior axis during the late stages o f Xenopus embryogenesis (Damjanovski et al., 1999: 
Damjanovski et al.. 2000: Damjanovski et al.. 2001). The embryo lethality during the late stages 
of embryogenesis caused by over-expression o f MMP-18 further indicates the restricted temporal 
and spatial expression o f this enzyme (Damjanovski et al.. 2001). The homologs o f collagenase 4 
in other species have not been identified.
(21 Gelatinases There are two members in this group: gelatinase A and gelatinase B. 
Although a gelatinase activity, which was retrospectively determined to be gelatinase B. was 
detected from rheumatoid synovial fluid in 1972 (Harris and Krane. 1972). it was about six years 
later that gelatinase activity was first separated from collagenase and stromelysin (Sellers et al.. 
1978). Whereas collagenase was the first described MMP to degrade native collagen into 
fiagments (Gross and Lapiere. 1962). gelatinases have activity against denatured collagens (or 
collagen fiagments) (Sopata et al.. 1974). Based on their sizes and substrate specificities, these 
two identified gelatinases are named 72-kDa gelatinase (gelatinase A. MMP-2) and 92-kDa 
gelatinase (gelatinase B. MMP-9). respectively. The early experiments demonstrated that both 
gelatinases were also able to digest soluble type IV collagen, producing characteristic V* N- 
terminal and V* C-terminal fragments (Liotta et al.. 1979: Mainardi et al.. 1980: Fessler et al.. 
1984: Murphy et al.. 1989). Therefore, gelatinase A and B are also called 72-kDa and 92-kDa 
type IV collagenase. respectively. However, it has been questioned whether MMP-2 and MMP-9 
are true type IV collagenases in vivo since the full-length type IV collagen is not susceptible to 
cleavage by either enzyme (Mackay et al.. 1990: Moll et al., 1990). Structurally, gelatinases are 
characterized by three repeats o f type II fibronectin-like gelatin binding regions, which enable 
gelatinases to bind to denatured collagens (O'Farrell and Pourmotabbed, 1998).
The 72-kDa gelatinase A (MMP-2) is processed to an approximately 62 kDa active enzyme 
via a membrane-dependent mechanism, while most other MMPs are activated extracellularly
- 7 -
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(Brown et al., 1990: Strongin et al., 1993). In addition to gelatin and type IV collagen, MMP-2 
possesses proteolytic actions on type I (Aimes and Quigley, 1995), type V (Okada et al., 1990), 
type VII (Seltzer et al., 1989), and type X (Gadher et al., 1989; Welgus et al., 1990) collagens, 
and other ECM components such as elastin (Senior et al.. 1991), laminin (Giannelli et al., 1997), 
vitronectin (Imai et al.. 1995a), and aggrecan (Fosang et al.. 1992; Fosang et al., 1996b). 
Surprisingly. MMP-2 also cleaves the non-ECM component amyloid protein precursor with a P* 
secretase-like activity- (LePage et al.. 1995), indicating its involvement in Alzheimer's disease. It 
is because o f this wide range o f substrate specificities that enables MMP-2 to play important roles 
in a  number o f cellular processes, such as cell proliferation, differentiation, adhesion, and 
migration. Most importantly. MMP-2 also has a significant role in tumor invasion and 
angiogenesis. It binds integrin a ,p 3. facilitating the pericellular proteolysis during tumor invasion 
and angiogenesis (Brooks et al.. 1996).
In addition to the cysteine-rich repeats o f type II fibronectin-like inserts in the catalytic 
domain. MMP-9 also has a unique proline-rich type V collagen-like insert at the end o f  its hinge 
region: the significance o f which is still unclear (Wilhelm et al., 1989). The predicted molecular 
weight o f MMP-9 from its cDNA is about 76 kDa. However, the molecular weight determined by 
biochemical analyses is about 92 kDa. This difference is due to N- and O-linked glycosylation on 
this enzyme (Wilhelm et al.. 1989; Murphy and Crabbe. 1995). The active form of MMP-9 is 
approximately 82 kDa. but progressive proteolytic and/or autolytic cleavage on the N- and C- 
termini of the enzyme may process it into 65 kDa or even smaller forms (Fridman et al., 1995; 
Murphy and Crabbe. 1995: Sang et al.. 1995). MMP-9 shares a similar range o f substrates with 
MMP-2 (Table 1-3). Distinct from MMP-2. MMP-9 is not able to hydrolyze type I collagen. 
However, it has been reported that MMP-9 cleaves the N-terminai telopeptide o f type I collagen 
in an acidic environment (Okada et al.. 1995bb). Although MMP-9 degrades aggrecan, and link 
protein, which stabilizes the interaction between aggrecans and hyaluronate in proteoglycan
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aggregates, its efficiency is much lower than MMP-2 (Fosang et al., 1992; Nguyen et al., 1993). 
MMP-9 is also localized on the cell surface, where CD-44 serves as a docking protein to promote 
tumor invasion and angiogenesis (Yu and Stamenkovic, 1999; Yu and Stamenkovic, 2000). 
Accumulating evidence indicates that MMP-9 is a major MMP in a variety o f normal 
physiological processes such as implantation (Librach et al., 1991; Behrendtsen et al.. 1992), and 
bone development (Reponen et al.. 1994; Blavier and Delaisse, 199S; Vu and Werb, 2000). Not 
surprisingly, high levels o f MMP-9 expression are also observed in pathological conditions, 
including tissue injury- (Partridge et al.. 1993; La Fleur et al.. 1996; Pender et al.. 1997), 
inflammation (Weeks et al.. 1993; Leppert et al.. 1995a; Leppert et al., 1995b; Opdenakker et al., 
2001), arthritis (Stein-Picarella et al.. 1994), and wound healing (Salo et al., 1994; Buisson et al.. 
1996). and tumor angiogenesis (Bergers et al.. 2000). Additionally, its expression has been 
demonstrated in tumor cells from diverse sites o f the body including colorectum (Pyke et al..
1993; Nielsen et al.. 1996). bone (Vu et al.. 1998), bone marrow (Ries et al.. 1994). brain (Rao et 
al.. 1993). breast (Farias et al.. 2000). liver (Ashida et al.. 1996), lungs (Canete-Soler et al.. 1994; 
Farias et al.. 2000). skin (Pyke et al.. 1992), and prostate (Dong et al.. 2001).
(3) Stromelvsins The stromelvsins include stromelysin-1 (MMP-3) and stromelvsin-2 
(MMP-10). These two enzymes are classified into their own subgroup because they lack the 
ability to cleave the triple helical regions o f collagen, even though they share a similar domain 
structure with the collagenases (Stemlicht and Werb. 2001). Furthermore, they are distinguished 
from other MMPs by their amino acid sequences being noticeably similar to each other, but not to 
other MMPs (Muller et al., 1988). Lastly, they possess a  9-amino acid residue insert in the hinge 
region, which is absent from other MMPs.
The first neutral non-collagenolytic proteinase activity was noticed in human cartilage 
(Sapolsky et al.. 1974) and in the conditioned medium from rabbit synovial fibroblasts (Werb and 
Reynolds. 1974) at the same time by two independent research groups. The enzyme was later 
named "stromelysin" because it was produced by stromal cells (Chin et al., 1985). Historically,
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stromelysin was also known as "collagenase activator protein” (Treadwell et al., 1986) and 
"transin” (Matrisian et al.. 1986). cDNA cloning ultimately determined that the three proteins 
were the same metalloproteinase, MMP-3 (stromelysin I) (Matrisian et al., 1985; Whitham et al.. 
1986; Fini et al., 1987; Wilhelm et al.. 1987; Saus et al.. 1988). The latent form o f  MMP-3 has a 
molecular mass o f 56 kDa. while the active form is about 45 kDa (Nagase, 1995; Nagase, 1998). 
Asn-linked glycosylation is also observed in MMP-3 (Wilhelm et al., 1987). However, not all the 
secreted MMP-3 is glycosylated, for example. 80% of MMP-3 from fibroblasts is unglycosylated, 
while the remaining ones are produced as a glycoprotein (Nagase. 1995). MMP-3 hydrolyzes 
numerous ECM components including aggrecan (Wilhelm et al.. 1993). cartilage link protein 
(Nguyen et al.. 1989). gelatin (Murphy et al.. 1992a). vitronectin (Imai et al.. 1995a). tenascin 
(Imai et al.. 1994). fibronectin (Muir and Manthorpe. 1992). versican (Perides et al.. 1995). 
clastin (Murphy et al.. 1992a). laminin (Bejarano et al.. 1988). perlecan (Whitelock et al.. 1996). 
proteoglycan (Fosang et al.. 1991). and type II. IX. X. and XI collagens (Wu et al.. 1991). 
However, it is unable to hydrolyze triple-helixal collagen peptide (Lauer-Fields et al.. 2000).
Stromelysin 2 (MM P-10) was the first MMP to be identified directly from rat cDNA clones 
(Breathnach et al.. 1987). The deduced protein was also designated as transin 2. which has 71% 
identity to MMP-3 (transin 1) at the amino acid level. The human M M P-10 was subsequently 
cloned from human tumors (Muller et al.. 1988). MMP-10 is capable o f activating pro-MMP-8 
(Knauper et al.. 1994). There is limited information about the substrate specificity o f MMP-10. 
except its ability to effectively degrade cartilage link protein (Nguyen et al.. 1993) and gelatin 
(Sanchez-Lopez et al.. 1993). In human endometrium. MMP-10 mRNA expression increases 
during premenstrual and menstrual phases (Hampton and Salamonsen. 1994; Osteen et al., 1994). 
The function o f MMP-10 during tumor progression is still not clear.
(4) Membrane-type metalloproteinases (MT-MMPs) At present, there are six
membrane-type metalloproteinases: MTl-MMP (MMP-14), MT2-MMP (MMP-15), MT3-MMP 
(MMP-16), MT4-MMP (MMP-17). MT5-MMP (MMP-24), and MT6-MMP (MMP-26). MT-
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MMPs contain a cleavage site for furin proteinases between the propeptide and catalytic domains, 
providing the basis for furin enzyme-like dependent activation o f latent MT-MMPs prior to
secretion.
The notion that pro-MMP-2 is activated on the cell membrane rather than in the extracellular 
environment led to the discovery o f MT-MMPs. MT1-MMP. the first member o f the membrane- 
type MMP subfamily, was cloned from a human placenta cDNA library (Sato et al.. 1994). 
Distinct from all other MMPs that have been identified, this enzyme has a hydrophobic 
transmembrane segment at the C-terminus following the hemopexin domain. Indeed. MT1-MMP 
activates pro-MMP-2 (Sato et al.. 1994). Subsequent studies suggest that this activation process 
also involves TIMP-2. which binds to MT1-MMP to form a MT1-MMP/TIMP-2 ”co-receptor” 
for pro-MMP-2. The latter is then presented to an adjacent, active MT1-MMP. which cleaves the 
propeptide domain o f  pro-MMP-2. initiating the activation process (Deryugina et al.. 1997: Butler 
et al.. 1998: Cao et al.. 1998; Cao et al.. 1999: Murphy et al.. 1999b). In addition. MT1-MMP 
converts latent MMP-13 (collagenase-3) to the active form (Knauper et al.. 1996c). Moreover. 
MT1-MMP also functions as a  proteolytic enzyme, capable of cleaving various ECM 
components, including type I. II. and ID collagen, gelatin, fibronectin. laminin-1. vitronectin, 
cartilage proteogly cans, and fibrillin-1 (Imai et al.. 19%: Pei and Weiss. 1996: d'Ortho et al.. 
1997; Ohuchi et al.. 1997; Aznavoorian et al.. 2001).
MT2-MMP was identified from a human lung cDNA library’ (Will and Hinzmann. 1995). 
MT2-MMP is predominantly expressed in liver, placenta, intestine, colon, and testis (Will and 
Hinzmann. 1995). MT2-MMP also activates pro-MMP-2. Different from MT1-MMP. however, 
MT2-MMP activates pro-MMP-2 via a pathway independent of TIMP-2 (Morrison et al., 2001). 
MT2-MMP also degrades laminin. fibronectin. and tenascin (d’Ortho et al.. 1997).
Having been identified at the same time as MT2-MMP. MT3-MMP was originally 
designated as MT-MMP-2 (Takino et al.. 1995). MT3-MMP is primarily expressed in the brain. 
MT3-MMP activates pro-MMP-2 and also hydrolyzes gelatin, casein, type III collagen, and
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fibronectin (Shimada et al.. 1999: Kang et al.. 2000), and can be detected in membrane-bound and 
soluble forms (Matsumoto et al.. 1997: Shofuda et al.. 1997).
In addition to its original identification in breast carcinoma, MT4-MMP is also expressed in 
normal tissues including brain, colon, ovary, and testis (Puente et al.. 1996). MT4-MMP is 
structurally different from other MT-MMPs Instead o f having a 20-amino acid tail after the 
transmembrane domain (as observed in other MT-MMPs), MT4-MMP has a very short or no 
cytoplasmic tail following the putative transmembrane domain(ltoh et al.. 1999). Further 
sequence and biochemical analyses suggest that the C-terminus o f MT4-MMP acts as a 
glycosylphosphatidylinositol (GPI) anchoring signal, rather than as a  transmcmbrane domain 
(Itoh et al.. 1999). MT4-MMP is the first GPI-anchored proteinase in the MMP family. This 
property enables it to be shed from plasma membranes by endogenous enzymes. MT4-MMP 
converts membrane-bound pro-TNFa to its mature form (Wang et al.. 1999b: English et al.. 
2000). There are contradictory reports regarding its capability to activate pro-MMP-2 
(Kolkenbrock et al.. 1999: Wang et al.. 1999b: English et al.. 2000). MT4-MMP is unable to 
hydrolyze collagen types I. II. III. IV. and V. fibronectin. laminin or deconn, but degrades gelatin 
and some synthetic MMP substrates (Kolkenbrock et al.. 1999: Wang et al.. 1999b).
MT5-MMP. originally identified from a human brain cDNA library, activates latent MMP-2 
and is predominantly expressed in brain, kidney, pancreas, and lung (Llano et al., 1999: Pei. 
1999a). It is highly expressed in brain tumors (Llano et al.. 1999). Interestingly, MT5-MMP is 
also shed from the cell membrane by a furin type convertase. suggesting that it may function both 
as a membrane-bound and soluble proteinase (Pei. 1999a: Wang and Pei. 2001). Proteoglycans 
are the preferred substrates for MT5-MMP (Wang et al.. 1999a).
MT6-MMP was cloned from leukocytes (Pei. 1999b). Thus, it is also called leukolysin (Pei. 
1999b). High levels o f MT6-MMP expression was also observed in brain tumors (Velasco et al.,
2000). MT6-MMP is the second GPI-anchored enzyme in the MMP family, showing a similar C- 
terminal sequence as MT4-MMP (Kojima et al.. 2000). MT6-MMP activates pro-MMP-2
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(Velasco et al.. 2000). and cleaves type-IV collagen, gelatin, fibronectin and fibrin, but not 
laminin-1 (Pei. 1999b: English et al., 2001: Kang et al., 2001). Cytokines may play an important 
role in processing this enzyme from secretory vesicles and plasma membrane to the extracellular 
milieu as a soluble, active protein (Kang et al.. 2001).
(51 M atrilvsins Currently, two members have been identified in this subfamily, 
matrilysin I (MMP-7) and matrilysin 2 (MMP-26). They are the smallest MMPs since they lack 
the hemopexin domain.
MMP-7 was first purified from the postpartum involuting rat uterus (Sellers and Woessner. 
1980: Woessner and Taplin. 1988). Its cDNA was cloned and sequenced from a  human tumor 
library (Quantin et al.. 1989). This enzyme was also previously named as PUMP-l (putative 
metalloproteinase-1). Due to its simple domain organization. MMP-7 is small in size, with a  28 
kDa latent and 19 kDa active forms (Wilson and Matrisian. 1998). However, the minimal domain 
structure docs not affect its broad substrate specificities at all. MMP-7 hydrolyzes type IV 
collagen (Murphy et al.. 1991), gelatins (Quantin et al.. 1989). laminin (Imai et al.. 1995a), 
fibronectin (Imai et al.. 1995b). elastin (Imai et al.. 1995b). vitronectin(Imai et al.. 1995a). 
aggrecan (Fosang et al.. 1992). cartilage link protein (Nguyen et al.. 1993), proteoglycan (Imai et 
al.. 1995b: Halpert et al.. 1996). fibulin (Sasaki et al.. 1996). and entactin (Sires et al.. 1993). 
MMP-7 is involved in many normal tissue remodeling events by being expressed in the uterus 
(Sellers and Woessner. 1980). hair follicles and sweat glands, small intestinal crypts, skin, and 
airway epithelium (Giambemardi et al.. 1998: Wilson and Matrisian. 1998). Distinct from other 
MMPs. expression o f MMP-7 is restricted to glandular epithelium, and is secreted apically. 
MMP-7 is also expressed by malignant epithelial cells in tumors o f the breast (Heppner et al.. 
1996). prostate (Klein et al.. 1997). colon (Yoshimoto et al.. 1993), lung (Bolon et al.. 1997). and 
gastrointestinal tract (Adachi et al.. 2001). This is unlike other MMPs, whose source is the 
stromal cells that surround epithelial tumors, rather than the tumor cells themselves (Wilson and 
Matrisian. 1996: Wilson e ta l., 1997).
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A novel metalloproteinase (MMP-26) has been recently identified independently by several 
groups (de Coignac et al., 2000: Park et al., 2000; Uria and Lopez-Otin. 2000; Marchenko et al..
2001). Even though this enzyme has a high homology' (45% identity') with M M P-12 (macrophage 
metalloproteinase). its protein structure is more related to MMP-7 (matrilysin) by having the 
minimal domain organization, which consists o f  only the signal peptide, propeptide and catalytic 
domains (de Coignac et al.. 2000; Marchenko et al.. 2001). Furthermore, MMP-26 also contains a 
Thr(207) residue upstream o f the zinc binding motif, which is a specific feature o f all known 
matrilysins (Abramson et al.. 1995; Uria and Lopez-Otin. 2000; Marchenko et al.. 2001). 
Accordingly, the name matrilysin-2 has been suggested for this novel MMP (Uria and Lopez- 
Otin. 2000: Marchenko et a l . 2001). The name "endometase" has also been used for this enzyme 
as it is derived from a human endometrial tumor cDNA library (Park et al.. 2000). Distinct from 
other MMPs. MMP-26 has a unique "cy steine switch" motif sequence PHCGVPD. which 
replaces the highly conserved motif PRCGXXD. indicating its activation may be sensitive to pH 
(Marchenko et al.. 2001). O f note. MMP-26 may not be a  classical matrilysin in that there is low 
sequence similarity between MMP-26 and MMP-7. Also, they are located on different 
chromosomes and they have dissimilar predicted surface modeling. MMP-26 has a  diverse array 
of substrates, including gelatins, fibronectin, fibrogen. vitronectin. However. MMP-26 is unable 
to degrade types I-IV collagen, tenascin C. and laminin V (Uria and Lopez-Otin. 2000; 
Marchenko et al.. 2001). MMP-26 is highly expressed in the placenta (de Coignac et al.. 2000; 
Park et al.. 2000). the uterus (Uria and Lopez-Otin. 2000) and a  number of developing fetal 
tissues (Marchenko et al.. 2001). Expression o f MMP-26 in carcinomas o f the endometrium, lung, 
and prostate suggests its unique role in the progression o f epithelial tumors (Uria and Lopez-Otin, 
2000).
(6) O ther MMPs Based on structure and substrate specificity, several MMPs do not fit into 
any o f the subgroups describe so far. although some investigators argue that matrilysin and 
macrophage metalloelastase should be included in the group o f stromelysins.
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Stromelysin-3 (MMP-11) was first cloned from a  breast carcinoma cDNA library . Its 
expression is restricted to the stromal cells surrounding the tumor cells (Basset et al.. 1990).
While stromelvsins 1 and 2 share a  76% identity to each other in amino acid sequence, MMP-11 
only shows 39% and 36% sequence identity to other stromelvsins and other MMPs. respectively 
(Sang and Douglas. 1996). Structurally. MMP-11 is also different from stromelvsins 1 and 2. 
MMP-11 contains a 10-amino acid residue insert (RXK/RR) at the end o f the propeptide domain, 
w hich resembles a furin-like recognition site (Pei and Weiss. 1995). Indeed, intracellular 
activation o f pro-MMP-11 by Golgi-associated furin enzyme, which is different from the 
extracellular activation o f other MMPs. was observed (Pei and Weiss. 1995). The just described 
characteristics distinguish MMP-11 (stromelysin-3) from the subfamily o f stromelvsins.
Although MMP-11 cleaves some ECM proteins such as type IV collagen, laminin. fibronectin. 
and aggrecan. its efficiency is much lower than stromelysin-1 (Murphy et al.. 1993b). However. 
MMP-11 is critical for tumor progression, since MMP-11-deficient mice are resistant to 
chemically-induced tumors (Noel et al.. 1996: Basset et al.. 1997). It has also been postulated that 
expression o f  MMP-11 in adjacent cells is pivotal for the epithelial-to-mesenchvmal conversion 
o f tumor cells (Ahmad et al.. 1998). This tumor promoting capability o f MMP-11 may result from 
its ability to release mature or active growth factors from the corresponding latent forms 
sequestered in the extracellular matrix (Basset et al.. 1997).
Macrophage metalloelastase (MMP-12) was first purified from the mouse as a 22 kDa 
enzyme (Banda and Werb. 1981). which is processed from its 54 kDa latent form by conventional 
propeptide removal and atypical processing at the C-terminus (Shapiro et al.. 1992). Cloning and 
sequence analysis o f  mouse and human MMP-12 revealed that this enzyme has a domain 
structure typical o f collagenases. but it only shares 33-48% homology with other MMPs at the 
amino acid level (Shapiro et al.. 1992: Shapiro et al.. 1993). Although MMP-12 is unable to 
hydrolyze interstitial collagens. it cleaves a wide array o f ECM components including elastin, 
type IV collagen, type I gelatin, vitronectin, fibronectin. proteoglycans, laminin-1, and myelin
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basic protein (Chandler et al., 1996; Gronski et al., 1997). MMP-12 has been related to a number 
o f macrophage-involved diseases such as pulmonary' emphysema (Hautamaki et al., 1997) and 
Lewis lung carcinoma (Dong et al.. 1997).
Human MMP-19 was the first MMP identified by using the EST (expressed sequence tags) 
database search, although its 5 ' end was determined by 5'-RACE (Cossins et al.. 1996). These 
investigators called their enzyme M M P-18, without being aware that the then newly identified 
Xenopus MMP was already given this designation. Two identical cDNAs. which were designated 
as MMP-19. were later cloned from a human liver cDNA library and a library' constructed from 
rheumatoid arthritis synovium (Kolb et al.. 1997; Pendas et al., 1997b). Since the latter research 
was done on rheumatoid arthritis synovium inflammation, the enzyme was also called RASI-1 
(Kolb et al.. 1997). MMP-19 lacks all the specific structural features o f collagenases. gelatinases. 
and membrane-type mctalloproteinases. For example. MMP-19 has a 16-acidic residue insert in 
the hinge region rather than the 9-residue insertion rich in hydrophobic amino acids that is 
specific for stromelvsins (Pendas et al.. 1997b). MMP-19 is a  potent basement membrane enzyme 
capable o f hydrolyzing type IV collagen, laminin. fibronectin. type I gelatin, nidogen. tenascin. 
aggrecan. and cartilage oligomeric matrix protein (COMP) (Stracke et al.. 2000a: Stracke et al.. 
2000b). MMP-19 is highly expressed in intestine, ovary, spleen, heart pancreas, lung, thymus, 
testis, prostate, and placenta, indicating that it may plav a role in remodeling events in these 
tissues (Cossins et al.. 1996: Pendas et al.. 1997b). Furthermore, the expression o f  MMP-19 in 
capillary endothelial cells o f acutely but not chronically inflamed synovium, demonstrates that it 
may be involved in angiogenesis (Kolb et al.. 1999). Interestingly. MMP-19 expression is 
observed in tumor and endothelial cells o f benign tumors, while it disappears as the tumor 
progresses towards the invasive and neoplastic phenotypes (Djonov et al., 2001). This suggests 
that MMP-19 may be important for tumor survival but not progression.
Enamelysin (MMP-20) was first cloned from a  cDNA library o f porcine enamel organ 
(Bartlett et al.. 1996). Its human homolog was subsequently cloned from an odontoblastic cell
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cDNA library (Llano et al., 1997). The deduced MMP-20 protein consists o f 483 amino acid 
residues, bearing a  54 kDa molecular mass. Although MMP-20 has the characteristic domain 
organization o f MMPs. the specific structural features o f collagenases, gelatinases. membrane- 
type MMPs. and stromelvsins are absent in MMP-20. MMP-20 degrades amelogenin, casein, 
aggrecan. and cartilage oligomeric matrix protein (COMP), but has weak action against gelatin 
(Llano et al.. 1997; Stracke et al.. 2000a). The restricted expression o f MMP-20 signifies its 
importance in the processing o f  enamel matrix during tooth enamel formation (Grant et al.. 1999). 
Moreover. MMP-20 expression is also detected in odontogenic tumors and tongue carcinomas 
(Takata et al.. 2000; Vaananen et al.. 2001). (ntriguingly, MMP-20 is expressed in granulosa 
cells, and is highly elevated by bradykinin treatment indicating its specialized role during 
ovulation (Kimura et al.. 2001).
MMP-21 (XMMP) was first cloned from Xenopus laevis (Yang et al.. 1997). Different from 
other MMPs. MMP-21 has a 37-amino acid-residue insert at the c-terminal end o f the propeptide 
domain. This insert, resembling a vitronectin segment, is followed by an RRKR motif, a furin­
like recognition site that is present in stromelysin-3 and MT-MMPs. In addition. MMP-21 lacks 
the hinge region, which is typically present in other MMPs for connecting the catalytic and 
hemopexin domains. Another specific feature o f  MMP-21 is that its C-terminal domain consists 
of four repeats o f vitronectin-like segments (Yang et al.. 1997). The expression o f MMP-21 is 
transiently induced at the gastrula stage, maintained at the neurula stage, but down-regulated in 
the pre-tailbud embryo, suggesting its unique role during early embryo development of Xenopus 
laevis. The human homolog o f MMP-21. which shows 73% homology to XMMP at the amino 
acid level, has been recently identified (Marchenko et al.. 2001). However, its substrate 
specificity, and involvement in physiological and pathological processes require further 
investigation.
MMP-22 (CMMP) was characterized in chicken embryo fibroblasts (Yang and Kurkinen,
1998). In the catalytic domain. MMP-22 has a  unique cysteine residue in the sequence motif that
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interacts with the structural (noncatalytic) zinc ion. A homologous cysteine residue is also present 
in XMMP (Yang et al.. 1997) and MMP-19 (Cossins et al., 1996; Pendas et al., 1997b). The 
recombinant MMP-22 enzyme digests casein and gelatin (Yang and Kurkinen, 1998), suggesting 
that it possesses collagenoiytic and gelatinolytic activities. The presence o f  MMP-22 in 
mammalian species is not known at this time.
MMP-23 was first cloned from human uterus and testis cDNA libraries, but it was named 
MMP21/22 by the investigators (Gururajan et al.. 1998a; Gururajan et al.. 1998b). The identical 
sequence was re-discovered from a human ovary cDNA library, bearing the name MMP-23 
(Velasco et al.. 1999). The mouse and rat homologs were also reported at the same time[(Pei, 
1999c); rat homolog with GenBank accession number ABO 10960 by Ohnishi et al.. 1999], In all 
of these species, the domain organization of MMP-23 is strikingly different from all other MMPs 
in that it lacks not only a recognizable signal peptide at the N-terminus and the cysteine switch 
consensus PRCGVPD in the propeptide domain, but also the hemopexin-like sequence at the C- 
terminal end. which is replaced by an Ig-like C2 type (or ILIR-Iike) domain (Pei. 1999c; Velasco 
et al.. 1999) Although the cysteine switch motif is absent in MMP-23. the enzyme contains a 
conserved furin recognition sequence (RRRR). which is also present in MMP-11 (stromelysin-3) 
and MT-MMPs. suggesting it has an activation mechanism different from other MMPs (Pci. 
1999c; Velasco et al.. 1999). Surprisingly, a cysteine array motif, which is located downstream of 
the catalytic domain, is noted in mouse MMP-23 (Pei. 1999c). while it is not mentioned in the 
human homolog (Velasco et al.. 1999). Thus, this enzyme is also named cysteine array matrix 
metalloproteinase or CA-MMP (Pei. 1999c). Even though the typical signal peptide is absent. 
MMP-23 contains a hydrophobic segment at the N-terminal end (Pei. 1999c). Studies 
demonstrate that this hydrophobic region serves as a  signal anchor to localize MMP-23, enabling 
it to act as a  type II transmembrane MMP [type I transmembrane has either a  transmembrane 
segment (M T l. 2. 3. 5-MMPs) or a  glycosylphosphatidylinositol region (MT4,6-MMPs) at the 
C-terminus|, which couples enzyme secretion and activation by a  single proteolytic cleavage (Pei
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et al.. 2000). This novel mechanism may establish a new pathway for regulating MMP 
trafficking. The recombinant MMP-23 degrades a common synthetic MMP substrate and gelatin 
(Pei. 1999c: Velasco et al., 1999). In addition to its expression in adult tissues such as heart and 
lung, MMP-23 is predominantly expressed in reproductive tissues including prostate, ovary, and 
testis. However, its expression in placenta is relatively low or negative (Pei, 1999c: Velasco et al..
1999). The expression o f MMP-23 in the ovary will be discussed in a later section.
MMP-27 is a newly identified member in the MMP family, and has a  domain organization 
characteristic o f collagenases. However, although the sequence information has been reported in 
the NCBI (GenBank accession number NM_022122 by de Coignac). there are no reports 
regarding the biochemical and molecular properties, or tissue expression and cellular localization 
of this enzyme.
MMP-28 (Epilysin) is a  novel MMP member identified independently by two research 
laboratories (Lohi et al.. 2001: Marchenko and Strongin. 2001). Since this novel endopeptidase is 
prominently expressed in the epidermis, it is appropriately designated as "epilvsin”. MMP-28 
contains the characteristic signal peptide, propeptide, catalytic, hinge, and hemopexin domains, 
characteristic o f most MMPs. It also has several peptide sequences typical o f MMPs. such as the 
conserv ed cysteine switch sequence PRCGVTD and the catalytic domain sequence HEIGH (Lohi 
et al.. 2001: Marchenko and Strongin. 2001). Unlike other MMPs. however, a unique feature o f 
its catalytic domain is that it has threonine residues (HEIGHTLGLTH). Structurally. MMP-28 is 
similar to MMP-11 (stromelysin-3) in that it has a furin recognition sequence (RRKKR) 
following the cysteine switch sequence. But phylogenetic analysis on the catalytic domains of 
MMP-28 and other MMPs demonstrates that this enzyme is most closely related to MMP-19. 
w hich shows 46% identity to MMP-28 (Lohi et al.. 2001). Therefore, it has been postulated that 
MMP-28 is the first member o f  the MMP-19 subgroup (Marchenko et al., 2001). The 
recombinant MMP-28 protein has caseinolytic activity, which can be completely inhibited by 
EDTA and a synthetic MMP inhibitor, batimastat (Lohi et al., 2001). In addition to its strong
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expression in keratinocvtes, MMP-28 expression is also observed in a broad range of fetal tissues 
(lung, brain, skeletal muscle, and kidney), adult tissues (kidney and pancreas), and a  number of 
carcinomas including colon adenocarcinoma, ovarian carcinoma, and pancreatic adenocarcinoma 
(Marchenko et al.. 2001). This suggests that this novel MMP may have a significant role in 
normal tissue remodeling and tumor progression.
2. Regulation of M M P activity
MMP activities are pivotal for normal physiological processes, while over-expression of 
these enzymes typically results in a  variety o f diseases and pathological conditions. Therefore, the 
temporal expression and spatial localization o f MMPs need to be closely coordinated with 
activity. This requires strict regulation of MMPs. which occurs at different levels.
(11 Transcriptional regulation As a general rule. MMPs arc not constitutively 
expressed in most tissue types. Instead, the transcriptional expression o f MMPs can be induced by 
a variety o f growth factors and cytokines, while their expression can also be suppressed, for 
example, by transforming growth factor beta (TGFP) and glucocorticoids (Matrisian. 1990).
Other extracellular signals regulating MMP expression also include extracellular matrix proteins, 
integrin-derived signals, and cell stress factors.
The regulation by the above extracellular signals is ultimately accomplished by acting on the 
promoters o f MMP genes (Borden and Heller. 1997). The most common promoter found in MMP 
genes is the AP-l cis-element. which is usually localized at 65 to 79 base pairs upstream o f the 
transcriptional start site. MMP-1. -3. -7. -9. -10, -12. -13, and -19 are under the regulation o f the 
AP-l promoter (Gack et al.. 1994; Quinones et al.. 1994; Korzus et al.. 1997; Pendas et al.,
1997a; Chapman et al.. 1999; Mueller et al.. 2000; Campbell et al., 2001; Wu etal., 2001). Other 
inducible cis-regulatory elements, such as Ets, SP1, SP3, and NF-kB, are also present in the 
promoter region o f most MMPs (Borden and Heller, 1997). Thus, transcriptional regulation of
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MMPs is complex, since there are numerous signal transduction pathways for extracellular 
signals, and one promoter may be affected by various signaling components. For example, the 
AP-l cis-element is switched on when an AP-l transcription factor complex, which consists of 
members o f Jun and Fos proteins, is attached (Curran and Franza, 1988). c-Jun and c-Fos 
components are under the regulation o f at least three distinct signaling pathways, including 
mitogen-activated protein kinases (MAPKs), stress-activated protein kinase/Jun N-terminal 
kinases (SAPK/JNKs). and p38 (Heldin, 1995). Interactions between multiple signaling 
components may. therefore, influence the expression pattern o f MMPs (Korzus et al.. 1997; 
Simon et al.. 2001).
Different from most other MMPs, MMP-2 is often constitutivelv expressed at the 
transcriptional level. Gene structure analysis found that the MMP-2 promoter has high similarity 
with the other two molecules that are involved in its activation process: TIMP-2 and MT1-MMP. 
In vivo studies further demonstrated that MMP-2. MT1-MMP, and TIMP-2 are coordinated 
expressed in a  number o f tissue types (Apte et al.. 1997: Chen and Wang, 1999; Kan war et al.. 
1999: Kurschat et al.. 1999: Longin et al.. 2001). suggesting that not all members of this protein 
family are regulated at the same levels.
(2) Activation o f latent MMPs As potent proteolytic enzymes on various ECM 
components. MMPs are also tightly regulated at the activational level. MMPs are produced as 
latent forms, and most are subsequently activated by extracellular proteolytic cleavage. The 
latency o f MMPs is maintained by the cysteine switch consensus sequence in the propeptide 
domain. The conserved cysteine residue covalently interacts with the catalytic zinc ion in the 
active core o f the enzyme. The latter is thus prevented from interacting with a  water molecule 
(Van Wart and Birkedal-Hansen. 1990). Either proteolytic cleavage on the propeptide by 
proteinases. or chemical modification on the SH group o f cysteine residues, can bring about 
disruption o f the Zn2*-Cvs interaction, allowing the catalytic zinc ion to interact with H20  
(Nagase. 1997). The activity o f MMPs is attained by this intramolecular reaction. The final step
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may also involve autocatalytic removal of the propeptide. Chemical modification is achieved by 
reagents such as 4-aminophenylmercuric acetate (APMA), HOCL. and denaturants. Also, the 
propeptide o f  most MMPs is susceptible to cleavage by extracellular proteinases such as trypsin, 
plasmin. chymotrypsin. and MMPs themselves (Nagase, 1997; Murphy et al., 1999b; Nagase and 
Woessner, 1999). Therefore, these proteinases may serve as endogenous activators of MMPs.
Unlike other MMPs. MMP-11 (stromelysin-3) and all MT-MMPs have an additional 10- 
amino acid residue furin-like enzyme recognition motif (RxK/RR) at the C-terminal end o f  the 
propeptide domain (Pei and Weiss. 1995). The same insert is also observed in a  novel member of 
the MMP family. MMP-23. which does not possess the typical cysteine switch consensus 
(PPCG[V/N1PD) in the propeptide domain (Pei. 1999c). This structural feature indicates that 
these MMPs can possibly be activated intracellularly rather than extracellularly, by furin. a Golgi- 
associated subtiiisin-like proteinase. Indeed, it has been demonstrated that furin is able to process 
latent MMP-11 to its active form (Pei and Weiss. 1995). Furthermore, this processing can be 
stopped by synthetic furin inhibitors (Santavicca et al.. 1996). The transmembrane-deleted MT- 
MMP1 can also be activated intracellularly (Pei and Weiss. 1996). Intracellular processing of 
MMP-23 is also observed (Pei et al.. 2000; Ohnishi et al.. 2001). even though furin is unable to 
enhance MMP-23 processing in a transfection model (Ohnishi et al.. 2001).
Notably , although MMP-2 harbors the characteristic cysteine switch motif in its propeptide 
domain, it is resistant to cleavage by many proteinases that are able to activate most other MMPs. 
Instead, it is activated by membrane-type metalloproteinases (MT-MMPs) (Sato et al., 1994; Sato 
and Seiki. 1996; Murphy et al.. 1999a; Seiki, 1999). Among them, MT1-MMP is the most 
studied. Efficient activation of pro-MMP-2 by MT1-MMP requires TIMP-2, which forms a 
trimeric complex by binding to MTI-MMP to form a "co-receptor*’ for pro-MMP-2. On the cell 
surface, an adjacent active MTI-MMP then cleaves the propeptide o f pro-MMP-2 to initiate the 
activation process (Cao et al.. 1998; Zucker et al.. 1998; Deryugina et al., 2001). However,
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TIMP-2 may not be necessary for activation by other MT-MMPs. For example, MT2-MMP 
activates pro-MMP-2 in a  TIMP-2 independent manner (Morrison et al., 2001).
(3) Inhibition by endogenous inhibitors Once activated, the activity o f MMPs in the 
extracellular milieu is controlled by a group o f endogenous inhibitors known as tissue inhibitors 
o f metalloproteinases (TIMPs), which belongs to a  multigene family (Woessner and Nagase,
2000). Other proteinase inhibitors, such as a-macroglobulins, also inhibit MMP activity (Sottrup- 
Jensen. 1989). There are two significant aspects regarding the roles o f TIMPs and a2- 
macroglobulin. On the one hand. a2-macroglobulin. which is abundantly present in all tissue 
fluids and acts nonspecificallv against MMPs. may serve as a major inhibitor throughout the 
entire body, whereas TIMPs may regulate MMP activity locally by their tissue or cell specific 
expression. On the other hand, the inhibitory action o f a2-macroglobulin on MMPs is irreversible 
until the a2-macroglobulin/MMP complexes are eliminated via scavenger receptor-mediated 
endocytosis. while the inhibition o f MMPs by TIMPs is reversible (Stemlicht and Werb. 2001).
In addition to a2-macroglobulin and TIMPs. another group of inhibitors is emerging. Recent 
studies suggest that ECM proteins may play dual roles during tissue remodeling. Besides their 
functions as structural components for supporting cells and tissues and as targets o f MMPs for 
ECM turnover, they may also regulate MMP activities via their proteolytic products. For 
example, the noncollagenous NC1 domain of type IV collagen possesses not only sequence 
similarity with TIMPs but also inhibitory activity against MMPs (Netzer et al.. 1998), being 
capable o f inhibiting tumor progression and angiogenesis (Petitclerc et al.. 2000). The C-terminal 
domain o f procollagen C-terminal proteinase enhancer (CT-PCPE) also shows MMP inhibitory 
activity by reverse zvmography (Mott et al., 2000). N-terminal sequencing and structural 
comparison further demonstrate that this fiagment harbors six cysteine residues, which are 
conserved in the N-terminal domain o f TIMPs (Murphy and Willenbrock, 1995). Nevertheless, 
although the inhibitory effects o f the C- and N-terminal fragments o f CT-PCPE on MMP-2 are
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remarkably lower than TIMPs (Netzer et al.. 1998; Mott et al., 2000), they may present a new 
group o f inhibitors whereby they are released upon proteolytic cleavage of the full length 
molecule.
3. TIMPs
TIMPs specifically and reversiblv inhibit the activity o f MMPs. So far. four members of the 
tissue inhibitors o f metalloprotcinases (TIMPs) gene family are known; TIMP-1, -2. -3. and -4. 
Table 1-4 summarizes some of the basic molecular and biochemical features o f these inhibitors. 
All TIMPs have 12 conserved cysteine residues, which form six disulfide bonds and 6-looped. 2- 
domain structures. Loops 1-3. which are localized at the N-terminal domain, are highly 
conserved. The importance of these loops is established by the fact that they are necessary and 
sufficient for the inhibitory ability' o f TIMPs against MMPs (Murphy and Willenbrock. 1995; 
Woessner and Nagase. 2000). The three loops at the C-terminus domain (loops 4-6) may be 
responsible for determination of preferred MMP targets of individual TIMPs (Willenbrock and 
Murphy. 1994). Overall, the four TIMPs show 37-51% sequence identity (Woessner and Nagase.
2000). The ability o f TIMPs to block the autocatalytic activation o f latent MMPs and to limit the 
degradative actions o f activated MMPs is attained by their capability to bind both latent and 
active MMPs with a 1:1 stoichiometric ratio (Bode and Maskos. 2001). The relatively high 
variability in the C-terminal domains o f TTMPs may contribute to determine their preferred MMP 
targets (Brew et al.. 2000; Bode and Maskos. 2001). In addition, the differential regulation and 
wide tissue localization o f each individual TIMP are associated with their corresponding distinct 
biological functions.
TIMP-1 is a  28.5 kDa N-linked glycoprotein (Gasson et al., 1985). Although it has been 
generally recognized that TIMP-1 inhibits the activities o f all known MMPs (Edwards. 2001), it 
has no or very low inhibitory’ actions on MT-MMPs (Will et al., 1996). TIMP-1 preferentially
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binds to MMP-9 by interacting strongly with the hemopexin domain o f  MMP-9 with its C- 
terminai domain (Goldberg et al., 1989: Murphy and Willenbrock, 1995).
TIMP-2 is an unglycosylated protein with a  molecular mass o f about 2 1 kDa (De Clerck et 
al.. 1989: Stetler-Stevenson et al.. 1989). Unlike other TIMPs, the C-terminal sequence o f TIMP- 
2 is extended and negatively charged (Murphy and Willenbrock. 1995). TIMP-2 readily forms 
complexes with MMP-2 through its C-terminal domain (Goldberg et al., 1989: Kolkenbrock et 
al.. 1994).
TIMP-3 is an N-glycosylated protein (Apte et al.. 1995). Its molecular mass ranges from 24 
to 27 kDa depending on the degree o f glycosyiation. It preferentially inhibits the activity’ of 
MMP-1. -2. -3. -9. and -13 (Apte et al.. 1996: Knauper et al., 1997a: Butler et al., 1999). TIMP-3 
is the only TIMP that is strongly associated with the ECM (Leco et al.. 1994; Yu et al.. 2000).
The biological importance of TIMP-3 is highlighted by the fact that mutation in this molecule 
results in Sorsby's Fundus Dystrophy, an autosomal dominant disorder that is manifested by early 
degeneration o f the retina (Apte et al.. 1995).
TIMP-4 has a molecular mass o f about 24 kDa (Greene et al.. 1996: Liu et al.. 1997). It is 
not known whether this protein is glycosylated. TIMP-4 is the only member o f the TIMP family 
that was identified by using the expressed sequence tag approach (Greene et al.. 1996). The full- 
length cDNA was cloned from a human heart cDNA library (Greene et al., 1996). The gene 
structure of TIMP-4 was determined from genomic DNA (Olson et al.. 1998). Homology analysis 
revealed that TIMP-4 is closer to TIMP-2 and TIMP-3 (51%) than to TIMP-1 (37%). In addition 
to the original observation o f its abundant presence in human heart tissues (Greene et al., 1996), 
TIMP-4 is also highly expressed in a  broad range o f rodent tissues, including brain, heart, ovary, 
and skeletal muscles ((Leco et al.. 1997: Wu and Moses, 1998), suggesting its role as an 
important tissue-specific regulator o f ECM turnover. TIMP-4 significantly inhibits tumor growth 
and metastasis o f human breast cells probably via its potent inhibitory action on a  number o f 
MMPs, including MMP-I, -2, -3, -7. -8, -9, -12, -13, and -14 (Bigg et al., 1997; Liu etal., 1997;
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Wang et al., 1997; Stratmann et al., 2001a; Stratmann et al., 2001b). This is achieved primarily 
through TIMP-4"s reliance on residue 2 (Ser2) in its inhibitory domain (Stratmann et al., 2001a). 
TIMP-4 binds to MMP-2 with high efficiency similar to TIMP-2. However, unlike TIMP-2, 
which promotes activation o f pro-MMP-2 by coupling MMP-2 and MTI-MMP to form a trimeric 
complex on the cell membrane. TIMP-4 inhibits pro-MMP2 activation (Bigg et al., 2001; 
Hernandez-Barrantes et al.. 2001). Therefore, the balance between TIMP-2 and TIMP-4 may be 
part o f a mechanism that dictates the local regulation o f MMP-2 activity'.
4. Non-conventional functions of MMPs and TIMPs
Accumulating evidence suggests that MMPs are multifunctional proteins. In addition to 
facilitating ECM turnover. MMPs have broad substrate specificities on non-ECM proteins (Table 
1-3).
One notable example o f the novel functions o f MMPs is their ability to regulate the activity 
o f enzymes, including themselves. MTI-MMP can activate pro-MMP-2 on the cell surface (Sato 
et al.. 1994). while MMP-3 initiates the activation o f pro-MMP-1. -3. -7. -8. -9 and -13 (Nagase. 
1995; Nagase. 1998). In addition, proteolytic enzyme activity is mainly regulated by endogenous 
inhibitors. For example, serine proteinase inhibitors (serpins) inhibit plasmin, which belongs to a 
class o f proteases that has a serine amino acid residue in their active site. These inhibitors, in turn, 
are cleaved by MMP-9 (Liu et al.. 2000) and MMP-11 (Pei et al.. 1994), resulting in their 
inactivation, which alters the balance between enzymes and their inhibitors.
Cleavage o f ECM proteins by MMPs can regulate the availability o f growth (actors and 
cytokines, which are associated with matrix protein. For example, fibroblast growth factor (FGF) 
is released when perlecan is cleaved by MMP-1 and MMP-3 (Whitelock et al., 1996), while 
transforming growth factor (3 (TGFf3) becomes available when decorin is degraded by MMP-2, -
3. and -7 (Imai et al., 1997). Furthermore, there are a  number o f growth factors and cytokines that 
are synthesized as pro-forms, which are biologically inactive. Direct cleavage of these precursors
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by MMPs processes them into their active forms. For example, MMP activity is required for 
release o f  TN Fa from its cell membrane bound form (Gearing et al., 1994; McGeehan et al.,
1994; Lombard et al.. 1998), while removal o f the N-terminal sequence o f  interleukin ip  (ILip) 
by MMP-2. -3, and -9 converts it to its biologically functional form (Schonbeck et al., 1998). On 
the other hand, the biological activity o f these cytokines can also be down-regulated by MMPs. 
N-terminal proteolytic processing of monocyte chemoattractant protein 3 (MCP-3) by MMP-2 
results in a MCP-3 antagonist which binds to MCP receptors, but does not induce signal 
transduction (McQuibban et al.. 2000). Furthermore, MMPs act on growth factor receptors. For 
example, cleavage o f FGF receptor type I by MMP-2 releases its ectodomain from the cell 
surface. This soluble FGF receptor then alters the availability o f FGF to its cell membrane 
receptors (Levi et al.. 1996).
Cell-cell and cell-matrix interactions are important for cell migration and invasion. MMPs 
influence these processes by directly cleaving cell adhesion molecules, such as integrin P4 and E- 
cadherin (Lochter et al.. 1997; von Bredow et al.. 1997). Proteolytic cleavage of E-cadherin by 
MMP-3 and MMP-7 releases an 80 kDa fragment which stimulates cell migration and invasion 
(Noe et al.. 2001). Keratinocyte migration, on the other hand, is induced by MMP-2 dependent 
cleavage of laminin-5 (Giannelli et al.. 1997). Lastly, hydrolysis o f  cell adhesion molecule CD-44 
and cell surface tissue transglutaminase (tTG) by MTI-MMP alters tumor cell adhesion and 
migration (Belkin et al.. 2001; Kajita et al.. 2001).
Besides MMPs. the TIMPs are also a multifunctional group o f  proteins. In addition to 
inhibiting MMP activity. TIMP-1 and -2 exhibit growth promoting ability on several different cell 
lines (Docherty et al.. 1985; Gasson et al.. 1985; Stricklin and Welgus, 1986; Hayakawa et al.. 
1992; Hayakawa et al.. 1994; Nemeth et al.. 1996). Also, TIMP-1 is associated with 
steroidogenesis in rat gonadal cells (Boujrad et al., 1995). Furthermore, the nuclear localization o f 
TIMP-1 shows a  cell cycle dependent pattern (Zhao et al., 1998), indicating that this protein may
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regulate the cell cy cle. In addition to its inhibitory activity', TIMP-2 facilitates pro-MMP-2 
activation by assembling an MTI-MMP/TIMP-2/pro-MMP-2 tn-molecular complex on the cell 
surface (Butler et al .. 1998). Lastly , a death domain is found in the N-terminus o f the TIMP-3 
protein (Bond et al.. 2000). Indeed. TIMP-3 over-expression induces apoptosis in smooth muscle 
cells (Baker et al.. 1998). This may be due to its ability to induce the type II apoptotic pathway 
(Bond et al.. 2002).
Taken together. MMPs regulate cell proliferation, survival, adhesion, migration, and cell-cell 
and cell-matrix interactions by their proteolytic actions on non-ECM proteins that include the 
precursors and receptors o f growth factors and cytokines, these hormones themselves, cell 
adhesion molecules, and enzymes. As a group of proteins w ith small molecular masses. TIMPs 
also affect cell growth and survival. Because they possess multiple functions, the roles o f MMPs 
and TIMPs in physiological and pathological processes are even more complex (Chambers and 
Matrisian. 1997: Blavier et al.. 1999: McCawley and Matrisian. 2000).
III. MMPs/TIMPs in Follicular Development and Atresia
In all mammalian species, the follicle is a morphological and functional unit which sustains 
oocyte growth and maturation. Follicular growth begins with primordial follicles which are 
located in the inner part o f the ovarian cortex. Entry of primordial follicles into the growth phase 
is characterized bv conversion o f the non-growing, flattened (squamous) pre-granulosa cells 
surrounding the oocyte into a single layer o f cuboidal granulosa cells. At this stage, it is termed a 
primary follicle, which is also distinguished by the formation o f a  zona pellucida around the 
oocyte (Cortvrindt and Smitz. 2001). Granulosa cells continue to proliferate resulting in the 
oocyte being surrounded by two or three layers o f these cells. At this stage, they are termed 
secondary follicles. As secondary- follicles grow, stromal cells next to the basement membrane of 
the follicle become aligned and form the theca cell layer. At the end o f  this stage, a  vascular 
network is also developed (will be discussed in section VI) in the theca layer. The blood supply
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not only provides nutrients and oxygen for the growth o f the follicle, but also exposes the follicle 
to factors circulating in the blood stream, which influence follicle development. In the tertiary 
follicle, the granulosa and theca cells undergo further development and a cell-free, fluid-filled 
cavity called an "antrum'' (means cave in Greek) is formed. Therefore, the follicle at this stage is 
also called the antral follicle. Based on the appearance and the size of the antrum, the follicles at 
this stage can be further distinguished as "preantraT or "early antral"'. In the theca layer, the cells 
next to the basement membrane become epitheliod in appearance and form a  so-called theca 
interna, while the peripheral cells, which form the theca externa, maintain their spindle shape.
The theca interna cells undergo cytodifferentiation and acquire organelles characteristic of 
steroid-secreting cells such as mitochondria and smooth endoplasmic reticulum. As follicles 
continue to grow and synthesize hormones, they will reach the final stage called the Graafian 
follicle.
Taken together, follicular growth and development are characterized by proliferation of 
granulosa cells, differentiation of theca cells from the ovarian stroma, and deposition of a 
basement membrane separating the vascular theca from the avascular granulosa cell layer. As the 
follicular membrane expands within the limits o f the ovarian stroma, the surface area o f the 
follicle dramatically increases. For example, the bovine follicle increases approximately 360.000 
fold from the primordial to the preovulatory stage. In primates, the mature follicle is almost 400 
fold larger than the primordial follicle. Follicle development is accomplished in an extracellular 
environment that consists of collagen, laminin. and fibronectin. Thus, extensive tissue remodeling 
is required to accommodate the rapid cellular proliferation as follicles develop. Indeed, the 
composition o f follicular basement membrane changes during bovine follicle development 
(Rodgers et al.. 1998). In addition, modification o f the surrounding ovarian stroma is also 
necessary for the growing follicle to reach a place on the surface o f the ovary where the oocyte 
can be released at ovulation. Remodeling o f the ECM during angiogenesis also occurs within the
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theca layer. These structural reorganization events in the ovarian ECM are thought to be 
achieved at least in part, by the MMPs/TIMPs system.
MMPs appear to play a role in follicular development o f cattle. In the bovine ovary, MMPs 
constitute one family o f the most relevant genes that are associated with differentiated follicles 
bearing developmentally competent oocytes (Robert et al.. 2001). Both MMP-2 and MMP-9 
activities were detected in bovine follicular fluid (Khandoker et al.. 2001). In vitro studies on 
bovine follicles further indicate the expression of MMP-9 is related to follicle health, and thus can 
be used as a  marker to assess follicle development (McCaffery et al.. 2000). O f note, MMP-9 
expression in the bovine follicle is augmented by ascorbic acid (Thomas et al.. 2001). which has 
been postulated to be important for follicular health.
In developing rat follicles. MMP-2 and MMP-9 mRNAs are localized to the theca cells and 
the surrounding stroma (Liu et al.. 1998; Curry et al.. 2001). Consistent with its mRNA 
distribution. MMP-9 protein is restricted to theca and interstitial cells (Bagavandoss. 1998). 
However. MMP-2 immunoreactivity is observed in both theca-interstitial and granulosa cells, 
although the latter has a lower expression than the former (Bagavandoss. 1998). This discrepancy 
may be due to the inability (low sensitivity) o f in situ hybridization to detect the low copies of 
MMP-2 mRNA in granulosa cells. Although MMP-2 mRNA is expressed in theca-interstitial 
cells. MTI-MMP. the activator of pro-MMP-2. is detected in both granulosa cells and theca- 
interstitial cells (Liu et al.. 1998). Similar to MMP-2. the expression o f MTI-MMP is also up- 
regulated by gonadotropins during follicle development (Liu et al.. 1998). MMP-13 (collagenase- 
3) is also detected in theca-interstitial but not granulosa cells o f rat growing follicles, suggesting a 
potential role o f  this MMP in follicular development (Balbin et al., 1996). Indeed, significant 
increases in MMP-13. MMP-2. and MMP-9 mRNA, and the corresponding collagenolytic and 
gelatinolytic activities, are observed during folliculogenesis induced by gonadotropin (Cooke et 
al.. 1999). In the intact mouse follicle culture modeL MMP-2 activity is up-regulated by ascorbic 
acid (Murray et al.. 2001). suggesting that the promoting effects o f this vitamin on follicle
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integrity and survival may be mediated by regulating MMP activity. During gonadotropin-primed 
follicular development in rats. MMP-23 expression is switched from granulosa cells to theca- 
extema and the ovarian epithelium (Ohnishi et al., 2001). FSH, via the cAMP signal transduction 
pathway, reduced MMP-23 expression in granulosa cells, while the expression o f MMP-23 is 
increased in theca-interstitial cells regardless o f  the presence o f LH (Ohnishi et al.. 2001). This 
indicates that MMP-23 is not only involved in follicle development but is also regulated in a cell 
specific manner.
Besides MMPs. TIM P-1 mRNAs are also localized to theca and stroma during follicle 
development in the rat (Curry et al.. 2001). TIMP-1 protein is localized in the thecal cells of 
follicles, and blood vessels o f the ovary (Bagavandoss. 1998). The co-localization o f MMPs and 
TIMPs indicates that the tissue remodeling events during follicular development are strictly 
regulated.
Among species with long reproductive cycles. TIMP-1 is also detected in ovine (Smith and 
Moor. 1991; Smith et al.. 1993; Smith et al.. 1994a; Mclntush et al.. 1996). bovine (Smith et al.. 
1996). porcine (Smith et al.. 1994b; Driancourt et al.. 1998; Shores and Hunter. 2000). primate 
(Chaffin and StoufFer. 1999). and human (Curry et al.. 1988) follicles. TIMP-1 mRNA is 
increased in bovine (Smith et al.. 1996) and ovine (Smith et al.. 1994a) preovulatory follicles, 
while ovine TIMP-1 protein in the ovary' (Mclntush et al.. 1996) is only observed after the 
gonadotropin surge. As suggested in a Sertoli cell model. TIMP-1 expression may be stimulated 
by FSH via a cAMP. PKA-dependent pathway. Furthermore, the PKC pathway also mediates 
signals that up-regulate TIMP-1 production (Ulisse et al.. 1994).
TIMP-2 mRNA expression is observed in bovine (Smith et al., 1996), and ovine (Smith et 
al.. 1995) follicles. In the latter. TIMP-2 is primarily expressed in theca cells, but its expression 
was not affected by the gonadotropin surge (Smith et al.. 1995). However, after the gonadotropin 
surge, a  remarkable increase in TIMP-2 expression is induced in the bovine ovary (Smith et al., 
1996). TIMP-2 is also present in theca and granulosa cells, and follicular fluid o f large and small
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pig follicles (Shores and Hunter. 2000). TIMP-2 mRNA is expressed in the theca and stromal 
compartments during rat folliculogenesis (Curry et al.. 2001). Although TIMP-2 expression can 
be up-regulated by FSH via a cAMP. PKA-dependent pathway, it is resistant to stimulation 
through the PKC pathway (Ulisse et al.. 1994).
The localization o f TIMP-3 mRNA exhibits a different pattern from that for TIMP-1 and -2. 
Although TIMP-3 mRNA is detected in theca and stroma of developing rat follicles, its 
expression in granulosa cells is only observed in certain follicles, but not in the follicles that are 
adjacent to them (Curry et al.. 2001). In the mouse ovary. TIMP-3 mRNA is also expressed in the 
theca and granulosa cells o f small and large follicles (Inderdeo et al.. 1996). Similarly. TIMP-3 is 
observed in pig small and large follicles (Shores and Hunter. 2000). The study o f TIMP-1. -2. and 
-3 production in pig follicles shows that the expression o f these TIMPs is regulated by factors 
such as follicular size and the phase o f follicular development (Shores and Hunter. 2000).
Although TIMP-4 is abundantly expressed in ovarian tissue (Leco et al.. 1997). its 
localization in the follicular compartments has not been elucidated. Reverse zvmography 
demonstrates that this inhibitor may be present in equine follicular fluid (Riley et al.. 2001).
Because o f their specialized ovarian structure and ovulation pattern, the equine gonads are a 
good model to study the tissue remodeling events in follicle growth and development. Different 
from the ovaries o f other mammalian species, in which follicles can ovulate from any site on the 
ovarian surface, the follicles in equine ovaries migrate from the stroma to the ovulatory fossa, 
where ovulation occurs. Both MMP-2 and MMP-9 are present in equine follicular fluid. While 
MMP-2 is the predominant geiatinase. its level does not vary significantly during follicle 
development (Riley et al.. 2001). However. MMP-9 increases dramatically, when follicles grow' 
from < 10mm to 1 l-20mm in diameter. Both these gelatinases are localized to the granulosa, 
theca. and stromal cells. Furthermore, all four tissue inhibitors o f metalloproteinases (TIMPs 1-4) 
are also present in follicular fluid, but their levels do not change significantly during follicle 
development (Riley et al.. 2001). Similar to the localization of MMP-2 and MMP-9, all these
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TIMPs are immunolocalized to follicular granulosa and theca cells and the surrounding stromal 
cells. The co-localization of MMPs and TIMPs suggests that MMP activity is locally regulated 
during the tissue remodeling that occurs when follicles develop and migrate to the ovulation fossa 
in mares. Furthermore, accumulating evidence suggests that one o f the roles o f reiaxin during 
ovarian follicle development and ovulation is to regulate proteolytic enzyme activity. In an in 
vitro equine ovarian stromal cell (EOSC) culture sy stem, reiaxin increases both latent and active 
MMP-2. latent MMP-9. TIMP-1, and TIMP-2 (Song et al.. 1999). This suggests that reiaxin may 
contribute to equine follicle growth and migration, and facilitate ovulation by modulating the 
degradation o f ECM in ovarian stromal tissue. The growth factor. TGFp. also plays an important 
role, as it significantly stimulates the activity of MMP-2 and MMP-9 and TIMP-1 production by 
EOSC (Song et al.. 1999). The PKC signal transduction pathway may be involved in the 
stimulation o f MMP-2. MMP-9. TIMP-2. and TIMP-3. since PMA (phorbol 12-mvristate 13- 
acctate) increases the production of these enzymes and inhibitors (Song et al.. 1999).
Follicles also undergo atresia, a process that involves apoptosis. Abnormal proteolytic 
degradation o f the ECM may initiate an apoptotic signal or mediate the apoptosis process. In 
human ovary, low levels of MMP-1 in the apical wall o f the follicle are associated with atresia. 
The level of stromelysin-1 (MMP-3) is inversely related to follicle size (Bogusiewicz et al..
2000). In the mouse model, although stromelysin-3 (MMP-11) is coordinatelv expressed with 
apoptotic follicles, the stromeiysin-3-deficient mouse shows no difference in the apoptotic rates 
of follicles from the wild type (Haggiund et al.. 2001). Therefore, stromelysin-3 may not be 
sufficient for inducing or completing follicle atresia, but it may be involved in this process. In 
non-atretic follicles, interstitial collagenase activity is high in granulosa and thecal cells and low 
in follicular fluid. Atresia is associated with declining collagenase activity in both cell types and 
increasing activity in follicular fluid (Garcia et al.. 1997). GelaUnase activities are also correlated 
with follicular atresia. Specifically, active MMP-2 and pro-MMP-9 are present only in atretic 
follicular fluid (Khandoker et al., 2001).
- 3 3 -
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The physiological roles o f these metalloproteinases. therefore, may include their direct 
actions on ECM components for modulating the local extracellular milieu, and their indirect 
effects on cell proliferation by processing growth factors from their latent forms and/or modifying 
their receptors.
IV. MMPs/TIMPs in Ovulation
Although a variety of hypotheses has been proposed for the mechanism of ovulation, most of 
them, if not all. include a coordinated series o f proteolytic degradative events which result in the 
breakdown of the follicle wall. As early as about one century ago (1916). Schochet pointed out 
the importance of proteolytic enzymes in the process of ovulation by degrading the ECM at the 
apex of a Graafian follicle. Numerous proteolytic enzymes were thereafter identified and 
characterized during the ovulation process (Espey. 1974; Parr. 1975; Tsafriri. 1995).
Besides oocyte maturation, deterioration of the follicle wall and follicle apex leads to 
ovulation (Thibauit and Levasseur. 1988; Murdoch and McCormick. 1992). The apical wall o f the 
preovulatory follicle, from the innermost to the outermost side, is composed o f granulosa cells, 
basement membrane, theca interna, theca externa, tunica albuginea, a second basement 
membrane, and epithelium. During ovulation, which is initiated by a surge of the pituitary 
gonadotropin, luteinizing hormone (LH). all these layers o f ECM and connective tissues have to 
be compromised for follicle rupture and expulsion o f the oocyte. These events begin with 
alterations in the vasculature o f the follicle, which results in the formation of an avascular area 
known as the macula pellucida or stigma (Parr. 1975). Then, the tunica albuginea is the first place 
w here disintegration occurs, followed by the degradation o f ECM in the epithelium. As a result, 
fibroblasts and epithelial cells are no longer in contact, and ultimately this leads to the loss o f 
integrity of the whole surface epithelium. In some species such as mouse and rat, the outer layer 
o f basement membrane, which lies beneath the surface epithelium, undergoes edema, which then 
causes fragmentation o f the collagen matrix. The blood capillaries in the theca layer subsequently
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disintegrate and the blood seeps into the interstitium. As the time of ovulation approaches, the 
follicle expands and the number o f layers o f fibrils decreases over the apex, resulting in the 
deterioration o f the basal lamina localized between granulosa and theca layers (Martin and 
Miller-Walker. 1983). Collectively, follicle wall breaching and the loss o f apical integrity 
eventually lead to leakage o f follicular fluid and release o f the oocyte.
One of the major breakthroughs in the early studies of ovulation was accomplished with the 
demonstration that antral pressure does not increase prior to follicle rupture (Bronson et al.,
1979). This observation, therefore, shifted the research focus to the deterioration and weakening 
of the follicle wall around the stigma area, which appears to be a necessary prerequisite to the 
ovulatory process (Parr. 1975: Martin and Miller-Walker. 1983). The degradation o f the follicle 
wall is reflected by the changes in collagen content during follicle development, which increases 
with increasing follicle volume (Morales et al.. 1983). However, right before ovulation, the 
collagen content decreases dramatically (Martin and Miller-Walker. 1983: Morales et al.. 1983). 
All these matrix degradation events during ovulation may be a consequence o f the proteolytic 
action o f MMPs. For example, collagenase and gelatinase activities are associated with the apex 
of preovulatory follicles (Fukumoto et al.. 1981: Murdoch and McCormick. 1992: Curry and 
Osteen. 2001).
Collagenase was the first proteolytic enzyme identified in the ovulation process. 
Collagenolytic activity is first detected in the rabbit and sow Graafian follicles during ovulation 
(Espey and Rondell. 1968). Higher collagenolytic activity is localized in the follicular apex area 
than the basal wall o f the ovulatory follicles, suggesting degradation o f extracellular matrix 
proteins may dictate the site o f follicle rupture (Murdoch and McCormick. 1992). In the rat ovary, 
collagenase activity is correlated with the ovulatory process (Curry et al.. 1985: Palotie et al., 
1987: Woessner et al.. 1989: Hirsch et al., 1993). An ovulatory dose o f hCG increases interstitial 
collagenase (MMP-1) mRNA about twenty-five times in rat follicles, where it is predominantly 
localized in both granulosa cells o f preovulatory follicles and the residual ovarian tissues (Reich
- 3 5 -
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
et al.. 1991). A continuous increase o f  neutral coliagenase activity is observed in the follicular 
wall during the ovulatory process in humans (Yajima et al., 1980). Further investigation shows 
that granulosa cells are the major cellular source o f coliagenase. which is produced at maximal 
levels at ovulation and decreases abruptly thereafter (Fukumoto et al., 1981).
In the domestic fowl, coliagenase activity is detected in the ovarian follicle wall (Fujii et al.. 
1981). Although there are no significant changes o f coliagenase activity observed up to the point 
of ovulation (Tojo et al.. 1982). local administration of proteolytic enzymes induced the rupture 
of the ovarian follicle (Nakajo et al.. 1973). LH and progesterone increased the total activity' of 
neutral and acid proteases and coliagenase. which are primarily concentrated in the stigma region 
(Ogawa and Goto. 1984). Retrospectively, the coliagenase activity described at this stage is 
interstitial coliagenase.
During ovulation o f rabbit follicles. MMP-1 is expressed in theca intema. theca externa, 
interstitial cells and germinal epithelium. In addition. MMP-1 is also induced in the capillary' 
lumina around the apex of preovulatory follicles, and increases in granulosa and theca intema 
cells that are around the orifice o f the ruptured follicles (Tadakuma et al.. 1993).
The ovulatory process is regulated by multiple factors. Gonadotropin induces an increase in 
collagenolytic activity (Curry et al.. 1985; Reich et al.. 1985; Hirsch et al.. 1993). which is 
reflected, in part by the increase in interstitial coliagenase expression at the transcriptional level 
(Reich et al.. 1991). Coliagenase 3 (MMP-13) is also highly expressed in thecal cells/stroma of 
rat antral follicles (Baibin et al.. 1996). suggesting a  plausible role for it during ovulation. It is up- 
regulated by LH via a tyrosine kinase -dependent pathway during ovulation in rats (Komar et al.,
2001). Besides gonadotropins, a  number of paracrine factors have regulatory effects on 
coliagenase activity'. Relaxin stimulates the release o f coliagenase activities from rat granulosa 
cells (Too et al.. 1984). Prolactin, on the other hand, is unable to promote collagenolytic activities 
(Hirsch et al.. 1993). Indomethacin (an inhibitor o f cyclooxygenase) blocks the stimulatory 
effects o f hCG on coliagenase mRNA expression and collagenolytic activity (Reich et al., 1985;
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Reich et al.. 1991). In the ewe. indomethacin negates the stimulated collagenolysis in follicular 
tissue by gonadotropin (Murdoch et al., 1986), suggesting that prostaglandins are involved in 
enhancing coliagenase activity. Prostaglandins have been shown to be stimulatory for proteolytic 
enzyme activity during ovulation in rabbits (Miyazaki et al.. 1991). Furthermore, coliagenase is 
also up-regulated by TNFa. which accumulates in the oocyte-cumulus cell complex (Johnson et 
al.. 1999). implying that multiple ceil types are involved in the regulation o f coliagenase activity 
during ovulation. In non-human primates, progesterone is indispensable for the stimulatory 
effects o f gonadotropin on interstitial coliagenase expression (Chaffin and Stouffer. 1999). 
However, progesterone, prostaglandin E2. prostaglandin F^. and 17p-estradiol have no effect on 
coliagenase activity in the human follicle wall (Norstrom and Tjugum. 1986). but relaxin and 
oxytocin increase coliagenase activity (Norstrom and Tjugum. 1986). Notably, oxytocin 
decreases collagen synthesis (Tjugum et al.. 1986). Collectively, these results suggest that the 
regulation o f coliagenase activity is diverse and may be species dependent.
Type IV collagenolytic activity' was first detected in human follicular fluid (Puistola et al.. 
1986). This activity' increases as ovulation approaches, and decreases after follicle rupture 
(Puistola et al.. 1986). In an in vitro culture model o f rat follicles, type IV coliagenase activity' is 
stimulated by gonadotropin, showing a similar pattern o f changes as type I collagenolytic activity 
(Palotie et al.. 1987). Retrospectively, these type IV collagenolytic activities are attributed to 
gelatinases (A and B). as confirmed by gelatin zymography (Curry et al.. 1992). The efficient 
degradation o f the major component of the basement membrane, collagen type IV. by these 
activities may be pivotal for ovulation. Furthermore, type IV collagenolytic activity is also 
present within the follicular fluid and increases toward ovulation (Puistola et al.. 1986). While 
interstitial coliagenase increases at 3-6 hours after hCG administration (Reich et al., 1985; Reich 
et al.. 1991). type IV coliagenase expression, on the other hand, peaks at 9 hours after hCG 
treatment (Reich et al.. 1991; Curry et al.. 1992). Increased expression o f MMP-9 in the late stage
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of the ovulatory process is also observed in macaque (Chaffin and Stouffer, 1999). Furthermore, 
interstitial coliagenase is expressed in both granulosa and residual cells, while type IV 
coliagenase is restricted to residual (thecal-interstitial) cells (Reich et al., 1991). The 
aforementioned type IV coliagenase activity is predominantly due to gelatinase B (MMP-9), 
which is highly expressed in the theca-interstitial compartment (Hurwitz et al., 1993; Curry et al.,
2001). Taken together, these observations indicate that interstitial coliagenase is expressed at the 
early stages o f  ovulation to loosen the connective tissues between the two basement membranes, 
while residual cells produce gelatinase B (type IV coliagenase activity) at the final stages of 
ovulation to tear the major boundaries, the two layers o f basal lamina, for oocyte extrusion. The 
abrupt decrease o f this enzyme after the rupture of follicles further suggests its unique role during 
ovulation (Puistola et al.. 1986). Other factors, such as interleukin-1 (IL-1), stimulate gelatinase B 
production by theca-interstitial cells (Hurwitz et al.. 1993). However, transforming growth factor- 
beta 1 (TGF-pi) attenuates the stimulatory action o f IL-1 (Hurwitz et al.. 1993), suggestinga 
complex intraovarian regulatory loop for fine-tuning this MMP activity.
The importance o f gelatinase A in the ovulatory' process was recognized in the ewe. when 
immunization with the N-terminal peptide o f inhibin a43 (aN) reduced the fertility. Specifically, 
latent and active MMP-2 levels increase as ovulation approaches (Russell et al.. 1995: Gottsch et 
al.. 2000). while immunization with aN  significantly reduces gelatinase A activity (Russell et al..
1995). The increase in MMP-2 activity at ovulation, however, is abolished by administration o f 
TNFa antiserum (Gottsch et al.. 2000). When combined with the in vitro data that shows the 
stimulatory effects o f TN Fa on MMP-2 activity (Gottsch et al.. 2000), these results indicate that 
MMP-2. which is regulated by inhibin and TNFa. is important for the tissue remodeling process 
during ovulation. In rats, relaxin stimulates the secretion o f MMP-2 from theca-interstitial cells 
but not granulosa cells. This autocrine or paracrine action o f relaxin on MMP-2 activity may 
contribute to its ability to facilitate ovulation (Hwang et al., 1996). Furthermore, MMP-2 and its
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cell surface activator, MT1-MMP. are up-regulated in theca-interstitial cells o f large preovulatory 
follicles after hCG stimulation (Liu et al.. 1998). This indicates that the MT1-MMP/MMP-2 
activation system may be associated with the tissue destruction events during ovulation. In the 
macaque. MMP-2 expression is also up-regulated via a progesterone-independent pathway during 
the ovulatory process (Chaffin and Stouffer, 1999).
In addition to the two major MMP subgroups- collagenases and gelatinases, other MMPs 
may also participate in the tissue destruction process during ovulation. For example, gonadotropin 
induces increased expression o f matrilvsin in the macaque ovary (Chaffin and Stouffer, 1999). 
Although stromelvsin-3 (MMP-11) is constitutively expressed during ovulation, maximal levels 
of MMP-19 in granulosa and theca-interstitial cells of large preovulatory’ and ovulating follicles 
are induced by hCG in the mouse ovary’ (Hagglund et al.. 1999). In the porcine ovary, bradykinin 
up-regulates expression o f  MMP-3. MMP-20. and MT1-MMP in granulosa cells (Kimura et al..
2001). ADAMTS-I (a disintegrin and metalloproteinase with thrombospondin-like motifs), which 
is a novel MMP-related proteolytic enzyme and which appears to be the regulatory target of 
progesterone, is induced in granulosa cells o f mouse preovulatory follicles by LH (Espey et al.. 
2000; R obkeretal . 2000).
Besides MMPs. the expression patterns o f metalloproteinase inhibitors are also altered. A 
metalloproteinase inhibitor activity was first identified in human follicular fluid (Curry' et al.. 
1988). Based on the characterized biochemical features, this metalloproteinase inhibitor activity 
is attributed to TIMP-1. Additionally, a-macroglobulins (a  1-macroglobulin. a2-macroglobulin. 
and a l  inhibitor3). a  group o f  plasma proteins with broad protease inhibitor activity, are also 
present in the follicular fluid of human and rat follicles (Curry et al., 1989; Curry et al., 1990: Zhu 
and Woessner, 1991). In the rat ovary, the activities o f these a-macroglobulins increase as 
ovulation approaches (Zhu and Woessner, 1991). The absence o f a2-macroglobulin mRNA in 
granulosa cells suggests that this serum-derived inhibitor is transported by the blood stream from
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other sources in the body (Curry et al.. 1990), while detection o f  TIMP-1 mRNA in granulosa 
cells indicates that this inhibitor may serve as a  local regulator o f proteolysis during ovulation 
(Curry et al., 1990; Hagglund et al., 1999; Curry et al., 2001). In addition to granulosa cells, 
TIM P-l is also localized to theca-interstitial cells in the mouse ovary (Hagglund et al., 1999). 
suggesting that there is probably a species difference in the tissue distribution o f this endogenous 
MMP inhibitor.
Similar to MMPs. the TIMPs are also regulated. TIMP-1 expression is dramatically 
increased in rat (Curry et al., 1989: Mann et al.. 1991) and mouse (Hagglund et al., 1999) ovaries 
after hCG administration. In rat granulosa cells, a  LH-cAMP-dependent protein kinase-A 
pathway or a cAMP-independent protein kinase-C pathway augments TIMP-1 expression (Mann 
et al.. 1991: Mann et al.. 1993), while neither prostaglandin nor estrogen affects the basal or LH- 
augmented TIMP-1 expression (Reich et al.. 1991: Mann et al.. 1993). In addition, calcium is also 
involved in modulating TIMP-1 expression, since the ionophore. A23187. decreases granulosa 
cell-derived TIM P-l activity (Cannon et al.. 1997). Although aN  is involved in the regulation of 
MMP-2 during ovulation (Russell et al.. 1995). the paracrine effects of this factor has not been 
determined for TIMP-1 (D haretal.. 1998). In non-human primates, the stimulatory'effects on 
TIMP-1 and TIMP-2 expression by gonadotropin are dependent on progesterone (Chaffin and 
Stouffer. 1999).
Proteolytic enzymes other than members o f the MMP family, such as plasminogen and 
plasminogen activator, are also found in the follicle wall (Beers, 1975: Shimada et al., 1983: 
Hsueh et al.. 1988: Liu et al.. 1991: Chun et al.. 1992: Hagglund et al., 1996: Liu, 1999).
Inhibitors o f plasminogen and plasmin significantly inhibit ovulation efficiency (Yoshimura and 
Wallach. 1987). Notably, the fertility in mice with a  deficiency o f either tPA or uPA is normal, 
while ovulation is reduced in mice lacking both PAs (Leonardsson et al., 1995). The plasmin 
inhibitor is effective only when it is administrated at the early stage (Woessner et al., 1989), while 
full inhibitory capability o f  the coliagenase inhibitor on ovulation is observed when it is
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administrated as late as 7 hours after LH (Butler et al., 1991). These findings suggest that plasmin 
may serve as the activator for collagenases during ovulation.
All in all. ovulation is a complex physiological process involving a number o f proteolytic 
enzymes and their corresponding inhibitors. MMPs and TIMPs undoubtedly play an important 
role in the proteolytic events during ovulation. Ovarian paracrine and autocrine factors, as well as 
gonadotropins, constitute a complex loop for regulating MMP activity. Further investigations on 
the temporal and spatial expression patterns, and regulatory mechanisms of proteolytic enzymes 
and endogenous inhibitors, are necessary for advancing our understanding of this exquisitely 
controlled tissue remodeling process.
V. MMPs/TIMPs in CL Formation. Maintenance, and Regression
The corpus luteum (CL) is a transient endocrine gland that secretes progesterone to establish 
and maintain pregnancy (Niswender and N ett 1994). The CL also plays a central role in survival 
o f the embryo, regulation o f cyclicity, and controlling ovulation and length o f the reproductive 
cycle. The CL develops from the remnants o f the follicle following ovulation (Niswender and 
Nett. 1994). Dramatic structural and functional changes are associated with the development, 
maintenance and regression o f the CL (Nisw ender and Nett. 1994). At the time of ovulation, the 
basement membrane breaks down, and the follicle wall folds toward the cavity o f the ruptured 
follicle (Pederson. 1951). During this process, theca interna cells, fibroblasts and endothelial cells 
undergo mitosis, and migrate into the central region of the postovulatory follicle, contributing 
towards the formation o f the CL (Parry et al.. 1980: Cavender and Murdoch, 1988; O'Shea et al.. 
1989: Zheng et al.. 1994). In addition, disruption o f the basement membrane facilitates invasion 
o f capillary vessels from the theca intema into the granulosa layer (Cavender and Murdoch,
1988). The latter, therefore, undergoes a striking transition from an avascular to a vascular 
compartment (Pederson, 1951: Ford et al., 1982: Wiltbank et al., 1988). This neovascularization 
provides a  blood supply for the differentiated theca-derived small and granulosa-derived large
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luteal cells (Dharmarajan et al., 1985: Wiltbank et al., 1988: Wiltbank et al., 1989), and is 
associated with increased progestin production by the CL (Smith et al., 1994c). During the mid­
cycle phase o f  luteal development, neovascularization is slowed down and the integrity o f the CL 
is maintained to provide a relatively steady environment for continued steroidogenesis (Jabionka- 
Shariff et al.. 1993). Regression of the CL at the end o f the cycle is also an example of a 
remarkable tissue reorganization process (Nett et al.. 1976: Niswender and Nett, 1994: Murdoch. 
1996).
These remodeling events in the CL require the participation o f MMPs and TIMPs. TIMP-1 is 
one o f the first members in this protein family identified to be closely associated with luteal 
physiology. In mouse adult tissues, the highest level o f TIMP-1 was detected in the ovary', where 
the expression is predominantly restricted to the CL (Nomura et al.. 1989: Edwards et al.. 1992). 
indicating a significant role o f this MMP inhibitor in luteal physiology. HM P-1 immunoreactivc 
staining is detected in rat (Bagavandoss. 1998). porcine (Tanaka et al.. 1992), and ovine 
(Mclntush and Smith. 1998) luteal capillaries. In addition, abundant expression of this inhibitor is 
predominantly localized in large luteal cells o f species with relatively long luteal phases, such as 
sheep (Mclntush and Smith. 1998). and pig (Tanaka et al.. 1992). More specifically. TIMP-1 is 
packed in the secretory' granules of large luteal cells (Mclntush et al.. 1996). While TIMP-1 
mRNA does not vary in the ovine CL over the estrous cycle (Smith et al.. 1994a), its levels are 
maximal in the early stage and decline with age o f bovine (Freudenstein et al.. 1990: Smith et al..
1996) and porcine (Pitzel et al.. 2000) CL. Although TIMP-1 is most abundantly expressed in the 
CL (Tanaka et al.. 1992) and thus the major secreted protein product o f the sheep ovary (Smith 
and Moor. 1991: Smith et al.. 1993). circulating concentrations o f  this protein remain at a 
consistent level over the estrous cycle (Mclntush et al.. 1997). In the bovine CL, immunoreactive 
TIMP-l-like protein is unchanged over the estrous cycle (Goldberg et al.. 1996). The expression 
o f TIMP-1 is also hormonally regulated (O'Sullivan et al., 1997). Triiodothyronine (T3) and
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follicle stimulating hormone (FSH), alone and in combination, stimulate TIMP-1 production in 
human luteinized granulosa cells (Goldman et al., 1997).
The 5 ' non-coding region o f bovine TIMP-1 is homologous to the protein coding region of 
the bovine StAR gene (Hartung et al., 1995), suggesting a  possible role o f TIMP-1 in steroid 
production. Indeed. TIMP-1 facilitates steroidogenesis in Leydig, granulosa, and theca cells in 
vitro (Boujrad et al.. 1995; Nothnick et al.. 1997; Shores and Hunter, 2000). In addition, TIMP-1 
deficient mice have lower serum testosterone concentration in males (Nothnick et al., 1998), but 
normal serum 17p-estradiol and progesterone levels in females (Nothnick et al., 1997). 
Collectively, these data suggest that TIMP-1 may act as a co-regulator o f steroidogenesis. 
However, the underlying mechanism o f TIMP-1 in steroidogenesis and whether it is involved in 
luteal steroid production require further investigation.
There are two species o f TIMP-2 mRNA; one migrates at 3.5 kb. while the other migrates at 
Ikb. Both mRNA species are detected in rat (Nothnick et al.. 1995; Simpson et al.. 2001) CL. 
While a single Ikb species is detected in ovine CL (Smith et al.. 1995), the 3.5 kb species is the 
only TIMP-2 mRNA in human CL (Duncan et al.. 1998). In the bovine CL. TIMP-2 transcripts 
and immunoreactive TIMP-2-like protein increase over the estrous cycle (Smith et al., 1996; 
Goldberg et al.. 1996). while ovine luteal TIMP-2 mRNA expression in the early luteal phase is 
greater than the mid- and late stages (Smith et al.. 1995). In contrast TIMP-2 mRNA expression 
does not vary in the human CL during the menstrual cycle (Duncan et al., 1998). It has been 
shown that the large luteal cells o f ovine CL are the cellular sources o f TIMP-2 (Smith et al., 
1995). However. TIMP-2 is localized to the theca-lutein cells and the surrounding connective 
tissue stroma in the human CL (Duncan et al., 1998). These data suggest that species differences 
may exist regarding the temporal and spatial expression patterns o f TIMP-2.
The gelatinases are detected in the conditioned medium o f luteal cells from the early bovine 
CL (Tsang et al., 1995) and luteinized bovine granulosa cells (Zhao and Luck, 1996). The early 
stage rat CL possesses higher levels o f  coliagenase and gelatinase activities than any other stage
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(Nothnick et al.. 1996). MMPs play important roles in CL development and function. During CL 
formation, ewes immunized with the N-terminal peptide o f inhibin a43-subunit (aN ) manifested 
incomplete infolding o f  surrounding tissues and theca/vessel invaginations. The reduced fertility 
that resulted was attributed to decreased levels o f MMP-2 (Russell et al.. 1995). Furthermore, 
immunization with MMP-2 antibody caused incomplete CL formation in ewes (Gottsch et al..
2001). In human (luteinized) granulosa cells, levels o f gelatinases are reduced while there is a 
concurrent increase in TIMP-l production following exposure to hCG (Aston et al.. 1996). 
suggesting one o f the actions o f gonadotropin (LH) in the CL is possibly to stabilize ECM 
remodeling at the early stages of CL development.
CL maintenance also includes active tissue remodeling events. MMP-2 and MMP-9 
activities are present in the bovine CL throughout the estrous cycle (Goldberg et al.. 1996).
Higher levels o f MMP-2. MMP-9. and MMP-1 gene expression are observed in the mid stage 
porcine CL than in the early stage (Pitzel et al.. 2000). In the rat. MT1-MMP is constitutivelv 
expressed in CL throughout pseudopregnancy (Liu et al.. 1999). While MMP-2 is mainly 
expressed during luteal development. MMP-13 (coliagenase 3) is only expressed in the regressing 
CL (Liu et al.. 1999). The MMP-2 protein is localized in endothelial and large luteal cells of the 
developing rat CL (Bagavandoss. 1998). Interestingly. MMP-9 is localized on the plasma 
membrane o f luteal and interstitial cells in rat CL (Bagavandoss. 1998). indicating that this 
enzyme may perform pericellular proteolysis through its cell surface receptor, such as CD44 (Yu 
and Stamenkovic. 1999). Besides MMPs. other proteolytic enzymes, such as proteoglycanase, are 
also associated with luteal maintenance (Nothnick et al.. 1996).
Extensive tissue deterioration occurs during CL regression (Niswender and Nett, 1994). 
During structural regression induced by PRL in the hypophysectomized ra t  both latent and 
active forms o f MMP-2 are increased (Endo et al.. 1993). Similarly, enhanced MMP-2 activity 
and mRNA expression are also observed in GnRH agonist (GnRHa) (Goto et al., 1999) and GH 
(Kiya et al., 1999) induced structural regression. During rat luteal regression induced by
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cloprostenol (a PGF:a analog), MMP-13 is induced only after progesterone levels decreases (Liu 
et al.. 1999), indicating that functional regression may initiate physiological signal(s) to bring 
about MMP expression, which are involved in structural regression. Indeed, the rise in MMP-2 
activity’ is coincident with the nadir in progesterone during the early onset o f luteolysis in ewes 
(Towle et al.. 2002). In the human CL. an increase in MMP-2 activity may be associated with 
luteolysis (Duncan et al.. 1998), since MMP-2 expression is decreased during luteal rescue 
(Duncan et al.. 1998) or following treatment with hCG in luteinized human granulosa cells 
(Stamouli et al.. 1996). In contrast. MMP-1 (coliagenase 1) expression is not changed during 
luteal rescue (Duncan et al.. 1998). During luteal regression o f the pseudopregnant rat 
coliagenase mRNA levels are increased (Nothnick et al.. 1996). Recently, this coliagenase was 
most likely determined to be collagenase-3 (Liu et al.. 1999).
TIMP-l expression is decreased during PGF;a-induced luteal regression in the cow (Juengel 
et al.. 1994) and the ewe (Towle et al.. 2002). Interestingly, in the ewe. this occurs before the 
decline o f progesterone and the rise in MMP-2 (Towle et al.. 2002). During porcine luteal 
regression induced by PGF:a. the serum concentration o f TIMP-1 is also significantly decreased 
(Mclntush et al.. 1997). A significant fall in TIMP-l expression is also observed in marmoset CL 
during PGF:a and GnRHa induced luteolysis (Duncan et al.. 1996a). In these species, the reduced 
level o f TIMP-1 may result in enhanced MMP activity, which favors ECM degradation during 
luteal regression. However, in the ra t  TIMP-1 levels are increased during luteal regression (Liu et 
al.. 1999). Furthermore, during rescue o f the human CL, TIMP-l and TIMP-2 expression do not 
vary (Duncan et al.. 1996b: Duncan et al., 1998). Therefore, there may be species differences 
regarding the expression o f TIMP-1 during luteal regression.
VI. MMPs/TIMPs in Ovarian Angiogenesis
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Follicle development is accompanied by blood vessel recruitment (Cavender and Murdoch. 
1988; Fraser and Lunn, 2000; Mattioli et al., 2001; WulfFet al., 2001). The rapid and 
hypertrophic growth o f the CL, which requires an abundant supply o f oxygen and nutrients, 
depends on concomitant vascular growth or angiogenesis (Reynolds et al., 2000). Angiogenesis. 
the formation o f new capillaries from preexisting vessels, is critical for follicle development and 
CL formation. Angiogenesis is exquisitely orchestrated by the cell-cell and cell-matrix 
interactions in the capillary. The process o f angiogenesis can be divided into the following steps:
(1) production o f angiogenic factors from the demand tissue; (2) spatiotemporal regulation of 
endothelial cell gene expression by these angiogenic factors; (3) fragmentation o f existing 
capillary basement membrane; (4) migration o f  endothelial cells; (5) proliferation o f  endothelial 
cells: and (6) recruitment o f pericytes and formation o f capillary lumen (Moses, 1997; Klagsbrun 
and Moses. 1999).
MMPs are involved in various steps o f the angiogenic process. MMP-deficient mice 
demonstrate delayed or reduced angiogenic events during normal development and tumor 
progression (Itoh et al.. 1998; Vu et al.. 1998). Furthermore, both endogenous and synthetic MMP 
inhibitors block angiogenesis in vivo and in vitro (Knauper et al.. 1996b; Hiraoka et al.. 1998). 
Thus, it seems likely that MMPs also play central roles in ovarian angiogenesis.
The interest in ovarian angiogenesis originates in the finding that this organ is a rich source 
o f angiogenic factors (Gospodarowicz and Thakral. 1978; Frederick et al.. 1984; Makris et al.. 
1984). Follicular fluid initiates angiogenesis (Frederick et al., 1984; Frederick et al., 1985), 
through its stimulatory effects, in part on endothelial cell proliferation (Rose and Koos, 1988). In 
addition, both intact follicles and dispersed granulosa cells produce a vascular chemoattractic 
factor (Rone et al.. 1993). Intense expression o f vascular endothelial growth factor (VEGF) 
mRNA and protein is confined to granulosa and theca cells at the late stage o f follicle 
development consistent with the establishment o f a  vasculature around the follicle wall at this 
time (Ravindranath et al.. 1992; Kamat et al., 1995). The importance o f  VEGF in follicle
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development is further established in the human ovary, where it is only expressed in healthy 
follicles, but not atretic ones (Gordon et al., 1996; Yamamoto et al., 1997). Furthermore, 
inhibition o f ovarian angiogenesis by administration o f a  VEGF antibody in the late follicular 
phase o f rhesus monkeys delays follicle development (Zimmermann et al., 2001). The expression 
of angiogenin, another potent angiogenic factor, is also closely correlated to follicle development 
(Lee et al.. 1999). With the exception that TIMP-1 is localized in blood vessels surrounding 
developing follicles (Bagavandoss. 1998). little is known about the expression and localization o f 
MMPs and TIMPs in capillaries around follicles. As in the case o f tumor angiogenesis, however, 
MMPs and TIMPs produced by theca and interstitial cells may facilitate blood vessel recruitment 
during follicle development.
CL development is associated with extensive angiogenesis (Basset 1943: Meyer and 
McGeachic. 1988: Tsukada et al.. 1996). Right before ovulation, the basement membrane that 
separates the granulosa and theca layers is fragmented. At the same time, capillary basement 
membrane in the theca intema compartment is also broken down (Matsushima et al.. 1996: 
Tsukada et al.. 1996). Immediately following ovulation, endothelial cells migrate into the 
previously avascular granulosa layer to form new blood vessel sprouts. Accompanying this 
process, there are a series o f changes in the microvascular extracellular matrix, including 
fibronectin. collagen type IV. and laminin (Matsushima et al.. 1996: Amselgruber et al., 1999). 
However, there are contradictory reports regarding whether endothelial cells or pericytes lead the 
outgrowth o f the newly formed vessels (Matsushima et al.. 1996: Redmer and Reynolds. 1996: 
Amselgruber et al.. 1999: Reynolds et al.. 2000). This discrepancy may be due to technical limits 
o f the research methods applied in the studies. Pericytes play important roles during capillary 
formation and vasculature survival (Nehls et al.. 1992: Hirschi and D'Amore, 1996). Further 
investigation on the cellular angiogenic events during CL formation may provide valuable 
information regarding the interactions between endothelial cells and pericytes.
- 4 7 -
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
The luteal angiogenic process is so intense that endothelial cells make up 85% of the 
proliferative cell population during CL development (Reynolds et al.. 1994). By mid cycle, 
endothelial cells are the most abundant cell type in the bovine CL, and constitute about 50% of 
total number o f  cells (Lei et al.. 1991; Zheng et al., 1993; Zheng et al., 1994). At this stage, the 
CL is so vascularized that the majority of steroidogenic ceils are in contact with one or more 
capillaries, and the blood flow in this gland is among the greatest of any tissue in the body 
(Reynolds et al.. 1992; Redmer and Reynolds. 1996).
Consistent with this rapid development of the vasculature, various angiogenic factors are 
identified in the CL. including FGF (fibroblast growth factor), NGF (nerve growth factor), EGF 
(epidermal growth factor). IGF (insulin-like growth factor). TGF (transforming growth factor). 
VEGF (vascular endothelial growth factor), and angiopoeitins (Gospodarowicz et al.. 1977a; 
Gospodarowicz et al.. 1977b; Gospodarowicz and Thakral. 1978; Gospodarowicz et al.. 1985; 
Phillips et al.. 1990; Reynolds et al.. 1992; Kamat et al.. 1995; Redmer and Reynolds. 1996; 
Laitinen et al.. 1997; Abulafia and Sherer. 2000). Among these factors, heparin-binding factors, 
such as FGFs and VEGFs. have been postulated to be key regulators (Redmer and Reynolds.
1996: Reynolds et al.. 2000). VEGF is expressed in the primate and human CL from early to late 
stages, but is absent in regressing tissues (Ravindranath et al.. 1992; Gordon et al., 1996). In 
addition, total angiogenic activity is present in the bovine CL throughout the estrous cycle, but 
there is a slight increase w ith age (Redmer et al.. 1988; Reynolds et al.. 2000). Therefore, it may 
not be appropriate to view the mid-stage CL as non-angiogenic (Goede et al., 1998). Indeed, in 
the human CL. although the total volume of luteal cells decreases in the late stage, the vascular 
volume progressively grows until the late regressing stage (Gaytan et al., 1999). This is consistent 
with the observation in the bovine CL. where blood vessel regression lasts several weeks after 
luteolysis (Augustin et al.. 1995). It has been postulated that the vasculature in the early stages of 
luteolysis may serve as a  route for degradation products destined for breakdown and excretion 
(Redmer et al., 1988). Besides the endometrium, the CL also exhibits blood vessel regression.
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Endothelial cell detachment and vessel occlusion are two major phenomena during luteal blood 
vessel regression (Modlich et al.. 1996). These phenotypic changes o f luteal endothelial cells may 
be mainly related to changes in their cell surface adhesion molecules (Augustin et al.. 1995).
MMPs and TIMPs may participate in the regulation of the luteal angiogenic process. In the 
rat (Bagavandoss. 1998) and sheep (Mclntush et al.. 1996). TIMP-1 is localized in luteal 
capillaries, suggesting that this endogenous MMP inhibitor may participate in maintaining the 
integrity o f the capillary. Administration o f a MMP-2 antibody in ewe results in abnormal luteal 
vasculature and incomplete CL formation (Gottsch et al.. 2001). implicating the critical role of 
this enzyme in luteal angiogenesis.
Ovarian angiogenesis shares similarities with tumor angiogenesis. For example, in both 
processes, angiogenesis is view'ed as a response to nutrient deficiency, and the same regulators 
and angiogenic factors, such as hypoxia-inducible factor 1 (HIF-1) and VEGF. are involved 
(Waleh et al.. 1995; Necman et al.. 1997). Therefore, elucidation o f the molecular mechanisms of 
ovarian angiogenesis and the normal capillary degeneration process during luteolysis. especially 
those that involve MMPs and TIMPs. may provide insights toward a better understanding of 
tumor angiogenesis.
VII. Perspectives
Ovarian physiological events, such as follicle development, ovulation, corpus Iuteum 
development and angiogenesis. require the participation o f proteolytic enzymes and their 
endogenous inhibitors, such as MMPs and TIMPs. respectively, to orchestrate the associated 
dynamic tissue remodeling that occurs By modify ing the extracellular milieu. MMPs and TIMPs 
modulate the cellular or biochemical properties o f cells, facilitating proliferation, growth, or 
differentiation. Beyond this. MMPs also affect other physiological events by liberating growth 
factors and cytokines from their biologically inactive forms, or modifying the receptors for 
growth factors or cytokines. In addition. TIMPs may directly modulate cellular behaviors, such as
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steroidogenesis and proliferation. However, a great deal o f work remains before the physiological 
functions of MMPs and TIMPs in the reproductive system are fully elucidated. From the above, it 
is clear that the ovary is an excellent research model for studying the roles o f MMPs and TIMPs 
during normal tissue remodeling and angiogenesis. The information obtained will perhaps prove 
valuable in designing therapeutic strategies for physiological processes associated with infertility 
or for pathological conditions, such as cancer, retinopathies, and rheumatoid arthritis.
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Table 1-1 The MMP family
MMP
number
Trivial name Other names EC
number
Subfamilies
MMP-l Coliagenase 1 Interstitial coliagenase 3.4.24.7 Collagenases
MMP-2 Gelatinase A 72 kDa gelatinase 
type IV coliagenase
3.4.24.24 Gelatinases
MMP-3 Stromelvsin-1 Transin. proteoglycanase 3.4.24.17 Stromelvsins
MMP-4* Procollagen peptidase =MMP-3 -
MMP-5* ^-coliagenase -MM P-2 -
MMP-6* Acid metalloproteinase =MMP-3 -
MMP-7 Matrilvsin Pump-1 3.4.24.23 Matrilvsins
MMP-8 Collagenase-2 Neutrophil coliagenase 3.4.24.34
MMP-9 Gelatinase B 92 kDa gelatinase 
type IV coliagenase
3.4.24.35 Gelatinases
M M P-10 Stromelvsin-2 Transin 2 3.4.24.22 Stromelvsins
M MP-11 Stromelvsin-3 Furin motif Others
M M P-12 Macrophage elastase Metalloelastase 3.4.24.65 Others
MMP-13 Collagenase-3 Rodent interstitial 
coliagenase
Collagenases
MMP-14 Membrane-type I 
metalloproteinase
MT1-MMP. MT-MMP1 MT-MMPs
MMP-15 Membrane-ripe 2 
metalloproteinase
MT2-MMP. MT-MMP2 MT-MMPs
M M P-16 Membrane-ripe 3 
metalloproteinase
MT3-MMP. MT-MMP3 MT-MMPs
MMP-17 Membrane-ripe 4 
metalloproteinase
MT4-MMP. M I -MMP4 MT-MMPs
MMP-18 Coilagenase-4 Xenopus coliagenase Collagenases
M M P-19 No trivial name RASI-1. Stromelvsin-4 Others
MMP-20 Enameivsin Others
MMP-21 XMMP Others
MMP-22 CMMP Chicken metalloproteinase Others












MMP-26 Matrilvsin-2 Endometase Others




Note: I . Asterisks denote names that are not longer used.
2. Adapted from Stemlicht and Werb (2001) Annu Rev Cell Dev Biol 17:463.
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Table 1-2 Biochemical and molecular features of MMPs






L A Human Mouse
Collagenases
Coliagenase-1 MMP-1 52 42 Ilq22-q23 B
Collagenase-2 MMP-8 85 64 Uq21-q22 B
Collagenase-3 MMP-13 52 42 llq22.3 9(A1-A2) B
Collagenase-4 MMP-18 53 42 B
Gelatinases Gelatinase A MMP-2 72 66 16q 13 8(42.9) C
Gelatinase B MMP-9 92 84 20ql 1.2-q 13.1 2(H1-H2) D
Stromelvsins Stromelvsin-1 MMP-3 57 45 1 lq23 9(1.0) B
Stromelvsin-2 MMP-10 54 44 Ilq22.3-q23 B
MT-MMPs
MT-MMP1 MMP-14 66 54 14q 11-q 12 14(12.5) F
MT-MMP2 MMP-15 72 60 16ql3-q21 8(45.5) F
MT-MMP3 MMP-16 64 53 8q21 4(3.6) F
MT-MMP4 MMP-17 57 53 12q24.3 5(1.0) G
MT-MMP5 MMP-24 73 62 20q 11,2-q 12 2(1.0) F
MT-MMP6 MMP-25 63 62 I6p 13.3 G
Matrilysins
1
Matrilvsin-1 MMP-7 28 19 Ilq21-q22 9(1.0) A
Matrilvsin-2 MMP-26 29 19 l lpl5 A
Other MMPs
Stromelvsin-3 MMP-11 64 46 22q 11.2 10(40.9) E
Metalloelastase MMP-12 54 22 1 Iq22.2-q22.3 9(1.0) B
RASI-1 MMP-19 54 45 12q 14 10(71.0) B
Enamelvsin MMP-20 54 22 Uq22.3 9(1.0) B
XMMP MMP-21 70 53 H
CMMP MMP-22 51 43 1 lq24 B
CA-MMP MMP-23 44 31 lp36.3 1
MMP-27 B
Epilysin MMP-28 59 45 17ql 1.2 E
D/O = domain organization. Lettters denote arrangement of domains described in Figure 1-1.
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| |  Furin-like recognition site 
Hemopexin-like domain |  Fibronectin type II-like insert
Transmembrane domain [ ]  Collagen type V-like insert
Glycophosphatidyl inositol-anchoring domain Cytoplasmic tail
Cysteine/proline rich IL-1 receptor like sequence ^  Hinge region 
|  Vitronectin-like sequence Note: Letters (A-I) denote domain organization
111
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Table 1-3 ECM and non-ECM substrates of MMPs
MMP





Collagen I, II, III. VII. VIII. 




aggrecan cartilage link 
protein, myelin basic 
protein, tenascin decorin
MCP-1, MCP-3, MCP-4, 




IGF-BP-2, IGF-BP-3, a l -  















Collagen I. II. III. VI. IX. 
X. XIV; gelatin I. 
fibronectin. vitronectin, 
aggrecan. osteonectin
MCP-3. SDF. Pro-TNFa Hormones
Pro-MMP-13. Pro-MMP-9 Enzvmes
a  1 -antichymotrypsin. 
o2-macroglobulin
Inhibitors




Collagen I. III. IV. V. VII. 




cartilage link protein, 




Pro-TGFpi. 2; Pro-TNFa. 
Pro-ILip. Big endothelin- 














Collagen IV. V. XL XIV; 
gelatin 1. decorin. elastin. 
fibrillin, laminin. 
vitronectin, aggrecan. 
cartilage link protein, 
myelin basic protein, 
osteonectin.
Pro-IL-8. SDF, GROa. 
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Stromelvsins
MMP-3
Collagen III, IV. V. VII. 





cartilage link protein, 
myelin basic protein, 
osteonectin, tenascin
MCP-1, MCP-2, MCP-3, 















Collagen III. IV. V; gelatin 
I. elastin. fibronectin. 









Collagen types I. II. Ill: 
gelatin, fibronectin. 
vitronectin, aggrecan
MCP-3, SDF. Pro-TNFa Hormones












Collagen type III. 
fibronectin
Pro-TNFa Hormones
Cell-surface bound tTG CAM
i
i Pro-MMP-2 Enzvmes














a  1-proteinase inhibitor Inhibitors
Matriiysins MMP-7





cartilage link protein, 
myelin basic protein, 
osteonectin, tenascin
Pro-a-definsin, Cell 
surface bound Fas-Ligand, 
Pro-TNFa
Hormones





a  1-proteinase inhibitor, 
a2-macroglobulin
Inhibitors




IGFBP-1. a  1 -proteinase 
inhibitor
Inhibitors
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Other MMPs
MMP-11 Fibronectin, laminin, 
aggrecan
IGFBP-l
a  1-proteinase inhibitor 
a2-macroglobulin
Inhibitors






a  1-proteinase inhibitor Inhibitors
MMP-19 Collagen type IV, gelatin, 
laminin, Gbronectin 
tenascin.
entactin, aggrecan, COMP, 
Gbrin/Gbrinogen
MMP-20 Amelogenin. COMP, 
aggrecan
MMP-21 no substrates defined
MMP-22 no substrates defined
MMP-23 Gelatin
MMP-27 no substrates defined
MMP-28 no substrates deGned
1. Abbreviations: CAM: cell adhesion molecules: GROa: growth related oncogene a ;  PF-4: platelet 
factor 4; CTAP-III/NAP-2: connective tissue activating protein III/ neutrophil-activating peptide-2: 
SDF: Stromal cell-derived factor: COMP: cartilage oligomeric matrix protein: Cell-surface (tTG): 
cell surface tissue transglutaminase: TNFa: Tumor necrosis factor a : TGFf): Transforming growth 
factor (3: IL: Interleukin: HBEGF: Heparin-binding epidermal growth factor. FGFR: Fibroblast growth 
factor receptor. ILR: Interleukin receptor. MCP: Monocyte chemoattractant protein.
2. Adapted from McCawley and Matrisian (2001) Curr Opin Cell Biol 13: 534
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TIMP-l 29 Glvcosvlated diffusible Xpl 1.3-11.23 0.9 kb
TIMP-2 21 Unglycosylated diffusible I7q25 3.5 kb and 1 kb
TIMP-3 24-27 glycosylated ECM bound 22ql2 .1-13.2 4.5.2.8, and 2.4 
kb
TIMP-4 23-24 unresolved diffusible 3p25 1.2 kb
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CHAPTER II
BOVINE MATRIX METALLOPROTEINASE-2 (MMP-2): MOLECULAR CLONING, 
EXPRESSION IN THE CORPUS LUTEUM, AND INVOLVEMENT IN ANGIOGENESIS
Abstract
Angiogenesis and other tissue remodeling events in the corpus luteum (CL) are mediated 
by matrix metalloproteinases (MMPs). Previously, we cloned the bovine homolog o f membrane- 
type I metalloproteinase (MT1-MMP). and showed that active MT1-MMP is correlated to MMP- 
2 activity in the CL during the estrous cycle. The aims o f the present study' were to clone the 
bovine MMP-2 gene, to investigate its temporal and spatial expression in three ages o f CL 
obtained over the bovine estrous cycle, and to determine its potential roles in endothelial cells 
during capillary tube formation. The bovine MMP-2 cDNA. which was isolated from a UNI-ZAP 
II capillary endothelial cell cDNA library-, encoded a protein of 661 amino acids. Luteal tissues 
were collected from non-lactating dairy cows on days 4. 10. and 16 (n=3/dav: day 0 = estrus) of 
the estrous cycle. Northern blotting and Western blotting revealed that the levels o f MMP-2 
mRNA (3. Ikb) and immunoreactive pro-MMP-2 protein (68 kDa) did not differ (P>0.05) in any 
age of CL examined. In addition to large luteal cells. MMP-2 was localized in endothelial cells in 
ail ages of CL by immunohistochemistry. The potential roles of MMP-2 in angiogenesis were 
evaluated using bovine capillary endothelial (BCE) ceils in a Matrigel capillary' tube-formation 
assay. Tube formation by BCE cells was remarkably suppressed by a neutralizing antibody 
against MMP-2. Taken together, these data suggested that the activity o f MMP-2 and its 
localization in endothelial cells may be critical for CL development e.g., by regulating capillary 
tube formation.
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Introduction
The formation and development o f the corpus luteum (CL) include extensive matrix 
remodeling events. After ovulation, the basement membrane degrades, and the follicle wall folds 
toward the cavity o f the collapsed follicle (Niswender and Nett, 1994: Smith et al.. 1994). 
Fibroblasts and luteinized theca intema cells proliferate and migrate into the cavity o f the 
ruptured follicle, where they mix with luteinized granulosa cells (Pederson, 1951). In addition, 
endothelial cells from capillaries in the theca intema compartment invade the granulosa layer to 
form new blood vessels (Plendl. 2000). This process o f new capillary formation is termed 
angiogenesis (Moses. 1997). These tissue remodeling events likely require the participation o f a 
large family o f zinc and calcium dependent proteolytic enzymes, matrix metalloproteinases 
(MMPs). which collectively degrade all known components of the extracellular matrix (ECM) 
(Massova et al.. 1998: Smith et al.. 1999: Curry and Osteen. 2001).
Among the more than 25 members o f the MMP family, only a  few have been studied in 
the CL. The patterns of expression and activities o f MMP-2 and MMP-9 have been investigated 
in bovine (Tsang et al.. 1995: Goldberg et al.. 1996: Zhang et al.. 2002). ovine (Russell et al.. 
1995: Towle et al.. 2002). porcine (Pitzcl et al.. 2000). rat (Nothnick et al.. 19%: Bagavandoss. 
1998: Liu et al.. 1999). and human (Duncan et al.. 1998) CL. Furthermore. MMP-1 (collagenase- 
1) expression was detected in rat (Nothnick et al.. 1996) and human (Duncan et al.. 1998) CL, 
while MMP-13 expression was found in bovine (Zhang and Tsang: unpublished data), ovine 
(Ricke et al.. 2002). and rat (Liu et al.. 1999) CL. Within this select group of enzymes, the action 
o f MMP-2 is most notable because its reduced levels impair CL formation (Russell et al., 1995). 
In part this may be attributed to the broad substrate specificity of MMP-2, especially its efficient 
degradative action on type IV collagen, the major component o f the basement membrane (Yu et 
al.. 1998). Additionally, administration o f a MMP-2 antibody blocks vasculature formation
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during CL development, supporting the potential role o f  this enzyme in blood vessel recruitment 
(Gottsch et al.. 2001).
Another distinguishing feature of MMP-2 is its activation process. Most MMPs are 
secreted as zymogens and then cleaved extracelluiarly into their active forms by serine 
proteinases (Murphy et al.. 1999). However. pro-MMP-2 is activated, instead, on the cell surface 
by membrane-type 1 metalloproteinase (MT1-MMP) (Murphy et al.. 1999). Previously, we 
cloned the bovine MT1-MMP gene, and demonstrated that the active form of MT1-MMP is 
correlated to MMP-2 activity in three ages of CL obtained over the estrous cycle (Zhang et al.. 
2002).
However, much remains to be learned about MMP-2. especially in domestic ruminants, 
before \vc can elucidate its role or function in the CL. Therefore, in the present study, we have 
cloned the bovine MMP-2 cDNA. and profiled its temporal and spatial expression patterns in CL 
obtained during the estrous cycle. The role of MMP-2 during angiogenesis was studied by using 
an in vitro capillary tube formation assay.
Materials and Methods
1. Molecular Cloning and Sequence Analysis
A bovine UNI-ZAP II cDNA library was constructed using RNA isolated from BCE cells 
of the adrenal cortex with Oligo(dT) primers. The primers for cloning bovine MMP-2 were 
designed based on the conserved catalytic region o f known MMP-2 sequences o f other species. 
The cDNA encoding the catalytic domain of bMMP-2 was directly amplified from this cDNA 
library using the polymerase chain reaction (PCR). Successive rounds o f  PCR were performed 
using new primers designed based on the obtained sequence data to clone the rest o f bMMP-2 
cDNA. PCR products were cloned into PCR TA-cloning vector (Invitrogen, Carlsbad. CA) for 
subsequent DNA sequencing.
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Sequencing o f cDNA was performed using PCR-based automated sequencing methods 
(Biopolvmer Facility and DNA Sequencing Core Facility, Children's Hospital, Boston, MA). 
Protein database search was assessed with advanced BLAST service provided by the National 
Center for Biotechnology Information (http://www.ncbi.nim.nih.gov/) with default settings. DNA 
and protein sequence analysis was conducted using the MacVector 6.0 DNA sequence analysis 
software package (Accelrvs Inc. San Diego. CA). Multiple alignment analysis was performed 
using Genetyx Sequence Analysis Software (Software Development Company, Tokyo, Japan).
2. Tissue Distribution of Bovine MMP-2
For Northern blot analysis, a cDNA fragment consisting o f mostly the 5 '-untranslated 
region (UTR) o f bMMP-2 was used to generate cDNA probes, which were random primer- 
labeled with a 3:P-dCTP using the Ready Prime cDNA Labeling Kit (Amersham. Piscatawav.
NJ). Poly(A)' RNA from different bovine tissues was purified using a modified guanidinium 
thiocvanate method followed by poly (A)' RNA selection with two rounds o f  oligo(dT)-cellulose 
columns. After separation with 1.0% (w/v) agarose electrophoresis containing formaldehyde. 
RNA was transferred to nylon membranes (Schleicher & Schuell. Keene, NH). A Northern blot 
of 2.5 |ig polv(A)*-RNA was hybridized overnight at 65° C with the radiolabeled probes at a 
concentration o f 2x 107 cpm/10 ml. The blot was washed to a final stringency o f 0. lxSSC and 
0 1% SDS (w/v) at 65° C. Hybridized probes were detected with autoradiography.
3. Animals and Tissue Collection
Ail animal procedures in the present study were performed according to protocols 
approved by the Institutional Animal Care and Use Committee (IACUC) at the University o f New 
Hampshire. Corpora lutea were collected from regularly cycling, non-lactating dairy cows housed 
at the University o f New Hampshire Dairy- Teaching and Research Center. Luteal tissues were
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removed on days 4. 10. and 16 o f the estrous cycles (day 0 = estrus: n=3/day). For day 4 C L  the 
ovary was removed by colpotomv from animals under an epidural anesthesia [2% mepivacaine 
hydrochloride (w/v); 0.01 mL/kg body weight; Upjohn. Kalamazoo, NO], The CL tissues were 
then dissected from the ovarian stroma. The day 10 and 16 CL tissues were removed from the 
ovary by enucleation.
4. Expression of MMP-2 in the Bovine CL during the Estrous Cvde
Total RNA was extracted from luteal tissues using TRIZOL (GIBCO-BRL, Carlsbad,
CA) according to the manufacturer's instructions. Twenty micrograms o f total RNA were 
fractionated on 1.0% (w/v) agarose gels containing formaldehyde and were transferred onto 
Hybond™-N* nylon membranes (Amersham Pharmacia Biotech. Piscataway. NJ). Membranes 
were first incubated in pre-hybridization buffer [50% (v/v) formamide. 5xSSC. 0.2% (w/v) SDS. 
and 2% (w/v) blocking reagent| for two hours at 42°C. Hybridization was carried out in the pre- 
hybridization buffer containing MMP-2 cDNA probes at 50°C overnight. These cDNA probes 
were labeled with digoxigenin (DIG)-dUTP using the DIG DNA random-primed Labeling Kit 
(Roche Molecular Biochemicals. Indianapolis. IN). The blots were then washed twice at room 
temperature in 2xSSC with 0.1% (w/v) SDS. followed by higher stringency washes in 0.2xSSC 
with 0.1% (w/v) SDS at 65°C. Hybridized probes were detected using an anti-DIG antibody 
conjugated to alkaline phosphatase (used at 1:5000; Roche Molecular Biochemicals. Indianapolis, 
IN) in 1% (w/v) blocking reagent. The signals were detected by CSPD (Roche Molecular 
Biochemicals. Indianapolis. IN), a  chemiluminescent substrate for alkaline phosphatase. After 
visualization, the membranes were subsequently stripped according to manufacturer's 
instructions, and re-hybridized with cyclophilin cDNA probes.
5. Western Blot Analysis
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Total protein was extracted from luteal tissues as previously described (Zhang et al.,
2002). Equal amounts o f protein were subjected to SDS-PAGE on 10% (w/v) polyacrylamide 
gels, and were transferred to Protran® nitrocellulose membranes (Schleicher & Schuell, Keene, 
NH). Nonspecific binding sites were blocked by incubating the membranes with 5% (w/v) nonfat 
dry milk in TBST buffer [lOmM Tris-HCl, l50mM NaCI. 0.05% (v/v) Triton X-100, pH 8.0j. 
Membranes were then incubated with rabbit anti-human MMP-2 antibody (used at 1:5000; 
Chemicon. Temecula. CA). After extensive washes with TBST buffer (five times, 15 minutes per 
wash). HRP-conjugated anti-rabbit-IgG (1:10.000) was applied onto membranes as a secondary 
antibody. The signals were detected with the SuperSignal* West Pico Chemiluminescent 
Substrate (Pierce. Rockford. 1L) according to the manufacturer's instructions.
6. lmmunohistochemistrv
Frozen sections (6pm) were prepared from luteal tissues collected at three stages o f the 
estrous cycle using a  Crvotome (Shandon. Pittsburgh. PA). Sections were fixed in cold acetone 
for 5 minutes. The endogenous peroxidase activity' was quenched by incubating sections in 0.03% 
(v/v) H20 : for 30 minutes at room temperature. Nonspecific sites were blocked by 10% (w/v) 
BSA before incubating the slides with a mouse anti-human MMP-2 antibody (1:250; Oncogene 
Research Products. San Diego. CA). Following incubation with the biotin-conjugated goat anti­
mouse IgG secondary antibody (1:2000; Pierce. Rockford. IL), MMP-2 was visualized using 
VECTASTAIN® Elite ABC Kits (Vector Laboratories. Burlingame. CA). Sections were 
subsequently counterstained with Gill's 2 hematoxylin (Shandon, Pittsburg, PA). For each tissue 
sample, a consecutive section placed on the same slide was used as a  negative control, with BSA 
substituting for the primary antibody. For each tissue (3 corpora lutea for each age), 10 to 20 
sections were stained. A minimum o f 20 areas per section was examined.
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7. BCE Cell Culture and Gelatin Zvmogrrahic Analysis
SDS substrate zymography electrophoresis was performed based on a previously 
described method with modifications (Tsang et al., 1995; Zhang et al., 2002). Medium 
conditioned by BCE cells were mixed with non-reducing SDS sample buffer before fractionation 
in 10% (w/v) polyacrylamide gels containing 0.1% (w/v) gelatin (Bio-Rad, Hercules, CA). After 
electrophoresis, gels were washed twice with 2.5% (v/v) Triton X-100 (15 minutes per wash), 
followed by incubation with substrate buffer [50 mM Tris-HCl. 5 mM CaCL, 1 pM ZnCI;, and
0.02% (w/v) NaN3. pH7.6| at 37°C for 24 hours. The gels were stained with 0.1% (w/v) 
Coomassic Brilliant Blue R-250 (BioRad. Hercules..CA). and the gelatinolytic activities were 
shown as clear zones against a blue background.
To verify- that bMMP-2 is a bona fide metal-dependent proteinase, zymogram gels were 
incubated with substrate buffer containing a MMP-specific inhibitor 1.10 phenanthroline (10 
mM; Sigma. St. Louis. MO). The latent and active forms o f MMP-2 were distinguished by 
incubating BCE conditioned medium with ImM 4-aminophenylmercuric acetate (APMA) 
(Sigma. St. Louis. MO), an organomercurial activator o f MMPs. at 25°C for 30 minutes before 
zymographic analysis.
8. In Vitro Capillary Tube Formation Assay
The in vitro capillary tube formation assay was carried out as previously described 
(Kubota et al.. 1988). Cell culture surfaces were pre-coated with Matrigel (Becton Dickinson. 
Waltham. MA) at a density o f 100 pl/cm2 growth area. After incubating at 37°C for 30 minutes, 
culture surfaces were washed with PBS. BCE cells were plated at 25.000 cells/ cm2 growth area 
in growth medium that contains 5% (v/v) fetal bovine serum (FBS) and 1% (v/v) glutamine 
penicillin-streptomycin (GIBCO-BRL, Carlsbad. CA).
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To assess the potential function of MMP-2 in angiogenesis, the capillary tube formation 
assay was carried out under conditions that MMP-2 activity was neutralized by an anti-MMP-2 
antibody (1:100) (A lbinietal.. 1991; Pauly etal.. 1994; Kenagy et al., 1997), which was kindly 
provided by Dr. William Stetler-Stevenson at NDi. In the negative control, normal mouse serum 
was added in the same dilution.
9. Data Analysis
Densitometric intensities o f  bands on Northern and Western blots were determined by 
UN-SCAN-IT gel™ automated digitizing system (Silk Scientific, Orem, UT). Data were 
analyzed by ANOVA. followed by Tukev's test for multiple comparisons.
Results
I. Cloning and Sequence Analysis o f Bovine MMP-2
Bovine MMP-2 was PCR-cloned from a cDNA library' constructed using mRNA isolated 
from BCE cells o f the adrenal cortex. Compiled cDNA sequences o f bovine MMP-2 were aligned 
using MacVector sequence analysis software to generate a  cDNA of 2169 basepairs (bp), 
including an open reading frame (ORF) o f 1986 bp. a 5’-untranslated region (UTR) of 181 bp. 
and a partial 3 '-UTR o f 70 bp (Figure I A; GenBank accession number AF290428).
The predicted bovine MMP-2 protein is composed o f 661 amino acids with a calculated 
molecular mass o f about 74 kDa. From the amino terminus, bovine MMP-2 is composed o f the 
hydrophobic signal domain (M1 to \ M). the pro-domain (A31 to N 110), the catalytic domain (Ym 
to G447). the hinge region (A448 to L469). and the hemopexin domain (C470 to C661) (Figure IB). The 
catalytic domain contains a  conserved sequence HEXGHXXGXXHS/T, which functions as the 
binding site for the catalytic zinc atom (HEFGHAMGLEHS in the bovine MMP-2). In addition, 
the catalytic domain o f bovine MMP-2 is interrupted by three fibronectin type Q-like repeats, 
which function as binding sites for gelatin and serve as a hallm ark  o f gelatinases. Multiple
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sequence alignment analysis demonstrated that bovine MMP-2 shares 94.7%, 94.1%, 93.5%,
93%. and 95.9% sequence identity to its human, ra t mouse, rabbit and pig homologs, 
respectively (Figure 1C).
2. Tissue Distribution of Bovine MMP-2
Expression o f bMMP-2 in various bovine tissues was analyzed by Northern blotting 
(Figure 2A). Bovine MMP-2 is encoded by a  single mRNA species o f approximately 3 .1 kb. The 
density o f Northern blots was evaluated by scanning densitometry analysis, and relative 
expression levels o f MMP-2 mRNA in different tissues are presented as percentage o f density 
compared to that in the lung, w hich had the strongest expression and was assigned as 100% 
(Figure 2B). A moderate expression o f MMP-2 was also detected in the kidney (50.0%), heart 
(30.2%) and spleen (15.0%). However, there were extremely low and non-detectable levels of 
MMP-2 mRNA in the brain (6.7%) and in the liver (0%). respectively.
3. Expression and Localization of MMP-2 in the Bovine CL
The pattern o f MMP-2 expression in the early, mid-, and late stage CL during the estrous 
cycle was investigated at the mRNA level by Northern blot analysis (Figure 3A). and at the 
protein level by Western blot analysis (Figure 4A). Northern blot analysis detected a single 3.1 kb 
MMP-2 transcript in all CL tissues. No apparent differences in the levels o f bMMP-2 mRNA 
w ere observed among these three ages o f CL (p>0.05). Western blot analysis detected an 
approximately 69 kDa protein band, which corresponds to the latent form of MMP-2. in all three 
ages o f CL (Figure 4A). Densitometric analysis demonstrated that the level of the latent MMP-2 
did not change (p>0.05) during the estrous cycle (Fig 4B).
The spatial pattern o f MMP-2 expression in the bovine CL was studied by 
immunohistochemistry. In early (d4), mid (dlO). and late (dl6) cycle CL (Figure 5A-C, 
respectively), positive staining for MMP-2 was localized in endothelial and large luteal cells.
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Large (steroidogenic) luteal cells were identified based on cell size and presence of lipid droplets. 
Endothelial cells were identified by staining a consecutive section with an antibody for Factor 
Xm . an endothelial cell marker (Figure 5E). No staining was observed when the primary 
antibody was omitted (Figure 5D and 5F).
4. Detection of MMP-2 Activity in Bovine Capillary Endothelial (BCE1 Cells
MMP-2 activity' in BCE cells was studied using gelatin zymography A 68 kDa 
geiatinolytic activity, which corresponds to the protein size o f MMP-2. was readily detected in 
serum-free medium conditioned by BCE cells (Figure 6. lane 1). Under the cell culture 
conditions, the majority of gelatinase activity expressed by BCE cells is in the latent form. This 
was validated by incubation o f BCE conditioned medium with 1.0 mM APMA. which resulted in 
a conversion o f the 68 kDa proMMP-2 to the 62 kDa active forms (Figure 6. lane 2).The detected 
geiatinolytic activity was from an MMP because its activity was completely inhibited by an 
MMP-spccific inhibitor. I. 10-phenanthroline (Figure 6. lane 3).
5. MMP-2 is Required for In vitro Capillary Tube Formation
The role o f MMP-2 during angiogenesis was studied by using an in vitro capillary tube 
formation system. As shown in Figure 7 A. BCE cells formed extensive capillary-like structures 
w hen they were plated on Matrigel. The most extensive tube formation was observed at 8 to 12 
hours after cell plating and was dependent on the presence o f 5% serum (data not shown). When 
incubated with a monoclonal MMP-2 antibody at 1:100 dilution, BCE cells showed reduced 
degree o f in vitro capillary tube formation (Figure 7B).
Discussion
In addition to their involvement in pathological extracellular degradation events such as 
tumor invasion and metastasis, matrix metalloproteinases (MMPs) have been shown to be
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important in normal tissue remodeling processes that relate to female physiology-, including 
follicle development ovulation, CL development and regression, and implantation (Smith et al.. 
1999: Curry and Osteen. 2001). However, information regarding detailed expression profiles of 
these enzymes and their physiological functions, especially in species with long luteal phases, is 
limited. In the present study, we reported the full length cDNA sequence o f bovine MMP-2. its 
expression and localization in the bovine CL. and its involvement in capillary formation. The 
open reading frame of the bovine MMP-2 gene encodes a  protein consisting o f 661 amino acids, 
showing a  high degree of identity to its human, rat. mouse, rabbit, and pig homologs. This 
indicates that this enzyme is highly conserved among mammals. Bovine MMP-2 possesses the 
classical domain organization o f gelatinases. including the three head-to-tail repeats o f fibronectin 
type II-like inserts. These inserts function as binding sites for gelatin and are critical for the 
proteinase activity on ECM substrates such as casein, gelatin, and type IV collagen (Murphy et 
al.. 1994; Shipley et al.. 1996). The tissue distribution pattern o f bovine MMP-2 is not only- 
similar to that observed in mouse (Gack et al.. 1994). but is also correlated to its membrane- 
associated activator. MT1-MMP (Zhang et al.. 2002). Thus, in cattle, the coordinated expression 
of these two MMPs in multiple tissues suggests that MMP-2 is activated similarly in a variety of 
cell types.
Only a few studies have reported the activity and expression patterns o f MMP-2 in CL 
obtained during the estrous cycle or undergoing regression. The MMP-2 transcript and protein are 
highly expressed during the early stages of rat CL development (Liu et al.. 1999), while 
significant increases are observed in the late rather than the early and mid stages in the human CL 
(Duncan et al.. 1998). In the present study. MMP-2 transcript and pro-MMP-2 protein were 
constitutively expressed in early, mid. and late stages o f the bovine CL. Furthermore, enhanced 
MMP-2 expression is associated with luteoivsis in sheep (Towle et al., 2002), human (Duncan et 
al.. 1998). and rat (Endo et al.. 1993). Eight hours after a  systemic infusion o f the luteolysin, 
PGFio, MMP-2 activity is significantly increased (Towle et al., 2002). PGF2a also induces high
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production o f MMP-2 by porcine luteal cells (Pitzel et al., 2000). When human chronic 
gonadotropin (hCG) is given to rescue the human CL from regressing, MMP-2 expression is 
reduced (Duncan et al.. 1998). Collectively, these data indicate that there are species differences 
in the expression patterns o f MMP-2 in the CL. Furthermore, the degradation o f the ECM 
mediated by MMP-2 may be important for the involution o f the CL.
The temporal expression o f MMP-2 follows a pattern similar to its endogenous activator. 
MT1-MMP. While the latent forms o f MMP-2 and MT1-MMP remain unchanged during the 
bovine estrous cycle, the activities o f both enzymes paralleled each other, being low in the early 
stage CL. but significantly enhanced in the mid and late stages (Zhang et al.. 2002). Previously, 
zymography revealed the presence o f active MMP-2. which was validated by incubation with 
APMA to distinguish between latent and active forms o f MMP-2 (Zhang et al.. 2002). Thus, our 
inability to detect the active form of MMP-2 in immunoblots in the present study was most likely 
the result o f using a heterologous antibody. Besides MMP-2. MT1-MMP also activates MMP-13 
(collagenase 3). MMP-13 was expressed at a constant level in the bovine CL during the estrous 
cycle (Zhang and Tsang: unpublished data). However, in the rat CL. which predominantly 
expresses MMP-2 at the early stage. MT1-MMP is constitutively expressed in all stages 
examined, while MMP-13 is highly expressed in the late stage (Liu et al.. 1999). Following 
PGF;a-induced luteoiysis in sheep. MMP-2 and MMP-13 mRNA are increased by 6 hours, while 
MT1-MMP mRNA is increased by 15 minutes, and remains elevated through 48 hours (Ricke et 
al.. 2002). Thus, there is also species variation in the interplay between MMP-2 and MMP-13. 
and their activator in vivo. MT1-MMP.
Although MMP-2 transcripts are localized in human theca-lutein cells (Duncan et al., 
1998). MMP-2 mRNA and activity has been predominantly observed in large luteal cells o f  a 
variety o f species. Rat luteinized granulosa cells express MMP-2 mRNA (Curry et al., 2001), 
while immunoreactive MMP-2 is detected in luteal cells o f developing rat CL (Bagavandoss, 
1998). In addition. MMP-2 mRNA and activity are detected in porcine large luteal cell cultures
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(Pitzel et al., 2000). In the present study, immunohistochemistry demonstrated that large 
(steroidogenic) luteal cells expressed MMP-2, which is consistent with our previous observation 
that MMP-2 activity is present in conditioned medium of bovine luteal cell cultures (Tsang et al., 
1995). The co-localization o f MMP-2 and MT1-MMP in large luteal cells suggests that activation 
of pro-MMP-2 is locally regulated. For example. MMP-2. per se. binds to cell membranes via the 
integrin OvP3 (Brooks et al.. 1996). promoting localized pericellular proteolysis to accommodate 
the increasing size o f large luteal cells during CL development (Schwall et al.. 1986; Zheng et al.. 
1994). As proposed by Smith et al. (Smith et al.. 1999). the molecular regulation o f the 
luteinization process and the changes in the biochemical properties o f luteal cells are possibly 
attributed to dynamic interactions between the ECM and the cell.
Another example o f cell-cell and cell-matrix interactions is angiogenesis. a hallmark of 
CL development (Basset. 1943: Reynolds et al.. 2000). Angiogenesis is a multi-step process that 
involves the interplay between angiogenic factors, endothelial cell migration and proliferation, 
and ECM remodeling, which ultimately lead to recruitment of pericytes and formation o f 
capillary lumen (Moses. 1997: Klagsbrun and Moses. 1999). As a highly vascularized gland, the 
CL is a rich source of angiogenic factors (Reynolds et al.. 2000). Over the course o f  CL 
development. 85% of proliferative cells are endothelial cells (Reynolds et al.. 1994), which are 
the most abundant cell type in the mid cycle CL (Lei et al.. 1991: Zheng et al.. 1993).
Extracellular proteolysis, which requires the participation o f MMPs, is an integral part of 
the angiogenic process (Moses. 1997). Besides the large luteal cells. MMP-2 was also localized in 
endothelial cells o f the bovine CL. In the rat C L  MMP-2 is also detected in the same cellular 
compartments (Bagavandoss. 1998). The in vivo cellular localization of MMP-2 is supported by a 
recent in vitro study, showing that MMP-2 was the predominant gelatinase in CL-derived 
endothelial cells (Zhang et al.. unpublished data). The present study also showed that an MMP-2 
antibody inhibits capillary' tube formation by endothelial cells, an indispensable step in 
angiogenesis. Taken together, these data suggest that MMP-2 activity may be necessary for
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neovascularization (Hiraoka et al., 1998). In ewes, administration o f a  MMP-2 antibody results in 
incomplete CL formation, whereby the build up o f normal vasculature is blocked (Gottsch et al.. 
2001). In the same animal model, immunization o f the N-terminal peptide o f the inhibin (143- 
subunit (aN ) also causes incomplete CL development concurrent with reduced MMP-2 activity 
(Russell et al.. 1995). In addition. MMP-2 activity is critical for angiogenic processes in other 
tissues. For example, the MMP-2 gene knockout mouse shows remarkable resistance to tumor- 
induced angiogenesis (Itoh et al.. 1998). while corneal angiogenesis is diminished in MMP-2- 
deficient mice (Kato et al.. 2001).
MMP-2 may play multiple roles during angiogenesis. The cleavage o f plasminogen 
generates a 38 kDa internal fragment which is called angiostatin and has inhibitory action on 
angiogenesis (O'Reilly et al.. 1999). MMP-2 also cleaves big ET-1 into an active and potent 
vasoconstrictor. ET-l (Fernandez-Patron et al.. 1999). Moreover, the cleavage o f calcitonin gene- 
related peptide (CGRP). a potent vasodilator, by MMP-2. remarkably reduces its vasodilatory 
potency (Femandez-Patron et al.. 2000). In addition to its degradation on ECM components, 
therefore. MMP-2 may regulate angiogenesis and vascular function via diverse pathways.
Considering our previous observation that active MT1-MMP is correlated to MMP-2 
activity (Zhang et al.. 2002). the constitutive expression o f MMP-2 transcript during the estrous 
cycle suggests that MMP-2 activ ity is predominantly regulated at the level o f activation in the 
bovine CL. In addition, expression of MMP-2 in large luteal cells may facilitate pericellular 
proteolysis o f the ECM during CL development. Furthermore, localization o f  MMP-2 in 
endothelial cells and inhibition o f capillary tube formation by a MMP-2 antibody indicate that 
this enzyme may be critical for angiogenesis in the CL.
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Sequence and homology analysis of bovine MMP-2
6 6 1
q  - 1 9 1
gcacqaggcqgqctgggggccgggccacgctctgctgagccgggcaaagccgaggagaccgaataqaatagcccctrggagcgcagcgec - 9 1  
gcgcgggggageaggegccagecaggcggcqacgcggccacacgcaccgagcctgccacceccgggcgacgcgcggggcecgggagcgca - 1  
atgaccgaggcgcgagtgLcccggggcgcgctggccgcccttctgcgggcgctctgcgccctgggctgcctgttgggccgtgccgccgcc 90 
M T E A R V S R G A L A A L L F .  A I . C A L G C 1 . 1 .  3 R A A A  
gcgccgt cgeecatcatcaaaittcccggcgatgtcgcecccaaaacggacaaagagt tggctgtgcaatacctaaacaccttctacggc 160 
A P S ?  I  I  K F P G D V A F K 7 D K E L A V Q Y L M 7 F Y G  
tgcceeaaggagagctgtaacttgtttgtgctgaaggacaccctgaagaagatgcagaagttcttegggttaccccagacaggtgaactg 2^0 
C P K E S C N L F V L K D T L K K M Q K F F G L P Q T G E L  
gaceagagcaccatugagaccatgcggaagccgcgctgtggcaaccccgacgtggccaactacaacttcttcccccgaaagcccaagtgg 260 
^ G S T O E T M R K P R C G N P D V A N Y N F F P R K P K W  
gacaagaaccaqatcacatacaggatcattggctacacacctgacctggacceccagacagtggatgatgccttcgctcgtgcettccaa 4 5 0  
S K N S I T Y R I I G Y T P D L D P Q T V D G A F A R A F C  
gtctggagcgatgtgactccgetacggtcttctcggatccatgatggagaggetgacatcatgateaactttggccgctgggagcatgga 54  0 
V W S G V ? P L R F S R I H D G E A D I M : N F G R W E H G  
qatgggtacccttttgatggcaaagacgqgctcetggctcatgccttcgccccgggccctggagttgggggagattcccactttgatgac 6 3 0  
O G Y P F D G K O J G L L A H A F A P G P G V G G D S H F D D  
gatgagctgcggaccctgggagaaggacaagtggtccgtgtgaagtacgggaatgctgacggggaatattgcaagttccccttccggttc ?20 
0 E L S 7 L G E G C V V R V K Y G S A D G E Y C K F P F R F  
aac^gcaagqagta eaccagctgcacaqacacaggccgcagcgarggcttcetctggtgttecaccacatacaactttgacaaggacgqc 6 1 0  
N ' G K E Y T S C T D T G R S O G F ^ W C S T T Y S F D K G G  
aagtatggctretgecercatgaagcectgttcaecatgggcggcaacgccgacggacaqccctgcaagttcccgttccgcttecaqggc 90 0 
K Y G F Z P H E A L F T M G G N A D G G P C K F F F R F C o  
aegcctcaeqaeagctgcaccacggaqgqccgcacqgdcgqctdcegctqqtqtgqcaccaccgaqgactaccaccgcqacaaqqaqtac 
T S : 0 S C 7 T E G R T r G Y R W C G T 7 E D Y 7 R 2 K E Y  
gqcttctgcccggagaccgccargrccactgtgggcgggaactcggaaggtgccccatgtgtcctccccttcacettectgggcaacaag 1 0 6 0  
■ 3 F C P E 7 A M S 7 V G G M 5 E G A P C V L F F 7 F L G N K  
racgagagccgcaccagcgctgqcegcagtgatgggaagttgtggtgtgcgaccacctccaactacgatgatgaccgcaagtggggcttc 1 1 7 0 
H E S 0 7 S A G R S D G K L W C A T 7 S M Y D D 0 P .  K W G F  
tgccccgaccaacggtacagcctgttcctggtggcagcccatgagtttggccatgcaatggggctggagcacccacaggaccctgqagcc 1 2  6 0  
C P G Q G Y S L F L V A A H E F G H A M G L E H S G D P G A  
etgatggegcccactratacccacaccaaqaacttccqcctgtcceatqatgacatccagggcatccaagaacccratggggcctcccct 1 2 5 C  
1 . M A F  I  Y 7 Y 7 K N F R L . 3 K Z D I Q G I  3 E L Y G A S P  
gacat tgatactqgcaccggccccaccccaaccctgggccccgtcactcctgagctctgcaaacaggacatcgtcctcgacggcatrtct 1 4 4 0  
2 : G 7 G 7 G P 7 ? 7 « G ? V T P E L C K Q D : v F D G : s  
cagatccgtggggagatettccrctccaaggacccatteatetggcgaacagcgacaccacgtgacaagcccacagggcccctgctggta 1 5 3 0  
: : r g s : f f f k 3 r f : w r 7 V 7 P R d k ? 7 G p l l v  
gccacatt rrggcrrgagctgccggaaaagatcgatgctgtgtargaagacccacaggaggagaaggctgtgttctttgcagggaacgaa 1 6 2 0  
A 7 F W F E 1 . F E K I D A V Y E D P Q E E K A V F F A G N E  
tactgggtetattcagccageaccccggaqcgagggtaccccaagccactgaccaccccggggcteccccctggtgtccaqaaggtgqac 1“10
Y W V : £  A S 7  1  E R G Y ?  K ?  L 7  £  L G L P r  G V Q K V 2
gctgcccctaactggagcaagaacaagaagacgcacatcrregccggagacaaactctggagatacaatgaggtgaagaagaaaatggat 1600
A A F S M 5 K N K K 7 Y I F A G D K F W R Y M E V K K K M G  
ce tg g c c tc c c c a a g c c c a c c g c c g a tg c c tg g a a c g c c a tr c c tg a ta a c c r g g a c g c tg tg g tg g a c c tg c a g g g c g g g g g tc a c a g c  IS 90 
P G F r K L I A D A W N A I P D N L D A V V D L Q G G G H S  
ca cc tccrc a a g g g cg c c ta tc a c c tg a a g ttg g a g a a c c a a a g tc tg a a g a g c g tg a a g ttc g g a a g c a tc a a a tc c g a tc g g c tg g g c  1960
Y F F K G A Y Y  L K L E N Q S L K S V K F G S  I K S D W L G
c g e tg a g c tg g c tz c g c c tc e e c c a g g g c c tg c c e c te e a tc a c c tg c tg c a c a c c a g g g c c tg a g c a c c a g g g a a g g a c c c g g g tg g g c  2G~C
g tg g c a g c c e tc a g t tc tg ta a tta a tc a g c a ttc tc a c c c c c a c c tg g ta a t t ta a g a a a c c c ta g a g tg g c tc tg c c c tg tg c tc a a g  2160 
ta a a a c tg a  2163
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Species signal propeptide catalytic hinge hemopexin overall
Bovine 100 100 100 100 100 100
Human 70 98 96 86 97 94.7
Mouse 73 98 95 82 97 94.1
Rat 63 98 95 82 97 93.5
Rabbit 67 99 95 77 93 93
Pig 83 100 96 95 96 95.9
Figure 2-1. Sequence analysis of bovine MMP-2. A) Nucleotide sequence o f  the bovine 
M MP-2 cDNA and its deduced amino acid sequence. The protein sequence is shown in 
uppercase letters and the DNA sequence in lowercase. W hile the num bers on the left are 
for the amino acid sequence, the ones on the right are for the cD N A  sequence. B) 
Schematic diagram showing the domain organization of bovine MMP-2. Signal, Pro, Cat, Hinge, 
and Hex represent the signal peptide, propeptide, catalytic, hinge, and hemopexin/vitronectin 
domains, respectively. The fibronectin type II-like inserts and the Zn2* binding consensus site in 
the catalytic domain are also indicated. C) Multiple sequence alignment o f bovine MMP-2 and its 
homologs from other species. The numbers in the boxes indicate the percentages o f amino acid 
sequence identity in corresponding domains. The overall homology percentages for the entire 
molecule are shown on the right GenBank accession numbers o f  the sequences analyzed are 
bovine MMP-2 AAG28169, human MMP-2 A28153, mouse MMP-2 A42496, rat MMP-2 
S34780, rabbit MMP-2 S70365, and pig MMP-2 AAK97133.
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Figure 2-2. Tissue distribution of bovine MMP-2 mRNA expression. A) Northern blot analysis 
o f MMP-2 mRNA expression in various bovine tissues, including the brain, heart, kidney, liver, 
lung, and the spleen. A single transcript o f approximately 3.1 kb is marked by the arrow on the 
left. B). Relative expression levels o f MMP-2 mRNA in different bovine tissues. Densitometric 
intensities o f MMP-2 Northern blots were determined by UN-SCAN-IT digitizing systems (Salk 
Scientific, Orem, UT), and are presented in percentages as compared to that in the lung, which 
was assigned as 100%.
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MMP-2 mRNA expression in the bovine CL
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Figure 2-3. MMP-2 mRNA expression in luteal tissues. A). Northern blotting detected a 3.1 kb 
MMP-2 mRNA species in the early (E; day 4), mid- (M; day 10), and late (L; day 16) stage CL 
(upper panel). The same membranes were stripped and hybridized with a cyclophilin probe as a 
control for RNA loading (lower panel). B). Relative levels o f  MMP-2 mRNA are presented as 
ratios o f the densitometric value o f  MMP-2 to cyclophilin. Dissimilar letters denote significance 
at p<0.05.
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Figure 2-4. Representative Western blot o f MMP-2 in bovine CL obtained over the estrous cycle. 
A) This particular MMP-2 antibody detected the pro- (-69  kDa) but not the active form of MMP- 
2 in the early (E: day 4), mid (M; day 10), and late (L; day 16) stage CL. Molecular masses (kDa) 
o f prestained protein standards (Bio-Rad Laboratories, Hercules, CA) are shown on the left. HT 
denotes conditioned medium of HT1080 cells. B) Densitometric analysis showed that the levels 
o f pro-MMP-2 did not vary (p>0.05) among different stages o f CL. Dissimilar letters denote 
significance at p<0.05.
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MMP-2 localization in the bovine CL
/
P s ?  • * I "
S ^ T *  . i # - T # ;  ^  '% . % $
. > ;  "  ■' « * , > T  . V * ^
• w ^ ' * * 4  •
J r :  c  w M B a i^ v
a p f
* »
« ' .  •  » *•
p
i  _** *
B n # ’ • 1*38
Figure 2-5. Immunohistological staining o f MMP-2 in the early, mid-, and late stage CL. MMP-2 
protein expression was localized in endothelial (black arrows) and large luteal cells (white 
arrow's) o f the early (A; day 4), mid (B; day 10), and late (C; day 16) stages o f CL. Endothelial 
cells were identified (black arrows) based on staining with Factor V K  (E). No staining was 
observed in the negative controls (D and F, for MMP-2 and Factor VIII, respectively), in which 
the primary antibody was replaced by 10% BSA. Magnification is at 400x.
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MMP-2 activity in bovine capillary endothelial cells







Figure 2-6. Gelatin zymographic analysis o f medium conditioned by BCE cells. A major 68 and 
a faint 62 kDa band, which correspond to pro and active MMP-2, respectively, were observed in 
medium conditioned by BCE cells (lane 1). Incubation with APMA converted the 68 kDa pro- 
MMP-2 to its 62 kDa active form (lane 2). All zones o f clearance disappeared following 
incubation with 1, 10-phenanthroline. The molecular masses (kDa) o f Perfect Protein™ Marker 
(Novagen, Madison, WT) are indicated on the left.
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Effects of MMP-2 antibody on in vitro capillary tube formation of BCE cells
Figure 2-7. Effects o f a neutralizing antibody against MMP-2 on in vitro capillary formation of 
BCE cells. Phase contrast photography of capillary-like tube formation o f BCE cells cultured on 
Matrigel under control conditions (A), or in the presence o f a neutralizing anti-MMP-2 antibody
(1:100; B).
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CHAPTER III
BOVINE MEMBRANE-TYPE I MATRIX METALLOPROTEINASE (MT1-MMP): 
MOLECULAR CLONING AND EXPRESSION IN THE CORPUS LUTEUM
Abstract
Matrix metalloproteinase-2 (MMP-2) is produced as a zymogen, which is subsequently, 
activated by membrane-type 1 metal loproteinase (MT1-MMP). The objectives o f the present 
study were to clone bovine MTl-MMP and to investigate its expression in the corpus luteum 
(CL). CL were harvested from nonlactating dairy cows on day 4. 10. and 16 o f the estrous cycle 
(day 0=estrus; n=3 for each age). The bovine MTl-MMP cDNA contained an open reading frame 
of 1749 base pairs, which encoded a predicted protein o f 582 amino acids. Northern blotting 
revealed no differences (p>0.05) in MTl-MMP mRNA levels between any ages o f CL. Western 
blotting demonstrated that two species, the latent form (-63 kDa) and the active form (-60 kDa) 
o f MTl-MMP. were present in CL throughout the estrous cycle. Active MTl-MMP was lower 
(p<0.05) in the early CL than the mid- and late stages, where MMP-2 activity’, as revealed by 
gelatin zymography. was also elevated. Furthermore, immunohistochemistry revealed that M Tl- 
MMP was localized in endothelial, large luteal, and fibroblast cells o f the CL at different stages. 
Taken together, the differential expression and localization o f MTl-MMP in the CL suggest that 
it may have multiple functions throughout the course o f the estrous cycle, including activation of 
pro-MMP-2.
Introduction
The corpus luteum (CL) is a dynamic, transient endocrine gland, which develops from 
the postovulatory’ follicle (Niswender and Nett, 1994). In addition to functional changes, the
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development, maintenance and regression o f the CL are associated with structural events such as 
tissue remodeling and angiogenesis (Smith et al.. 1999; Reynolds et al., 2000). It is believed that 
this tissue remodeling process includes breakdown and resynthesis o f extracellular matrix (ECM) 
components (Luck and Zhao. 1995; Smith et al.. 1999). which require the participation of matrix 
metalloproteinases (MMPs) and tissue inhibitors o f metalloproteinases (TIMPs) (Hulboy et al., 
1997; Mclntush and Smith. 1998; Smith et al.. 1999). Although the literature is still emerging, a 
few of the secreted MMPs and TIMPs have been investigated in CL and follicles o f species with 
long luteal phases, including the bovine (Juengel et al.. 1994; Tsang et al., 1995; Goldberg et al.. 
1996; Smith et al.. 1996; Zhang and Tsang, 2000b). ovine (Murdoch et al.. 1986; Smith et al.. 
1994; Smith et al.. 1995). porcine (Pitzel et al.. 2000). human (Duncan et al.. 1998), and macaque 
(Chaffin and Stouffer. 1999).
Matrix metalloproteinases are secreted as latent proenzymes, which are proteolvtically 
cleaved to their active forms (Birkedal-Hansen. 1995; Massova et al.. 1998). It is proposed that 
some serine proteinascs. such as trypsin, neutrophil elastase and plasmin. can initiate the 
extracellular activation process o f pro-MMPs by a “cysteine switch" mechanism (Van Wart and 
Birkedal-Hansen. 1990). Unlike other secreted MMPs. however. pro-MMP-2 is inefficiently 
activated by this proteolytic activation mechanism, because its sequence is not susceptible to 
cleavage by serine proteinases (Collier et al.. 1988). Instead. pro-MMP-2 activation is localized 
on the ceil surface (Murphy et al.. 1992b). where membrane-type 1 matrix metalloproteinase 
(MTl-MMP) has been identified as its activator in placenta and several different kinds of tumor 
cells (Sato et al.. 1994; Sato et al.. 1997a).
Currently, six different membrane-type MMPs (MT1-MT6 MMP) have been identified 
(Ravanti and Kahari. 2000; Vu and Werb. 2000) with MTl-MMP being the most well studied. 
Similar to other non-membrane type MMPs, MTl-MMP is characterized by having a  signal 
peptide at the amino terminus, followed by a  pro-peptide, catalytic domain, hinge region, and 
hemopexin-like domain at the C terminus (Sato et al., 1994; Massova et al., 1998). In contrast to
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secreted MMPs, MTl-MMP contains a  distinct transmembrane domain, which has about 25 
hydrophobic amino acid residues, enabling it to be expressed on the cell surface (Massova et al., 
1998). The human MTl-MMP nucleic acid and protein sequence was the first to be deduced 
(Sato et al.. 1994). and subsequently, rat (Okada et al.. 1995a), mouse (Apte et al., 1997), and 
rabbit (Sato et al.. 1997b) MTl-MMPs were cloned and sequenced.
MTl-MMP possesses a variety of functions. As a matrix-degrading enzyme, MTl-MMP 
has collagenolytic and geiatinolytic activities during connective tissue remodeling (Imai et al.. 
1996: Ohuchi et al.. 1997). With the exception o f MT4-MMP. the most well known role o f MT- 
MMPs. including MTl-MMP. is their ability to activate pro-MMP-2. a key enzyme associated 
with a variety o f pathological and physiological processes. Thus, it is not surprising that M Tl- 
MMP expression is correlated with wound healing (Ravanti and Kahari. 2000) and a variety o f 
disease states including tumor invasion and metastasis (Polette and Birembaut. 1998). and 
rheumatoid arthritis (Yamanaka et al.. 2000). Interestingly. MTl-MMP expression is also 
associated with several physiological processes, including bone resorption, implantation, and 
mammary gland development (Vu and Werb. 2000). In rats and mice. MTl-MMP mRNA is 
expressed during follicular development, ovulation, and formation and regression of the CL (Liu 
et al.. 1998: Goto et al.. 1999: Hagglund et al.. 1999: Liu et al.. 1999).
In order to establish the presence and activity o f MTl-MMP in a domestic ruminant, the 
objectives o f the present study were to clone and sequence the bovine specific MTl-MMP, and 
determine the pattern o f mRNA and protein expression in relation to MMP-2 activity in early, 
mid. and late stage CL obtained throughout the estrous cycle.
Materials and Methods
1. Molecular Cloning and Sequencing of Bovine MTl-MMP cDNA
A bovine UNI-ZAP II cDNA library was constructed using RNA isolated from bovine 
capillary endothelial cells o f adrenal cortex with Oligo(dT) primers. The catalytic domain of
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bovine M Tl-M M P cDNA was amplified from this library using PCR primers designed according 
to the conserved regions o f MTl-MMP o f  other species (Massova et al., 1998). The remaining 
cDNA was amplified using primer-walking. PCR products were subsequently cloned into the 
PCRTA-cloning vector (Invitrogen. Carlsbad, CA) for DNA sequencing. cDNA sequencing was 
performed with PCR-based automated sequencing methods (Biopolymer Facility and DNA 
Sequencing Core Facility. Children's Hospital, Boston. MA). Protein database searches were 
assessed by using the BLAST service o f the National Center for Biotechnology Information 
(Bethesda. MD). DNA and protein sequence analyses were conducted using the Mac Vector 6.0 
DNA sequence analysis software package (Kodak. Rochester, NY).
2. Animals and Tissue Collection
Corpora lutea were collected from regularly cycling, nonlactating dairy cows that were 
housed at the University of New Hampshire Dairy Teaching and Research Center. Luteal tissues 
were removed on days 4. 10. and 16 o f the estrous cycle (day 0 = estrus: n=3 per day). For day 4 
CL. the ovary was removed by coipotomy after the cow received an epidural anesthetic [2% (v/v) 
mepivacaine hydrochloride: 0.01 mLAg BW: (Upjohn. Kalamazoo. MI)], and the CL was then 
dissected from the ovarian stroma. The day 10 and 16 CL were removed from the ovary by 
enucleation. All animal experimentation protocols were approved by the Institutional Animal 
Care and Use Committee (IACUC) at the University of New Hampshire.
3. Tissue Distribution of M Tl-M M P
In order to determine the tissue distribution o f MTl-MMP. poly(A)+ RNA from bovine 
liver, brain, kidney, lungs, heart and spleen was purified using a modified guanidinium 
thiocyanate method (Chomczvnski and Sacchi. 1987) followed by poly(A)+ RNA selection with 
two rounds o f  oligo(dT)-cellulose columns. Poiy(A)+ RNA (2.5pg) was fractionated on 1% 
formaldehyde agarose gels before transfer onto nylon membranes (Schleicher & SchuelL Keene,
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NH). A 700bp cDNA probe, corresponding to nucleotides 900 to 1600 of bovine MTl-MMP 
coding sequence, was labeled with 32p-dCTP using the Rediprime™ II Random Prime Labeling 
System (Amersham Pharmacia Biotech, Piscataway, NJ). The blots were then hybridized 
overnight at 65°C with radiolabelled probes at a concentration o f 2x 107 cpm/lOml, followed by 
washing with lxSSC (150mM sodium chloride. 15mM sodium citrate, pH 7.0) at room 
temperature and 0. lxSSC at 65°C.
4. Northern Blotting of Luteal Tissues
For analysis o f luteal tissues, the same cDNA probe described above was labeled with 
digoxigenin (DIG)-dUTP using the DIG DNA Labeling Kit (Roche Molecular Biochemicals. 
Indianapolis. IN). Total RNA was isolated from luteal tissues using the guanidine thiocyanate- 
phenol acid extraction protocol as described by Chomczynski and Sacchi (Chomczynski and 
Sacchi. 1987). Following quantification by absorbance at 260nm. 20pg o f total RNA was 
fractionated on 1 % (w/v) agarose gels containing formaldehyde and transferred onto Hybond™- 
N+ nylon membranes (Amersham Pharmacia Biotech. Piscataway. NJ) by capillary blotting using 
20xSSC (3M sodium chloride. 300mM sodium citrate. pH 7.0). After an overnight transfer, 
nucleic acids were cross-linked with a UV Crosslinker (Hoefer. San Francisco. CA). 
Prehybridization was performed at 50°C in standard hybridization buffer containing 50% (v/v) 
formamide. 5xSSC. 0.2% (w/v) SDS. and 2% (w/v) blocking reagent (Roche Molecular 
Biochemicals. Indianapolis. IN) for 2 hours. The membranes were then hybridized in the same 
buffer containing DIG-labeled MTl-MMP cDNA probe overnight at 65°C. The blots were 
washed twice at room temperature in 2xSSC in 0.1% (w/v) SDS, followed by higher stringency 
washes with 0.1 xSSC in 0.1% (w/v) SDS at 65°C. The membranes were then equilibrated in 
washing buffer [0 .1M maleic acid. 0 .15M NaCL 0.3% (v/v) Tween-20, pH 7.5] for 1 minute, 
followed by a  30-minute incubation in 1% (w/v) blocking solution (in washing buffer). The
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membranes were then incubated in the same blocking solution containing an anti-DIG antibody 
conjugated to alkaline phosphatase (1:5000; Roche Molecular Biochemicals, Indianapolis, IN). 
After two rinses with washing buffer, the blots were incubated with CSPD (Roche Molecular 
Biochemicals. Indianapolis. IN), a chemiluminescent substrate for alkaline phosphatase. Signals 
were visualized after development o f Kodak XAR-5 films by a Konica Medical Film Processor 
(Tokyo. Japan).
S. W estern Blot Analysis
Finely minced luteal tissue was homogenized in an extraction buffer [50mM Tris-HCl. 
150mM NaCl. 0.02% (w/v) sodium azide. lOmM EDTA. 1% (v/v) Triton X-100. lOpg/ml 
aprotinin. lpg/ml pepstatin A. Ipg/ml aminoethyl benzenesulphonyl fluoridej described by Lehti 
et al. (Lehti et al.. 1998) with minimal modification (pH 7.5). A ratio o f 0 .125g luteal tissue and 
1.0 mi extraction buffer was maintained. Following extraction, the samples were centrifuged at 
800g for 10 minutes at 4°C to enable collection of the supernatant fraction.
To assess the protein expression pattern of MTl-MMP in different ages o f CL. equivalent 
amounts o f tissue extracts were subjected to SDS-PAGE on 10% (w/v) polyacrylamide gels. 
Fractionated proteins were then electrophoreticallv transferred to Protran nitrocellulose 
membranes (Schleicher & Schuell. Keene. NH). Nonspecific binding sites were blocked with 5% 
nonfat powdered dry milk in TBST buffer [0.01M Tris-HCl. 0.15M NaCl. 0.05% (v/v) Triton X- 
100. pH 8.0] for 2 hours. A rabbit anti human MTl-MMP polyclonal antibody (1:500: Chemicon 
International Inc. Temecula. CA). which recognizes the conserved hinge region o f  the bovine 
molecule, was diluted in 5% nonfat dry milk in TBST. applied onto the membranes, and 
incubated overnight at room temperature. The membranes were then washed five times, 15 
minutes each, with TBST before a 1 hour incubation with anti-rabbit IgG conjugated to 
horseradish peroxidase (1:15.000: Pierce. Rockford, IL) at room temperature. After another five
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washes as described above, the blots were developed writh the use o f SuperSignal9 West Pico 
Chemiluminescent Substrate (Pierce. Rockford, IL) according to the manufacturer’s instructions. 
The protein bands were finally visualized after exposure to Kodak XAR-5 film (Kodak,
Rochester. NY). Low range Prestained SDS-PAGE Standard (Bio-Rad Laboratories, Hercules, 
CA) was run in adjacent lanes.
6. Gelatin Zvmographv
Gelatinolytic activity in luteal tissue samples was detected using a  modified protocol that 
was previously described (Goldberg et al.. 1996). Briefly, equivalent amounts o f tissue extracts 
were electrophoresed on 10% polyacry lamide gels impregnated with 0.5mg/ml gelatin. After 
electrophoresis. SDS was removed from gels by two 15-minute washes with 2.5% (v/v) Triton X- 
100. and then incubated overnight at 37°C in substrate buffer (50mM Tris-HCl. 5mM CaCL. 
50mM NaCl. pH 8.0). The gels were stained with 0.1% (w/v) Coomassie Brilliant Blue R-250 
(Bio-Rad Laboratories. Hercules. CA) for 30 minutes, and destained with distilled H ;0. 
Gelatinolytic activity was revealed as clear bands against a  blue-stained background. Perfect 
Protein™ Markers (Novagen. Madison. WT) and a positive control, the conditioned medium of 
HT1080 cells, were run in adjacent lanes.
In order to verify' that the gelatinolytic activities detected were metalloproteinases, gels 
were incubated with substrate buffer containing lOmM 1.10-phenanthroline (Sigma, St Louis. 
MO), a specific MMP inhibitor and a zinc ion chelator. By interfering with the zinc-containing 
active site o f MMPs. zones of clearance are prevented from forming. Furthermore, in order to 
distinguish between the latent and active forms o f MMPs. samples and conditioned medium of 
HT1080 cells were incubated with 2mM p-aminophenylmercuric acetate (APMA; Sigma, St 
Louis. MO) tor 2 hours at 37°C prior to zymography. This results in the cleavage o f latent MMPs
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to their "active'1 lower molecular weight forms, which may undergo further processing, i.e., 
autolvtic cleavage.
7. Immunohistochemistrv
Tissue sections (6pm) were cut onto Superffost slides (Fisher Scientific, West Chester, 
PA), and air-dried at room temperature for 30 min. Sections were then fixed in cold acetone for 
10 min. and washed with phosphate-buffered saline (PBS. pH 7.4). Endogenous peroxidase 
activity was quenched by incubating sections with 0.3% (v/v) hydrogen peroxide for 30 min. 
Nonspecific binding was blocked for 30 min by 5% (w/v) BSA. Sections were subsequently 
incubated at room temperature for 1 hour with a 1:250 dilution o f a polyclonal rabbit anti-MTl- 
MMP (Chcmicon International Inc. Temecula. CA). After washing, slides were incubated with 
biotin conjugated goat anti-rabbit IgG (1:200; Vector Laboratories. Burlingame. CA). before 
visualization with the VECTASTAIN'8 Elite ABC Kit (Vector Laboratories. Burlingame. CA) 
according to the manufacturer's instructions. For each tissue sample, an adjacent section placed 
on the same slide was used as a negative control, with BSA substituting for the primary antibody. 
After completion of the color reaction, the slides were counter-stained with Gill 2 Hematoxylin 
(Shandon. Pittsburgh. PA). For each tissue (3 corpora lutea for each age). 10 to 20 sections were 
stained. A minimum of 20 areas per section was examined.
8. Densitometry
Northern blots. Western blots, and zymograms were analyzed with UN-SCAN-IT gel™ 
automated digitizing system (Silk Scientific Inc. Orem. UT). For Northern blots, densities o f 
MT1-MMP and 28S rRNA were used to calculate the MTI-MMP/28S rRNA density ratio for 
each sample. Similarly, for zymography. levels o f latent and active MMP2. and the HT1080 
positive control were used to calculate the MMP2/HT1080 ratio for each sample.
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9. Statistics
Each sample was run in triplicate. Quantitative values were expressed as means ± SEM. 
All data were analyzed by ANOVA. followed by Tukev's test o f pairwise comparisons to 
determine differences between the three age groups o f  CL. A value of p<0.05 was considered 
significant.
Results
1. Sequence Analysis of Bovine MT1-MMP
The bovine MT1-MMP cDNA contained an open reading frame o f 1749 bp (GenBank 
accession number AF290429: July 27th. 2000). which encoded a protein o f 582 amino acids 
(Figure IA). All three characteristic regions of the MT-MMP subfamily, the 11-amino-acid 
insertion (IS-I) between the propeptide and catalytic domains, the 8-amino-acid (IS-II) insertion 
tn the catalytic domain, and the 75-amino-acid (IS-UI) at the C terminus, were also present at 
these positions in bovine MT1-MMP (Figure IB). Alignment of the predicted protein sequences 
revealed significant homology between the bovine MT1-MMP protein and other species, with rat 
being the highest (95.9%). followed by human (95.7%). mouse (95.0%). and rabbit (92.3%) 
(Figure 1C).
2. Tissue Distribution of MT1-MMP mRNA
Northern blotting revealed a 3.5 kb transcript in a variety o f  bovine tissues, with the 
strongest signal in the lungs, followed by spleen, kidney, heart and liver. The signal in the brain 
was undetectable (Figure 2).
3. Expression o f MT1-MMP in Bovine Corpus Luteum
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A single 3.5 kb transcript was detected by Northern blotting in luteal tissues collected at 
early, mid-, and late stages o f the estrous cycle (Figure 3A). However, the levels o f MT1-MMP 
mRNA. expressed as a ratio o f the MT1-MMP band density for each CL sample to its 
corresponding 28S rRNA band density, were similar (p>0.05) among the three stages (Figure 
3B).
MTl-MMP was studied in bovine CL by Western blot analysis. In all samples, two bands 
with a  relative molecular mass of -63 kDa, consistent with the latent form of MTl-MMP, and 
-60  kDa. consistent with the active form o f MTl-MMP. were observed (Figure 4A). The level of 
active MTl-MMP protein in the d4. early CL was significantly lower (p<0.05) than mid- and late 
stages (Figure 4B).
4. Expression of MTl-MMP is Correlated to Pro-MMP-2 Activation
MMP-2 activity in the bovine CL during the estrous cycle was determined by gelatin 
zymography (Figure 5 A). Visual observation revealed an -68 (pro-MMP-2) and -62  kDa (active 
MMP-2) species in all luteal samples. While the intensity- o f the -68 kDa species did not vary, the 
intensity o f the -62  kDa species in the d4. early CL. appeared to be less than the other two older 
stages. Incubation o f samples with 1. 10-phenanthroline prevented the appearance o f gelatinolytic 
zones of clearance (data not shown), indicating that these clear zones on the zymograms reflected 
MMP activities. Lastly, the decrease in band intensity- o f the -68 kDa band after treatment o f 
luteal samples and conditioned medium o f HT 1080 cells with APMA for two hours at 37°C 
suggested that this enzyme species was the latent form of MMP-2 (Figure 5C).
Densitometric analysis revealed that the levels o f the -68  kDa pro-MMP-2 were similar 
(p>0.05; data not shown) among the three stages o f CL. However, the level o f the -62  kDa active 
form o f MMP-2 increased during the progression o f the estrous cycle, being significantly greater 
(p<0.05) in dlO and d!6 CL than in the early stage (Figure 5B).
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5. Cellular Distribution of MTl-MMP
Immunohistochemistry was used to investigate the cellular localization o f MTl-MMP in 
the bovine CL. Overall, the cellular distribution o f  MTl-MMP varied throughout the life span of 
the CL. In the early (Figure 6A) and mid-cycle (Figure 6B) CL. MTl-MMP was localized in 
endothelial ceils, and on the cell membrane and cytoplasm of large luteal cells, consistent with 
cellular processing o f the MTl-MMP protein in cytoplasmic organelles before becoming resident 
on the cell membrane. In the late stage CL (Figure 6C). the expression o f MTl-MMP was 
predominantly observed in fibroblasts, which were identified based on cell shape. However, 
endothelial and large luteal cells were weakly stained in the late stage CL. No staining was 
observed when the primary antibody was omitted (Figure 6D).
Discussion
To date. MTl-MMP nucleotide and predicted protein sequences are known for the human 
(Sato et al.. 1994). mouse (Apte et al.. 1997). rat (Okada et al.. 1995a). and rabbit (Sato et ai.. 
1997b). while there are no reports, to our knowledge, regarding its sequence and expression in 
agriculturally important species such as domestic ruminants. In the present study, we report the 
bovine-specific MTl-MMP complementary nucleotide sequence and demonstrate its expression 
and localization in the bovine CL. The bovine MTl-MMP cDNA consisted o f 1746 bp 
nucleotides, which encode a 582 amino-acid protein. Sequence alignment indicated that the 
bovine M Tl-M M P was highly similar (>92%) to the ra t  human, mouse, and rabbit homologs. In 
addition, bovine MTl-MMP shares the characteristics typical o f  other membrane-type 
metalloproteinases. e.g.. the 11 amino acids insertion (IS-l) between the propeptide and the 
catalytic domains that serves as a putative convertase recognition site, the RXKR motif (IS-II) in 
the catalytic domain, and the transmembrane segment (IS-III) (Murphy et al., 1999a). These 
results strongly suggest that this molecule is highly conserved among the mammals investigated 
thus far. Furthermore, as in the human (Sato et al., 1994) and the rabbit (Sato et al., 1997b),
- 9 0 -
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
bovine M Tl-M M P had broad tissue distribution, suggesting multiple sites o f action in these 
species.
Since information regarding MTl-MMP and ovarian function is limited, the remainder of 
the present study focused on the bovine CL. Previously. MTl-MMP transcripts have been shown 
to be present in mouse ovaries (Hagglund et al., 1999) and in developing and regressing rat CL 
(Goto et al.. 1999; Liu et al.. 1999). Here, we found that MTl-MMP mRNA was constitutivelv 
expressed in all three stages o f luteal development, however, the level o f active MTl-MMP 
protein was greater in the mid- and late stage bovine CL than that in the early stage. A major 
function o f M Tl-M M P is to activate latent MMP-2. In contrast to other MMPs. the activation 
process o f pro-MMP-2 is unusual in that it is not through the extracellular proteolytic cleavage by 
serine proteinases (Murphy et al.. 1999b). but rather the activation o f pro-MMP-2 is localized on 
the cell membrane (Murphy et al.. 1992b). A ternary molecular complex model is hypothesized in 
which TIMP-2 binds to MTl-MMP forming a cell surface "co-receptor" for pro-MMP-2 (Butler 
et al.. 1998; Zucker et al.. 1998). This cell surface bound pro-MMP-2 is subsequently activated by 
the adjacent active MTl-MMP (Zucker et al.. 1998; Stetler-Stevenson. 1999). Indeed, in rats (Liu 
et al.. 1998). MTl-MMP and MMP-2 mRNA are coordinately expressed and localized during 
follicular development and ovulation. In the bovine CL. we demonstrated that active MMP-2 
enzyme levels correlated to that of active MTl-MMP. Thus, together with our observation that 
TIMP-2 was also coordinately expressed (Zhang and Tsang, 2001), we suggest that in the bovine 
CL. as is the case in other tissues. MTl-MMP is an endogenous activator of pro-MMP-2.
The cellular localization of MTl-MMP in luteal tissue was also investigated. The 
formation and development of the CL are associated with tissue remodeling and angiogenesis 
(Smith et al.. 1999; Reynolds et al.. 2000). Angiogenesis is the formation o f new capillaries from 
pre-existing vessels. This complex, multi factor-regulated process requires angiogenic factors to 
stimulate production o f  MMPs, which degrade the basement membrane surrounding endothelial 
cells (Moses. 1997; Klagsbrun and Moses. 1999). This alteration o f  the ECM leads to endothelial
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cell proliferation and migration. As vessels extend, additional MMPs are required to break down 
the ECM. accommodating the growth o f sprouting vessels (Klagsbrun and Moses. 1999). M Tl- 
MMP might mediate these processes because angiogenesis is impaired in MTl-MMP deficient 
mice (Zhou et al.. 2000). and it is highly associated with malignant tumor angiogenesis (Hiraoka 
et al.. 1998). In the present study. MTl-MMP was localized in endothelial cells of the young 
bovine CL. where it might directly digest ECM proteins (Imai et al.. 1996; Ohuchi et al., 1997; 
Butler et al.. 1998). Indeed, co-incubation o f purified MTl-MMP and collagen types I. IL and m  
before SDS-PAGE (Ohuchi et al.. 1997) yielded cleavage products, while very weak gelatinolytic 
activity by MTl-MMP mutants lacking a  transmembrane domain was observed using 
zymography (Imai et al.. 1996). This may explain the lack of a readily detectable band in 
zymograms of our luteal tissue samples. Besides MTl-MMP. MMP-2 is also required for 
angiogenesis (Moses. 1997). In an in vivo tumor system. MMP-2 activity is necessary for the 
switch to the angiogenic phenotype during tumor development (Fang et al.. 2000). Consistent 
with these findings is the fact that injection o f ewes with a MMP-2 antibody results in defects of 
the CL vasculature (Gottsch et al.. 2001). Together with our preliminary finding that MMP-2 is 
localized in bovine luteal endothelial cells (Zhang and Tsang, 2001). MTl-MMP might mediate 
the angiogenic process by activating pro-MMP-2. which in turn digests collagen type IV. a major 
component o f the basement membrane (Moses. 1997). Thus, following ovulation, when the 
follicle is transformed to become the richly vascularized CL. MTl-MMP might have a dual role 
as a proteolytic enzyme and an activator o f pro-MMP-2.
As the CL develops, ongoing angiogenesis is necessary to establish and maintain the 
mature vascular network (Dickson et al.. 2001). In fact, the density o f the vasculature is highest in 
mid-cycle cow (Zheng et al.. 1993) and mature human (Gaytan et al., 1999) CL. correlating with 
the high metabolic rate, and the high rate o f blood flow and progesterone production by the CL 
(Bruce and Moor. 1976; Zheng et al., 1993). Progesterone either decreases (Jaggers et al., 1996; 
Zhang et al.. 2000c) or increases (Chaffin and StoufFer. 1999; Luo and Liao, 2001) MMP activity
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and angiogenesis. In part this may be attributed to cell type or species differences. In the present 
study', the active form o f both MTl-MMP and MMP-2 enzymes increased in mid- and late stage 
CL. consistent with the need for MMP production and activity for vascular maintenance.
In addition to endothelial cells, MTl-MMP was prominently expressed on the 
membranes o f mid-cycle large luteal cells. Accompanying the development o f the luteal 
vasculature, there is also a rapid increase in luteal weight and size (Zheng et al., 1994), although 
this increase is primarily attributed to the proliferation of non-luteal cells such as fibroblasts and 
endothelial cells (Farin et al.. 1986: Lei et al.. 1991), and small luteal cells (Zheng et al., 1994). 
The sizes o f large luteal cells also enlarge from the early to mid-cycle stage (Schwall et al.. 1986: 
Lei et al.. 1991). To accommodate this growth. MTl-MMP might act directly or indirectly 
through activation of locally produced pro-MMP-2 to commence the pericellular degradation of 
the ECM (Hiraoka et al.. 1998). The activated MMP-2 may then bind to luteal cell membranes 
through an integrin such as OvP3 (Brooks et al.. 1996). Thus, in large luteal cells. MTl-MMP and 
its associated actions might facilitate cell-matrix and cell-cell interactions, which ultimately could 
regulate steroidogenesis (Smith et al.. 1999).
At the end o f estrous cycle, luteolysis ensues, whereby luteal progesterone production 
(Niswender and Nett. 1994). size and weight (Niswender and Nett. 1994: Zheng et al.. 1994) 
decrease dramatically. There is also apoptosis of luteal cells (Juengel et al.. 1993). In the present 
study. M Tl-M M P was localized in fibroblasts of the late stage, day 16 CL. At this time, these 
cells also undergo proliferation (Lei et al.. 1991). This switch in cellular distribution o f M Tl- 
MMP. when compared to the young and mid-cvcie CL. might occur in anticipation of the 
functional and structural changes that are soon to follow. Indeed, fibroblast M Tl-MMP might 
participate in the luteolvtic process by degrading connective tissue ECM as part o f the structural 
demise o f the CL.
Although the literature base is relatively small, there are reports o f differences or 
consistent trends in expression patterns o f  MMPs and TIMPs in species with long luteal phases.
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Similar to the present study, high MMP-2 activity is observed in the late stage human CL 
(Duncan et al.. 1998). and in mid and late stages o f the porcine CL (Pitzel et al., 2000). When 
MTl-MMP is low. MMP-9 (Goldberg et al., 1996) and TIMP-1 mRNA (Smith et al., 1996) are 
increased early in the cycle, while TIMP-2 protein (Goldberg et al.. 19%; Zhang and Tsang, 
2001) and mRNA (Smith et al.. 1996; Zhang and Tsang, 2001). along with MTl-MMP (present 
study), are increased during the mid-luteal phase in the bovine. In the human CL, MMP-9 peaks 
in early and late stages, but TIMP-1 and -2 do not change over the luteal phase (Duncan et al.. 
1998). In contrast TIMP-1 and -2 mRNA levels decline with age o f the porcine CL. while 
MMP-l and -9 are highest in the late phase (Pitzel et al.. 2000). However, in the sheep CL. 
TtMP-2 mRNA in the early phase is greater than the late phase (Smith et al.. 1995). but TIMP-1 
mRNA does not vary over the cycle (Smith et al.. 1994). Collectively, among the non-laboratory 
mammals, a number o f  MMPs. including MTl-MMP in the bovine, and TIMPs. may work in 
concert to regulate remodeling o f the vasculature and the ECM during the life span o f the CL.
In summary , the present study reports the cDNA and predicted protein sequences of 
bovine M Tl-M M P and the pattern o f mRNA and protein expression in CL harvested over the 
bovine estrous cycle. Active MTl-MMP and active MMP-2 protein levels were coordinately 
increased in mid- and late stage CL. supporting the role of MTl-MMP as an activator of pro- 
MMP-2 in vivo. The localization of MTl-MMP in endothelial cells, in large luteal cells, and in 
late cycle fibroblasts was associated with the angiogenesis and structural remodeling that occur 
over the life span o f the CL. Collectively, these data indicate that MTl-MMP might act on the 
ECM to modulate the local environment, which in turn may influence vascular development and 
the function o f luteal cells, e.g.. hormone biosynthesis, by affecting intercellular and cell-matrix 
communication.
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Sequence and homology analysis o f bovine MTl-MMP
ggcgtgggccccgccgcggagcccgcttggcccggctgcccggacagtcgcggacc 60 
a tg tc tc c c g c c c c a c g a c c c g c c tg c a g tc tg c tg c tc c c c g tg c tc a c g c tc g c c tc c  120 
1 M S P A P R P A C S L L L P V L T L A S
g cg c tcg cc tccc tcag c tc tg cccag ag cag c ttcag ccccg aag cc tg g c tg cag cag  180 
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41 H G Y L P P G D L R T H T Q R S P Q S L
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gaggccatccgcaaggcattccgagcgcgggagag tgcaacgccac tgcgctcccgagag  540 
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gtacccca tg c cc aca cc cg tg ag g g cc ac g ag a ag c ag g c cg ac ac ca tg a tc ttc ttc  600 
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181 A E G F H G D S T P F D G E G G F L A H
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ac tg tc cg g a ac g ag g a ccc aa ac g g g aa tg ac a tc tttc tg g tg g c tg tg c ac g ag c cg  780 
221 T V R N E D L N G N D I  F L V A V H E L
g g c c a tg c c c tg g g c c ttg a g c a ttc c a a c g a tc c c tc g g c c a tc a tg g c a c c c tttc a c  840 
241 G H A L G L E H S N D P S A I M A P F Y
cag tgga tggacacagagaac tccg tgc tgcc tga tgacgaccgccggggca tccagcaa  900 
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a g g c c ttcc g tcc cc g a ta ag c cc aa aa a tc cc ac c ta cg g g c cca ac a tc tg tg a tg g g  1020 
301 R P S V P D K P K N P T Y G P N I C D G
a a c tttg a c a c c g tg g c c a tg c ttc g a g g g g a g a tg tt tg tc t tc a a g g a g c g ttg g ttc  1080 
321 N F D T V A M L R G E M F V F K E R W F
tg g cg cg taag g aaaaaccag g tg a tg g acg g a tacccca tg ccca tcg g ccag ttc tg g  1140 
341 W R V R K N Q V M D G Y P M P I G Q F W
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c a c a tta a g g a g c tg g g c c g a g g a c tg c c ta c tg a c a g g a ttg a tg c tg c tc tc ttc tg g  1320 
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461 S P R G S F M G S D E V F T Y F Y K G N
aag ta c tg g a aa ttc aac aa cc ag a ag c tg aa g g ttg a g cc g g g c ta cc cca ag tca g cc  1560 
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ctgcgggactggatgggctgcccatcatcggggggccagccggatgaggggactgaggag  1620 
501 L R D W M G C P S S G G Q P D E G T E E
gagacggaggtgatcatcatcgaggtggacgaggaaggcagcggggcagtgagcgcggcc 1680 
521 E T E V I  I I E V D E E G S G A V S A A
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Figure 3-1. Sequence and homology analysis o f bovine MTl-MMP. A) Nucleotide sequence of 
bovine MTl-MMP cDNA and its deduced amino acid sequence. The protein sequence is shown 
in uppercase letters and the DNA sequence in lowercase. While the numbers on the left are for the 
amino acid sequence, the ones on the right are for the cDNA sequence. B) Alignment o f predicted 
MTl-MMP amino acid sequences o f bovine, human, mouse, rat, and rabbit. The asterisks indicate 
the amino acid residues that are conserved among the five MTl-MMPs. The consensus sequences 
of the convertase recognition site (IS-I), the catalytic domain insertion (IS-II), and transmembrane 
domain (IS-III) are shaded. The signal peptide, propeptide, catalytic, hinge, hemopexin-like, and 
transmembrane domains are also indicated. There was a 95.7%, 95%, 92.3%, and 95.9% 
homology of bovine MTl-MMP to human, mouse, rabbit, and rat MTl-MMP, respectively. C) 
Homology analysis o f  bovine MTl-MMP domains with other species. The signal peptide 
(Signal), propeptide (Pro), catalytic (Cat), hinge (Hinge), hemopexin (Hex), and transmembrane 
(TM) domains are indicated. Species names appear on the left. The whole molecule (Overall) and 
individual domains o f MTl-MMPs are compared. The numbers represent percentages. The 
identity scores are determined by setting the bovine MTl-MMP as 100 percent.
- 9 7 -
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.












Figure 3-2. Tissue distribution of bovine MTl-MMP mRNA. For Northern analysis, mRNA 
was extracted from bovine brain, heart, kidney, liver, lung, and spleen before probing with 
bovine MTl-MMP. The positions o f 28S and 18S rRNA are indicated on the left. A single 3. 
kb transcript was detected (arrow).
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MTl-MMP mRNA expression in the bovine CL
M
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Figure 3-3. Expression o f MTl-MMP mRNA in different ages o f bovine CL. A) The upper panel 
shows that a single 3.5 kb MTl-MMP transcript (arrow) was detected in early (E; day 4), mid- 
(M: day 10), and late (L; day 16) cycle CL. Corresponding positions o f 28S and 18S rRNA are 
indicated on the left. The lower panel shows ethidiutn bromide staining o f 28S rRNA. B) The 
levels o f MTl-MMP mRNA, expressed as the densitometric ratio of MTl-MMP to 28S rRNA, 
were not different (p>0.05) among any age o f CL. Dissimilar letters denote significant difference 
at p<0.05.
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M Tl-M M P protein expression in the bovine CL
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Figure 3-4. Expression o f MTl-MMP protein in different ages o f bovine CL. A) In early (E; day 
4). mid (M; day 10), and late (L; day 16) cycle CL, the -63 kDa latent and the -60  kDa active 
MTl-MMP species were observed. B) Densitometric analysis (average total pixelsxlO5) showed 
that the active form o f MTl-MMP in early (day 4) CL was significantly lower (p<0.05) than in 
mid (day 10) and late (day 16) CL. Dissimilar letters denote significant difference at p<0.05.
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MMP-2 activity in the bovine CL
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Figure 3-5. Gelatin zymographic analysis o f MMP-2 activity in bovine CL. A) Perfect Protein™ 
Markers (Novagen, Madison, WI) were loaded in lane 1 (MW). The positive control, PMA 
(Phorbol 12-myristate 13-acetate)-stimulated HT1080 conditioned medium (HT), was loaded in 
lane 2. Representative early (E; day 4), mid (M; day 10), and late (L; day 16) luteal samples were 
loaded in lanes 3 to 5, respectively. The arrows on the right indicate the pro- and active forms of 
MMP-2 in the positive control and CL samples. The relative molecular masses o f protein markers 
are indicated on the left. B) The active form of MMP-2, expressed as the densitometric ratio of 
CL samples to HT 1080 conditioned medium, was significantly lower (p<0.05) in early (day 4) 
cycle CL than in mid (day 10) and late (day 16) stages. Dissimilar letters denote significant 
difference at p<0.05. C) Treatment with APMA. Samples o f HT1080 conditioned medium (HT) 
and representative early (E; day 4), mid (M; day 10), and late (L; day 16) CL extracts were 
incubated at 37°C with (+) or without (-) 2mM APMA before zymographic analysis. Perfect 
Protein™ Markers were loaded in lane I. The numbers on the left indicate relative molecular 
mass (kDa). Arrows indicate the pro- and active forms o f MMP-2.
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Cellular localization o f M Tl-M M P in the bovine CL
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Figure 3-6. MTl-MMP immunohistochemistry in the bovine CL. A) In the early (day 4) cycle 
CL, positive staining is observed in endothelial (black arrows), and the cell membrane and 
cytoplasm of large luteal (white arrows) cells (x400). B) In the mid (day 10) cycle CL, the 
staining is localized on large luteal cell plasma membranes and cytoplasm (white arrows), and 
endothelial cells (black arrows; x400). C) In the late (day 16) stage CL, there was predominant 
staining in fibroblasts (white arrowheads; x400), and weak staining in endothelial (black arrows) 
and large luteal (white arrows) cells. D) Negative control of a representative section o f mid (day 
10) cycle CL. No positive staining was observed (x400).
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CHAPTER IV
TEMPORAL AND SPATIAL EXPRESSION OF TISSUE INHIBITORS OF 
MET AL LOPROTEINASES I AND 2 (TIMP-l AND -2) IN THE 
BOVINE CORPUS LUTEUM
Abstract
The matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue 
inhibitors of metalloproteinases (TIMPs), may mediate the dramatic structural and 
functional changes in the corpus luteum (CL) over the course of its life span. Besides 
regulating MMP activity, TIMPs are involved with a variety of cellular processes, 
including cell proliferation and steroidogenesis. In order to gain a greater understanding 
of the role o f TIMPs in luteal function, we investigated the temporal and spatial 
expression of TIMP-1 and TIMP-2 in the bovine CL. Luteal tissues were collected from 
early (4 days old, estrus=day 0), mid (10-11 days old) and late (16 days old) phases (n=3 
for each phase) of the estrous cycle. Northern blotting revealed that the TIMP-1 transcript 
(0.9kb) was expressed at a higher (p<0.05) level in early and mid cycle CL than in the 
late stage. On the other hand, two TIMP-2 mRNA species, one major I kb species and 
one minor 3.5kb species, were significantly increased (p<0.0S) in the mid and late cycle 
CL than in the early. Reverse zymography demonstrated four metalloproteinase 
inhibitory protein bands with relative molecular masses that are consistent with these 
reported for TIMP-1 to -4. TIMP-1 was the major species in the bovine CL. Western 
blotting showed no differences in TIMP-1 (29 kDa) protein levels between early and mid
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phases, while its levels decreased (p<0.05) from the mid to late stage CL. Conversely, 
TIMP-2 (22 kDa) protein was low in the early CL, but significantly increased (p<0.05) in 
the mid and late stages. Immunohistochemistry revealed that both TIMP-1 and -2 were 
localized in large luteal cells from all three ages of CL. Furthermore, TIMP-1 was also 
localized in vascular smooth muscle cells, but TIMP-2 was restricted to the endothelial 
cells in the capillary compartment. Overall, these results suggested that the variations in 
TIMP-l and -2 expression may suggest diverse roles for these multifunctional MMP 
inhibitors in the physiology of the CL during the estrous cycle.
Introduction
The corpus luteum (CL) is a transient, dynamic endocrine gland, which develops from 
the postovulatory follicle (Niswender and Nett. 1994). Dramatic structural and functional changes 
are associated with the development, maintenance and regression o f the CL (Niswender and N ett 
1994). These remodeling events require the participation o f matrix metalloproteinases (MMPs). a 
large family of zinc and calcium dependent proteolytic enzymes that collectively digest all known 
macromolecules constituting the extracellular matrix (Matrisian. 1990: Massova et al.. 1998). 
Generally, the catalytic activity o f the MMPs are highly regulated at three levels, gene 
expression, proteolytic activation of proenzymes, and inhibition by binding o f endogenous tissue 
inhibitors o f metalloproteinases (TIMPs) to the catalytic domain (Matrisian, 1990: Woessner and 
Nagase. 2000).
So far. four TIMPs. including TIMP-1 (Carmichael et al.. 1986), TIMP-2 (Stetler- 
Stevenson et al.. 1989). TIMP-3 (Pavloff et al.. 1992). and TTMP-4 (Greene et al., 1996), have 
been identified. TIMP-1. a glycoprotein with a molecular mass o f approximately 29kDa, is the 
first member o f this family to be cloned (Carmichael et al.. 1986). TIMP-1 can bind the active
- 105 -
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
forms o f all known MMPs (Woessner and Nagase, 2000). In addition, TTMP-1 also binds the 
latent form of MMP-9 (Itoh et al., 1995). Besides its capacity to inactivate the activity o f MMPs, 
TIMP-1 also possesses mitogenic activity to a variety o f cell types, such as gingival fibroblasts 
and erythroid precursor cells (Docherty et al.. 1985: Hayakawa et al.. 1992). In addition, TIMP-l 
may regulate steroidogenesis (Boujrad et al.. 1995). In CL from a variety of species, protein and 
messenger RNA expression o f  TIMP-l have been observed, including cow (Freudenstein et al.. 
1990; Goldberg et al.. 1996). sheep (Smith et al.. 1994), rat (Nothnick et al.. 1995), mouse 
(Indcrdeo et al.. 1996). monkey (Duncan et al.. 1996a). and human (Duncan et al.. 1996b).
Different from TIMP-1. TIMP-2 is an unglvcosylated protein with an approximate 
molecular mass o f 22 kDa (Stetler-Stevenson et al.. 1989: Goldberg et al.. 1989). TIMP-2 binds 
most active MMPs and inhibits their proteolytic activity' (Woessner and Nagase. 2000). Among 
all members o f the MMP family. TIMP-2 preferentially binds to MMP-2 (Goldberg et al.. 1989; 
Olson et al.. 1997). Paradoxically, however. TIMP-2 is also involved in pro-MMP-2 activation by 
forming a MTl-MMP/TIMP-2/pro-MMP-2 tri-molecular complex on the cell membrane 
(Deryugina et al.. 1997; Cao et al.. 1998; Butler et al.. 1998). Similar to TIMP-1. TIMP-2 
possesses potent stimulatory activity on proliferation of a variety o f ceil types (Hayakawa et al.. 
1994). TIMP-2 mRNA expression was observed in the sheep (Smith et al.. 1995). cow (Smith et 
al.. 1996). human (Duncan et al.. 1998). rat (Simpson et al.. 2001). and mouse (Inderdo et al..
1996) CL. while a TIMP-2-like protein was detected in the cow CL (Goldberg et al., 1996).
Because the variety and intensity of remodeling events that occur over the life span of the 
CL suggest a  temporal and spatial interplay between MMPs and TIMPs. we presently 
investigated the expression patterns and cellular distribution o f TIMP-1 and TIMP-2 in the early, 
mid. and late developmental stages o f bovine CL obtained over the estrous cycle.
Materials and Methods
1. Animal Model and Tissue Collection
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Corpora lutea were collected from cyclic, nonlactating dairy cows, which were housed at 
the University o f  New Hampshire Dairy Teaching and Research Center. CL were removed on day 
4. 10. and 16 o f the estrous cycle (day 0 = estnis; n=3 per day). For day 4 CL, the ovary was 
removed by an ecraseur after the cow received an epidural anesthetic [2% (w/v) mepivacaine 
hydrochloride: 0.01 mL/kg BW: Upjohn, Kalamazoo. MI], and the CL was then dissected from 
ovarian stroma. The day 10 and 16 CL were enucleated from the ovarian stroma. All animal 
experimentation protocols in the present study were approved by the Institutional Animal Care 
and Use Committee (IACUC) at the University o f New Hampshire.
2. Northern Blotting
TIM P-l and TIMP-2 mRNA expression in the CL were studied by Northern blotting as 
previously described (Zhang et al.. 2002). Briefly, total RNA was extracted from luteal tissues 
using TRIZOL (GIBCO-BRL. Carlsbad. CA) according to the manufacturer's instructions. 
Twenty micrograms of total RNA were fractionated on 1.0% (w/v) agarose gels containing 
formaldehyde and were transferred onto Hybond™-N~ nylon membranes (Amersham Pharmacia 
Biotech. Piscataway. NJ). Membranes were first incubated in pre-hybridization buffer [50% (v/v) 
formamide. 5xSSC. 0.2% (w/v) SDS. and 2% (w/v) blocking reagent| for two hours at 42°C. 
Hybridization was carried out in hybridization buffer containing TIMP-1 (Waterhouse et al.. 
1990). TIMP-2 (Stetler-Stevenson et al.. 1989). or cvclophilin (a generous gift from Dr. Robert 
Thompson. University o f Michigan) cDNA probes at 50°C overnight. These cDNA probes were 
labeled with digoxigenin (DIG)-dUTP using the DIG DNA random-primed Labeling Kit (Roche 
Molecular Biochemicals. Indianapolis. IN). The blots were then washed twice at room 
temperature in 2xSSC with 0.1% (w/v) SDS. followed by higher stringency washes in 0.2xSSC 
with 0.1% SDS at 65°C. Hybridized probes were detected using an anti-DIG antibody 
conjugated to alkaline phosphatase (used at 1:5000: Roche Molecular Biochemicals, Indianapolis,
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IN) in L% (w/v) blocking reagent. The signals were detected by CSPD (Roche Molecular 
Biochemicals, Indianapolis. IN), a chemiluminescent substrate for alkaline phosphatase. The blots 
were visualized by developing Kodak XAR-5 films with a Konica Medical Film Processor 
(Tokyo. Japan).
3. Reverse Zvmoeraphv
In order to simultaneously identify- total TIMP proteins in the bovine CL. reverse 
zymographic analysis was performed. Equivalent aliquots (15pl) o f CL tissue extracts were 
mixed with loading buffer [2% (w/v) SDS. 10% (v/v) glycerol. 0.1% (w/v) bromophenol blue. 
50mM Tris-HCl. pH6.8) and applied to 12% (w/v) polyacrylamide gels containing 0.1% (w/v) 
SDS and 0.5 mg/ml gelatin. After electrophoresis, gels were rinsed twice with 2.5% (v/v) Triton 
X-100. followed by incubation with conditioned medium of fibrosarcoma HT1080 cells for 4 
hours. After rinsing, gels were incubated overnight at 37°C in substrate buffer (50mM Tris-HCl.
0.2M NaCl. 5mM CaCU. pH8.0). Subsequently, gels were stained for 30 minutes with 0.1% (w/v) 
Coomassie Blue G-250. and destained with a  solution o f 30% (v/v) methanol and 10% (v/v) 
glacial acetic acid. TTMPs were visualized as blue bands on a clear background. Prestained SDS- 
PAGE standards (Bio-Rad Laboratories. Hercules. CA) were run along side samples as molecular 
weight references.
4. Western Blotting Analysis
To investigate the protein expression o f TIMP-1 and TIMP-2 in different ages o f CL. 
equivalent amounts o f tissue extracts were subjected to SDS gel electrophoresis on 12% (w/v) 
polyacrylamide gels under reducing conditions before transfer onto nitrocellulose membranes 
(Schleicher & SchuelL Keene. NH) Prestained SDS-PAGE standards (Bio-Rad Laboratories, 
Hercules. CA) were also loaded on the gel in an adjacent lane. Nonspecific binding sites were
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blocked with 5% (w/v) nonfat powdered milk in TBST [0.01M Tris-HCl, 0.15M NaCl, and
0.05% (v/v) Tween-20. pH8.0] for 2 hours. A mouse anti human TIMP-1 monoclonal antibody 
(1:100; Oncogene Research Products, Cambridge, MA) in 5% nonfat powdered milk in TBST 
was added onto the membrane, and allowed to incubate overnight at room temperature. The 
membranes were then washed five times with TBST (each time for 15 minutes), and then 
incubated for 1 hour with goat anti-mouse IgG conjugated to horseradish peroxidase (1:15.000. 
Pierce. Rockford. IL) at room temperature. After five. 15-minute washes, the blots were 
developed using the SuperSignal® West Pico Chemiluminescent Substrate (Pierce. IL). 
according to the manufacturer's instructions. The protein bands were finally visualized after 
development of Kodak XAR film (Konica Medical Film Processor. Tokyo. Japan).
S. Immunohistochemistrv
Frozen tissue sections (6pm) were cut onto Superfrost*/Plus slides (Fisher Scientific. 
Pittsburg. PA), and air-dried at room temperature for 30 min. Sections were fixed in cold acetone 
for 10 min. and then washed with phosphate-buffered saline (PBS. pH7.4). Endogenous 
peroxidase activity was quenched by incubating with 0.3% (v/v) hydrogen peroxide for 30 min. 
Nonspecific binding was blocked for 30 min by 5% (w/v) BSA. Sections were subsequently 
incubated at room temperature for 1 hour with a 1:40 dilution o f mouse anti human TIMP-1 
monoclonal antibody (Oncogene Research Products. Cambridge. CA) or with a 1:50 dilution of 
mouse anti human TIMP-2 monoclonal antibody (Oncogene Research Products, Cambridge, CA). 
After washing, slides were incubated with goat anti-mouse IgG followed by VECTASTAIN* 
Elite ABC Kit (Vector Laboratories. CA), according to the manufacturer's instructions.
To further validate the localization o f TIMP-1 in vascular smooth muscle cells (VSMC), 
consecutive sections were also stained with an antibody against a-actm. a cellular marker for
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VSMC. For every tissue, an adjacent section placed on the same slide was used as a negative 
control, where BSA substituted for the primary antibody.
For each tissue (3 corpora lutea for each age). 10 to 20 sections were stained. A minimum 
of 20 areas per section was examined.
6. Data analysis
Intensities o f Northern and Western blots were determined by UN-SCAN-IT gel™ 
automated digitizing system (Silk Scientific. Orem. UT). The data were analyzed by ANOVA. 
followed by Tukey's test for multiple comparisons.
Results
1. TIMP-1 and TIMP-2 mRNA Expression in the Bovine CL during the Estrous Cvde
Northern blotting demonstrated that a single TTMP-1 transcript (0.9kb) was present in all 
three stages o f CL (Figure 4-1 A). The 18S rRNA was used to normalize sample loading. The 
dcnsitometric ratio o f TIMP-1 mRNA to 18S rRNA was high in the early and mid- cycle CL. but 
decreased significantly (p<0.05) in the late stage (Figure 4 -IB).
Two TIMP-2 mRNA species, a major one at lkb and a  minor one at 3.5 kb. were present 
in all ages o f CL (Figure 4-2A). In contrast to the expression pattern o f TIMP-1 mRNA. both 
species o f TIMP-2 mRNA. shown as the densitometric ratio o f TIMP-2 mRNA to a  house­
keeping gene cyclophilin. were low in the early stage, but increased significantly (p<0.05) in the 
mid and late cycle CL (Figure 4-2B).
2. Mctalloproteinase Inhibitor Activities in the Bovine CL
Reverse zymography revealed four protein bands in luteal tissues. These four protein 
bands had relative molecular masses o f ~30kDa. ~27kDa. -  24kDa, and ~22kDa. corresponding
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those reported for TIMP-1. -3, -4. and -2, respectively (Figure 4-3). TIMP-1 was the predominant 
TIMP present in the bovine CL.
3. TIMP-1 and TIMP-2 Protein Levels in the Bovine CL
Western blotting revealed an approximately 30kDa immunoreactive TIMP-1 protein in 
all ages o f CL examined (Figure 4-4A). The level o f TIMP-1 protein was not different between 
the early and mid-cycle CL (p=0.324). but it was significantly decreased (p<0.05) in the late stage 
CL (Figure 4-4B). A 22 IcDa TIMP-2 immunoreactive protein was also observed in all three ages 
of CL (Figure 4-5 A). The TIMP-2 protein level in the mid and late cycle CL was significantly 
greater (p<0.05) than in the early stage (Figure 4-5B).
4. Cellular Localization of TIMP-1 and TIMP-2 Proteins in the Bovine CL
Immunohistochemistry demonstrated that TIMP-1 was present in both large luteal cells 
and vascular smooth muscle cells (Figure 4-6 B, D. and F). The localization o f TIMP-1 in VSMC 
compartments was validated with staining for a-actin. a  cellular marker for VSMC. Although 
large luteal cells from all three stages of CL expressed TIMP-1. visual observations revealed that 
the highest level of expression was in cells o f the mid-cycle CL. TIMP-1 was expressed in 
vascular smooth muscle ceils o f  the early and late, but not the mid cycle CL (Figure 4-6 B. D and 
F). Vascular smooth muscle cells were identified by staining with a-actin (Figure 4-6 G). In all 
ages o f CL. TTMP-2 was consistently localized in the endothelial and large luteal ceils (Figure 4-6 
A. C and E). No positive signals were observed in sections devoid o f  primary antibody (Figure 4- 
6 H).
Discussion
Accumulating evidence supports the notion that matrix metalloproteinases (MMPs) play 
important roles during CL development and demise. Once activated, these enzymes are strictly
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regulated by a  group o f endogenous inhibitors, the TIMPs. Furthermore, the two most studied 
members in this TIMP family. TIMP-1 and TIMP-2. possesses a variety o f other functions. 
Therefore, it is necessary to determine the temporal and spatial expression patterns o f these two 
inhibitors before their physiological roles in the CL can be elucidated.
In the present study. TIMP-1 mRNA was highly expressed in the early and mid cycle 
bovine CL. but was decreased in the late stage. This finding was similar to previous observations 
by others (Freudenstein et al.. 1990; Smith et al.. 1996). Likewise, in the porcine CL. TIMP-1 
transcript was also highly expressed in the early stage, and is slightly reduced as the estrous cycle 
progresses before it is significantly decreased in the regressing stage (Pitzel et al., 2000). In 
contrast. TIMP-1 mRNA expression in the ovine (Smith et al.. 1994) and human (Duncan et al..
1998) CL does not change throughout the estrous or menstrual cycle, respectively. In the 
pseudopregnant rat. yet a  different pattern emerges, whereby the strongest TIMP-1 mRNA 
expression is observed during CL formation and regression (Liu et al.. 1999). Clearly, there are 
species differences with regard to the temporal expression of the TIMP-1 transcript in the CL. 
Despite these differences, we chose to pursue our studies in cows. In particular, as a  relevant 
animal model for humans, cows have a relatively long cy cle length, during which a single ovum 
is shed. Also, a single CL provides sufficient tissue for multiple analyses.
The expression o f a TIMP-1 specific protein in three ages o f CL was also demonstrated 
in the present study. This is consistent with our previous study that showed the presence of a 
TIMP-l-like protein in CL obtained over the estrous cycle (Goldberg et al.. 1996). Furthermore, 
reverse zymographv showed that TIM P-1 was the predominant TIMP in the bovine CL, similar to 
the finding in sheep (Smith et al.. 1993). Lastly, the patterns o f TIMP-1 protein and mRNA 
paralleled each other, being high in the early and mid stages, but decreased in the late cycle CL. 
The high levels o f  TIMP-1 in the early and mid cycle CL may be needed to regulate the extensive 
tissue remodeling events that occur during CL formation and development. The reduced TIMP-1 
mRNA and protein expression in the late stage CL may portend the decline o f this inhibitor
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observed during luteolysis in bovine (Juengel et al., 1994), ovine (Towle et al., 2002), porcine 
(Pitzel et al., 2000). and primate (Duncan et al.. 1996a) CL. Collectively, these data implicate 
TIMP-1 might be an important player in the physiology o f the CL.
The TIMP-1 protein was localized in large luteal cells o f early, mid, and late stages o f the 
bovine CL. A similar observation was reported in the ovine CL. where TIMP-1 and oxytocin 
were co-localized in secretory granules o f large luteal cells (Mclntush et al., 1996). In addition. 
TIMP-1 expression was also detected in isolated ovine (Smith et al., 1994) and porcine (Pitzel et 
al.. 2000) large luteal cells, and luteinized human granulosa cells (Aston et al.. 1996). The 
presence o f TIMP-1 in steroidogenic cells may be associated with its ability to enhance steroid 
production (Boujrad et al.. 1995). In part, this may be related to a 124 bp-nucleotide sequence 
similarity between the protein coding region of the bovine steroidogenic acute regulatory (StAR) 
gene and the 5 ' non-coding region o f  TIMP-1 (Hartung et al.. 1995). Additionally, although 
female mice lacking the TIMP-1 gene do not show detectable differences in serum estradiol- 17p 
concentrations, the TIMP-1 deficient male mice produce higher levels of total serum testosterone 
than the wild type (Nothnick et al.. 1997: Nothnick et al.. 1998). Furthermore, cell culture studies 
demonstrated that TIMP-1 increases estradiol-17p production by granulosa cells from both 
TIMP-1 deficient and wild-type mice (Nothnick et al.. 1997). and enhances estradiol- I7p and 
progesterone production from porcine thecal cells (Shores and Hunter, 2000). Therefore, the 
strong expression o f TTMP-1 in large luteal cells may be related to its collateral role in 
steroidogenesis.
Because of the predominant expression o f TIMP-1 in large luteal cells, this inhibitor is 
used as a cellular marker for this cell type (Haworth et al.. 1998). However, other cell types in 
the CL are also positive for TIMP-1 expression. For example, the present study showed that 
TIMP-1 was also localized in the vascular smooth muscle cells (VSMC) o f the bovine CL. 
Although the cellular source was not specified, the capillary compartments in ovine (Mclntush et
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al.. 1996) and rat (Bagavandoss, 1998) CL also stain positively for TIMP-1. The localization o f 
TIMP-1 in the vascular smooth muscle compartment supports its potential role during 
angiogenesis and vascular maintenance. Indeed, over-expression o f  TIMP-1 in VSMC by 
exogenous gene transfer reduces VSMC cell proliferation and migration (Forough et al., 1996; 
George et al.. 1998). In addition, stimulation o f TIMP-1 expression impairs angiogenesis in a 
variety o f tumor types (Martin et al.. 1999; Guedez et al.. 2001; Bloomston et al., 2002). 
Therefore. TIMP-1 acts as a negative regulator o f blood vessel formation (Moses et al.. 1990). 
During early CL development, extensive angiogenesis occurs, and theca-derived luteal cells and 
fibroblasts invade through the breached basement membrane into the cavity o f the ruptured 
follicle. These early events in the angiogenic process require net proteolytic/MMP activity. In the 
last step o f angiogenesis. recruitment and maintenance of pericytes (VSMC) are critical for 
vascular maturation and survival (Nehls et al.. 1992; Hirschi and D'Amore. 1996). Thus, the high 
level o f TIMP-1 expression in VSMC in 4-day old CL may provide an environment where MMP 
action is inhibited as the vasculature matures. As the CL ages, its structure remains relatively 
stable. Although angiogenesis is ongoing, it is slowed-down during CL maintenance (Tsukada et 
al.. 1996; Amselgruber et al.. 1999; Dickson et al.. 2001). This may be the reason for the absence 
of TIMP-1 in the VSMC compartment at this stage of the bovine estrous cycle. In the 16-day old 
CL. TIMP-1 was detected again in the VSMC compartment. This localized expression of TIMP-1 
is consistent with the view of Redmer et al. (1988). who proposed that maintenance of the 
v asculature may be necessary for the transport of degraded products during luteoiysis, which 
ultimately results in a  massive decrease in CL size and weight as regression ensues.
Although TIMP-1 was the most abundant TIMP in luteal tissues, the other three TIMPs 
were also detected in the bovine CL by reverse zymography. Among them, we chose to focus our 
attention on TIMP-2. It has been reported that TIMP-2 is involved in the pro-MMP-2 activation 
process by binding a MT1-MMP to form a  "co-receptor” for pro-MMP-2 on the cell surface 
(Butler et al.. 1998). This bound pro-MMP-2 is then presented to an adjacent MTl-MMP for
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activation (Deryugina et al.. 1997; Butler et al., 1998). Although a transmembrane-deleted M Tl- 
MMP activates pro-MMP-2 without the participation of TIMP-2 (Pei and Weiss, 1996), TIMP-2 
deficient mice have a dramatically reduced ability to activate pro-MMP-2 (Wang et al.. 2000). In 
the present study, both TIMP-2 mRNA and protein levels were low in the early CL, but 
significantly increased in the mid and late stages. This expression pattern was similar to those for 
active MT1-MMP and MMP-2 (Zhang et al.. 2002), suggesting that the M T1 -MMP/TIMP-2/pro- 
MMP-2 tri-molecular system may be available for MMP-2 activation in vivo in the bovine CL. 
The coordinate expression o f these three molecules is also observed during embryo development 
(Apte et al.. 1997). which supports the presence o f this activation system in a variety o f tissue 
types.
In addition to the temporal correlation o f TIMP-2 with active MT1-MMP and MMP-2 
expression in the CL. TIMP-2 was also co-localized with these two molecules in endothelial and 
large luteal cells. TIMP-2 has a variety o f functions in endothelial cells. On the one hand, its 
stoichiometrically correlated expression with MT1-MMP and pro-MMP-2 may facilitate the 
activation process o f pro-MMP-2. which is critical for the angiogenesis process. On the other 
hand, inhibition o f angiogenesis by TIMP-2 cannot be excluded, because over-expression of 
TIMP-2 blocks vascular smooth muscle cell invasiveness (Cheng et al.. 1998) and reduces 
angiogenic ability (Li et al.. 2001). The latter observation is due. in part to down-regulation of 
vascular endothelial cell growth factor (VEGF) (Hajitou et al.. 2001). Furthermore, TIMP-2 also 
possesses growth inhibitory ability on endothelial cells (Murphy et al.. 1993a).
The localization of TIMP-2 in large luteal cells may also contribute to the activation o f 
pro-MMP-2 in this cell type by assembling the trimeric complex on the cell membrane. The in 
situ activated MMP-2 then binds onto integrin ou.p3, where localized pericellular proteolysis 
ensues. This resulting degradation o f the ECM is needed to accommodate the enlargement of 
large luteal cells from the early to mid and late stages (Schwall et al., 1988; Zheng et al., 1994). 
Although there is no direct evidence showing the involvement o f  TIMP-2 in steroidogenesis, the
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dynamic interactions between large luteal cells and their local ECM niche may induce 
biochemical changes related to the steroid biosynthetic process in this cell type (Smith et al.,
1999). For example, disruption o f  the links between ECM. integrins, and the cytoskeleton 
(Murdoch et al.. 1996) may perturb the intracellular transport of substrates, such as cholesterol, 
for steroidogenesis (Niswender et al., 2000). However, additional in vitro and in vivo studies are 
needed to elucidate the physiological roles o f these TIMPs in this endocrine gland.
In summary, the present study demonstrated that the temporal and spatial expression of 
TIMP-2 was correlated to the expression patterns of active MT1-MMP and MMP-2. This 
suggested that these three molecules might be coordinateiy expressed in the bovine CL to 
facilitate the activation o f pro-MMP-2 in vivo, and in turn coordinate physiological processes 
such as enlargement of large luteal cells and luteal angiogenesis. The expression pattern o f TIMP 
1 was temporally and spatially distinct from TIMP-2. The predominant expression of TIMP-1 in 
the CL suggested that it might be a key regulator in CL physiology.
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TIMP-1 mRNA in the bovine CL
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Figure 4-1. TIMP-1 mRNA expression in the bovine CL. A) Northern blotting o f TIMP-1 
mRNA in early (E), mid (M), and late (L) stage CL is shown in the upper panel. The arrow 
indicates the 0.9kb TIMP-1 transcript The ethidium bromide stained 18S rRNAs in 
corresponding luteal samples are shown in the lower panel. B) Changes in TIMP-1 mRNA, 
shown as a densitometric ratio o f TIMP-1 mRNA to 18S rRNA, are illustrated. Dissimilar letters 
denote significant difference at p<0.05.
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Figure 4-2. TIMP-2 mRNA expression in the bovine CL. A) The upper panel shows Northern 
blotting o f TIMP-2 mRNA in early (E), mid (M), and late (L) bovine CL. The arrows indicate the 
3.5 and 1 kb species. The lower panel is the same membrane hybridized with a human cyclophilin 
probe. B) Densitometric ratios o f the two TIMP-2 mRNA bands to cyclophilin in corresponding 
stages are shown. Dissimilar letters denote significant difference at p<0.05.
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Figure 4-3. Reverse zymographic analysis o f tissue inhibitors o f metalloproteinases (TIMPs). 
Inhibitor activities in the early (E), mid (M), and late (L) stages o f bovine CL are shown. Lane 1 
indicates the Prestained SDS-PAGE standards (STD; Bio-Rad Laboratories, Hercules, CA). Their 
corresponding molecular masses (kDa) are indicated on the left. Four bands possessing MMP 
inhibitory activities (indicated by arrows on the right) were observed in the luteal samples. These 
bands correspond to TIMP-1 (-30kDa), TIMP-3 (~27kDa), TIMP-4 (~24kDa). and TIMP-2 
(~22kDa), respectively.
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Figure 4-4. TIMP-1 protein expression in the bovine CL during the estrous cycle. A) A 
representative Western blot o f TIMP-1 in early (E), mid (M), and late (L) CL collected over the 
estrous cycle. Conditioned medium of HT1080 cells (HT) was ioaded in the first lane and was 
used as a positive control. The arrow indicates the 30 kDa immunoreactive TIMP-1 protein. B) 
TIMP-1 protein levels in different stages are presented as a ratio o f band intensity in luteal 
samples to that in HT1080 conditioned medium. Dissimilar letters denote significant difference at 
p<0.05.
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TIMP-2 protein expression in the bovine CL
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Figure 4-5. TIMP-2 protein expression in the bovine CL throughout the estrous cycle. A) A 
representative Western blot o f TIMP-2 in the bovine CL. Molecular masses (kDa) o f protein 
standards are shown on the left. As indicated by the arrow, a single 22 kDa TIMP-2 
immunoreactive protein band is present in early (E), mid (M), and late (L) stages of CL. B) 
Densitometric analysis o f TIMP-2 protein expression among different stages o f CL. Dissimilar 
letters denote significant difference at p<0.05.
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Figure 4-6. Immunohistochemistry of TIMP-2 (A, C, E; x400) and TIMP-1 (B, D, F; x200) in 
the early (A and B), mid (C and D), and late (E and F) stages o f CL. Vascular smooth muscle 
cells were identified by staining with a-actin (G; x200). Positive staining (red color) is indicated 
by white arrows, black arrows, and white triangles in large luteal cells, endothelial ceils, and 
vascular smooth muscle cells, respectively. In a representative negative control (H; x400), no 
positive staining was observed.
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CHAPTER V
REGULATION OF MATRIX METALLOPROTEINASE 2 (MMP-2) EXPRESSION IN 
ENDOTHELIAL AND LUTEAL CELLS BY CYTOKINES
Abstract
Our previous studies showed that MMP-2 activity varies in day 4, day 10. and day 16 
bovine CL obtained over the estrous cycle. We also observed that MMP-2 is localized in 
endothelial and large luteal cells. Although cytokines regulate progesterone and prostaglandin 
production by the corpus luteum (CL), little is known about their effects on MMPs in the ovary. 
Thus, the aim o f the present study was to investigate cytokine regulation c f  MMP-2 expression by 
endothelial and luteal cells. In experiment I. luteal ceils were isolated from mid cycle bovine CL 
(n=3). Dissociated cells were then incubated with I. 10. or 100 ng/ml tumor necrosis factor 
(TNFa) for 12 hours, or with 100 ng/ml TN Fa for 6. 12. 24. and 48 hours. Zymography revealed 
that the two highest doses of TNFa increased (p<0.05) the level of pro-MMP-2 above the 1 ng/ml 
treatment and control groups. In addition. pro-MMP-2 also increased in a  time-dependent 
manner, being the highest at 48 hours. Using concentrated medium. Western blotting showed that 
active MMP-2 was present in cells treated with the 100 ng/ml dose o f TNFa. Furthermore, the 
level o f active MMP-2 was the highest (p<0.05) at 48 hours. In experiment Q. endothelial cells 
were isolated from cow CL during early pregnancy. Luteal-derived endothelial cells were treated 
with either 100 ng/ml TNFa. 200 lU/ml interferon y (IFNy), or a combination o f  these two 
cytokines, for 24 hours. Zymographic analysis revealed that TNFa stimulated, while IFNy 
inhibited latent MMP-2 expression. Furthermore, when combined, IFNy attenuated the 
stimulatory effect by TNFa, and the level o f latent MMP-2 being not different from controls.
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Together, these data suggest that MMP-2 expression in the CL may be regulated, in part, by 
cytokines.
Introduction
Matrix metalloproteinases (MMPs) are a family o f zinc and calcium dependent 
proteolytic enzymes that have been shown to be important in ovarian physiology, including 
follicular development, follicle atresia, ovulation, corpus luteum development, and ovarian 
angiogenesis (Smith et al.. 1999). Among the more than 25 members that have been identified in 
this family, matrix metalloproteinase 2 (MMP-2: geiatinase A) is one o f  the most well studied. 
This may be due to its broad substrate specificity' on ECM proteins. In addition to its efficient 
degradation on gelatins. MMP-2 also cleaves type I (Aimes and Quigley. 1995). type V (Okada et 
al.. 1990). type VII (Seltzer et al.. 1989). and type X (Gadher et al.. 1989: Welgus et al.. 1990) 
collagens. and other ECM components such as elastin (Senior et al.. 1991). laminin (Imai et al.. 
1995b: Giannelli et al.. 1997). vitronectin (Giannelli et al.. 1997). and aggrecan (Fosang et al.. 
1992). In particular. MMP-2 efficiently hydrolyzes soluble collagen type IV. which is one of the 
major barriers encountered during structural remodeling in a variety o f tissues. Furthermore, this 
proteolytic enzyme affects cell behaviors by regulating the availability o f growth factors, 
cytokines, and their receptors (McCawley and Matrisian. 2001). For example, proteolytic 
cleavage o f biologically inactive pro- transforming growth factor (TGF) p 1 and P2 (Imai et al..
1997). pro-tumor necrosis factor a  (TNFa) (McGeehan et al.. 1994). and pro-interleukin ip 
(ILip) (Schonbeck et al.. 1998) by MMP-2 yields the active molecules. Also, N-terminal 
processing o f  chemokines. such as monocyte chemoattractant protein 3 (MCP-3) and stromal cell 
derived factor (SDF) l a  and ip results in loss of biological activity (McQuibban et al., 2000: 
McQuibban et ai.. 2001). Furthermore. MMP-2 acts on the Val368-Met369 peptide bond of the 
fibroblast growth factor receptor type 1 (FGFR1) ectodomain to release a  soluble extracellular
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domain, which modulate the mitogenic activities o f FGF (Levi et al., 1996). Together, these 
properties o f MMP-2 establish its complex but critical roles in tumor invasion and metastasis. 
Likewise, it may also be necessary for normal physiological processes, such as ovulation, and CL 
development.
MMP-2 has been identified in the bovine (Tsang et al., 1995; Goldberg et al.. 1996:
Zhang et al.. 2002). ovine (Russell et al.. 1995: Towle et al., 2002), porcine (Pitzel et al., 2000). 
rat (Nothnick et al.. 1996; Bagavandoss. 1998; Liu et al., 1999), and human (Duncan et al., 1998) 
CL. In ewes. MMP-2 activity is critical for CL development and luteal neovascularization 
(Russell et al.. 1995; Gottsch et al.. 2001). Increased MMP-2 expression or activity is also 
associated w ith luteal regression in a variety species, including rat (Endo et al.. 1992). sheep 
(Reike ct al.. 2002: Towle et al.. 2002), and human (Duncan et al.. 1998). Although luteinizing 
hormone (LH) has no effect on MMP-2 expression by luteal cells isolated from 4 day old bovine 
CL (Tsang et al.. 1995). its expression in vivo is augmented by prolactin and PGF;a in rat (Endo 
et al.. 1992) and sheep (Towle et al.. 2002) CL. respectively.
The regulation o f MMP-2 expression, which is unique and complex, occurs at the 
activational or translational level. Recently, we showed that MMP-2. and membrane type 1 MMP 
(MT1-MMP) and tissue inhibitor o f metalloproteinases 2 (TIMP-2), the two key regulators that 
activate it. are co-Iocaiized in endothelial and large luteal cells of the ovine CL (Zhang and 
Tsang. 2001: Zhang et al.. 2002). MMP-2 can also be regulated at the transcriptional level. 
Because it lacks well characterized regulatory' elements in the promoter region, MMP-2 has been 
long viewed intractable to either stimulatory or inhibitory reagents (Mauviel. 1993). In part, this 
may be the reason for the paucity o f in vitro studies on the regulation o f MMP-2 expression in the 
ovary'. However, a  recent study demonstrated that the MMP-2 promoter has a GC-rich region, 
even though it lacks a  typical TATA box (Qin et al.. 1998). Further sequence analysis revealed 
that a number o f  cis-acting regulatory elements, includingp53, AP-l, AP-2. Spl, Ets-l, C/EBP, 
CREB. and PEA3. are present in the up-stream regulatory region o f the MMP-2 gene (Bian and
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Sun. 1997; Qin et al.. 1998). Therefore, these elements could be involved in the regulation of 
MMP-2 by growth factors and cytokines. Notably, the CL is a  potentially rich source o f a  variety' 
o f cytokines (Pate. 199S: Terranova and Rice, 1997; Pate and Landis Keyes, 2001). Furthermore, 
cytokines participate in CL physiology, by being involved in steroidogenesis, apoptosis. 
angiogenesis. and luteolysis (Pate and Landis Keyes. 2001).
Among the cytokines identified in the CL. TNFa and interferon y (IFNy) have been 
implicated in regulating endothelial and luteal cell physiology. Towards this end. the aim of the 
current study was to investigate regulation o f MMP-2 by TN Fa and IFNy in luteal and 
endothelial cells isolated from bovine CL.
Materials and Methods
1. Isolation and culture of luteal cells
Corpora lutea were collected from regularly cycling, nonlactating dairy cows on day 10 
of the estrous cycle (day 0= estrus; n=3). After removing connective tissues. CL were dissociated 
as previously described (Tsang et al.. 1995). Briefly, luteal tissues were minced before placing 
into a spinner flask containing 25ml of Ham's F-12. with 1% bovine serum albumin (BSA). and 
Type I collagenase (Worthington Biochemical. Lakewood. NJ; 2000 units/g tissue) for one hour 
at 37°C. During this period, tissues were triturated every 10 minutes. After one hour, dissociated 
cells were centrifuged sequentially at I90g, 1 lOg, and 80g to remove collagenase, connective 
tissues and other tissue debris. Cell viability and number were determined by trypan blue 
exclusion and counting on a hemacytometer, respectively.
Luteal cells (1 x 106) were seeded in T25 flasks containing 4 ml Ham 's F-12 culture 
medium, supplemented with insulin/selenium/transfening (ITS; Upstate Biotechnology. Lake 
Placid. NY) and gentamicin (30pg/ml; GIBCO-BRL. Paisley. PA). After an overnight incubation, 
unattached cells were removed by rinsing with fresh Ham's F-12 medium. Then, for experiment
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1. luteal cells were treated with 1. 10, or 100 ng/ml TNFa (n=3 per dose; R&D Systems, 
Minneapolis. MN) for 12 hours. For experiment n . luteal cells were treated with TN Fa
( lOOng/ml) and incubated for 6, 12. 24. or 48 hours. Cell number was determined before 
treatment and at the end of each time point.
2. Endothelial cell isolation and culture
Endothelial cells from early pregnant cow CL were provided by Dr. Bo Rueda at the 
Massachuessets General Hospital and Dr. John Davis at the University o f Nebraska. The 
isolation, purification, and characterization o f these luteal-derived endothelial cells were 
commercially accomplished by BioWhittaker Molecular Applications (Walkersville. MD). 
Endothelial cells were then cultured in 24 well plates (5000 cells/cm:) in EGM-2 MV medium 
(BioWhittaker. Walkersville. MD) containing 3% fetal bovine serum (FBS) and a  cocktail of 
growth factors (BioWhittaker. Walkersville. MD) based on the manufacturer's recommendations. 
After the cells attained 90% confluency. the spent medium was replaced with serum-free EGM-2 
MV before they were treated with lOOng/ml TN Fa (Upstate Biotechnology. Lake Placid. N Y ). 
200 units/mi IFNy (a generous gift from Dr. Dale Godson), or a combination o f both for 24 hours 
(n=3 w ells per treatment). Cell numbers were determined at the end of the treatment period.
3. Gelatin rvmogranhv
MMP-2 activity was determined by zymographic analysis on 10% acrylamide SDS gels 
containing 0.5mg/ml gelatin (Zhang et al.. 2002). Conditioned medium o f luteal and endothelial 
cell cultures was normalized to cell number. Equivalent aliquots o f conditioned medium were 
loaded into the gels. Perfect Protein™ Markers (Novagen. Madison, WI) and a  positive control, 
the conditioned medium of H T 1080 cells, were run in adjacent lanes.
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Following electrophoresis, SDS was removed by rinsing twice with 2.5% (v/v) Triton X- 
100 (15 minutes per wash). The gel was then incubated in substrate buffer (0.05M Tris-HCl.
5mM C aC k 0.05M NaCl. pH 8.0) at 37°C for 18 hours, followed by staining with 0.1% (w/v) 
Coomassie Brilliant Blue R-250 (Bio-Rad Laboratories, Hercules, CA) for 30 minutes. 
Gelatinolytic activities were identified as clear zones against a blue background after destaining 
with ddH;0 .
4. Western blotting
Conditioned medium from luteal cell cultures was concentrated 20 times by using 
Microcon* YM-3 Centrifugal Filter Devices (Millipore. Bedford. MA). Aliquots o f concentrated 
medium equivalent to 10.000 cells were used for Western blot analysis as previously described 
(Zhang et al.. 2002). Briefly, media were separated on 12% acryiamide SDS gels under reducing 
condition, w hich was accomplished by including lOmM (final concentration) dithiothreitol 
(Sigma. St Louis. MO) in the loading buffer and boiling the samples for 3 minutes prior 
electrophoresis. Proteins were then electrophoretically transferred onto Protran® nitrocellulose 
membranes (Schleicher & Schuell. Keene. NH). Nonspecific binding sites on the membranes 
were blocked by incubation with 5% (w/v) nonfat dry milk in TBST buffer ( lOmM Tris. 150mM 
NaCl. 0.05% Tween-20. pH 8.0) for 2 hours at room temperature. A mouse anti human MMP-2 
monoclonal antibody ( lug/ml in 5% nonfat dry milk: Oncogene Research Products. San Diego. 
CA) was incubated with membranes overnight at 4°C. After four washes with TBST buffer (15 
minutes per wash), a  horse radish peroxidase (HRP) conjugated goat anti mouse IgG antibody 
(1:10.000: Pierce. Rockford. IL) was applied onto membranes for 1 hour. Immunoreactive protein 
bands were visualized with SuperSignal® West Pico chemiluminescent substrate (Pierce, 
Rockford, EL) according to manufacturer's instructions.
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5. Statistical analysis
Densitometric intensities o f bands on zymograms and Western blot membranes were 
analyzed by UN-SCAN-IT gel™ automated digitizing system (Silk Scientific, Orem, UT). The 
data were analyzed by ANOVA. The Dunnet test was used for comparisons between treatment 
and control groups, while the Bonferroni test was used for comparisons among different 
treatments (Zar. 1999). A value of p<0.05 was considered to be significantly different.
Results 
1. Dose dependent responses o f MMP-2 expression to TNFa in luteal cells.
Zymographic analysis o f luteal cell conditioned media revealed two major gelatinolvtic 
species with relative molecular masses o f 88 and 68 kDa. which correspond to MMP-2 and 
MMP-9 family members, respectively (Figure 5-1 A). While latent MMP-2 and MMP-9 were the 
major forms observ ed. less intense bands o f active MMP-2 and MMP-9 were also detected. 
Densitometric analysis demonstrated that the level o f latent MMP-2 increased coordinatelv with 
TN Fa concentration. Compared to the control group, latent MMP-2 was significantly increased 
(p<0.05) in cells treated with 10 ng/ml and 100 ng/ml TNFa (Figure 5-1B). Interestingly, latent 
MMP-9 also increased in a similar manner (data analysis not shown).
Western blotting of concentrated luteal cell conditioned medium demonstrated that active 
MMP-2 was only detected in the 100 ng/ml TN Fa treatment group, while latent MMP-2 was 
present in all samples (Figure 5-2A). Furthermore, levels o f active and latent MMP-2 were the 
greatest (p<0.05) in the 100 ng/ml of TN Fa treatment group, while no differences were observed 
among all other groups.
2. Time dependent responses of MMP-2 expression to TNFa in luteal frih.
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The stimulatory effect of TNFa ( lOOng/ml) on MMP-2 expression in luteal cells was shown 
to be time dependent. Gelatin zvmography revealed that latent MMP-2 was increased with length 
of incubation time (Figure 5-3 A). While no significant differences were detected between the 6- 
and 12-hour groups (Figure 5-3 B). latent MMP-2 at 24- and 48-hours was greater than the earlier 
time points. Furthermore, when compared to their contemporaneous control group, latent MMP-2 
expression in the presence of TN Fa was significantly greater (p<0.05) only at the 24 and 48-hour 
time points (Figure 5-3B).
Western blotting confirmed the pattern o f change observed in zymograms, whereby latent 
MMP-2 increased with incubation time. While latent MMP-2 was lowest and greatest at the 6- 
and 48-hour time points, respectively, there was no difference between the 12- and 24- hour time 
points. Also, latent MMP-2 in cells treated with TNFa was greater in contemporaneous controls 
at all time points except at 6-hours. Furthermore, active MMP-2 was detected in cells treated 
w ith 100 ng/ml TN Fa at all time points (Figure 5-4A). Notably, active MMP-2 was significantly- 
increased only at the 48-hour time point (Figure 5-4B).
3. Differential regulation of MMP-2 expression bv TNFa and IFNv in luteal-derived 
endothelial cells.
In luteal-derived endothelial cells, zvmography demonstrated that MMP-2 was the 
predominant gelatinase. since MMP-9 was undetectable. Furthermore, latent MMP-2 was the 
major form, while minor active MMP-2 was observed in all groups (Figure 5-5A). Treatment 
with TN Fa significantly increased (p<0.05). while IFNy inhibited (p<0.05) MMP-2 expression. 
When combined. IFNy attenuated the stimulatory effect of TN Fa alone, and the level o f latent 
MMP-2 expression was similar to the control group (p>0.05) (Figure 5-5B).
Discussion
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MMP-2 is critical for ovulation, luteal angiogenesis, and CL development (Gottsch et al., 
2000; Gottsch et al., 2001). Unlike other MMPs, the activation of pro-MMP-2 is accomplished on 
the cell surface by the coordinate interactions between MT1-MMP and TIMP-2 (Nagase, 1997). 
The regulation of MMP-2 gene expression is also unique among MMPs due to its atypical 
promoter organization (Qin et al.. 1999). Little is known regarding the regulation of this enzyme 
in the ovary. LH has no effects on MMP-2 expression by luteal cells from 4 day old bovine CL 
(Tsang et al.. 1995). while estradiol up-regulates MMP-2 production by human granulosa-lutein 
cells (Puistola et al.. 1995). In equine ovarian stromal cells, transforming growth factor p (TGFP) 
stimulates MMP-2 activity (Song et al.. 1999). In addition, a number of cytokines exhibit 
differential regulatory effects on MMP-2 expression. For example. TNFa up-regulates MMP-2 
activity in ovine follicular explants, while incubation with TNFa antiserum reduces MMP-2 
activity (Gottsch et al.. 2000). Furthermore, intrafollicular administration o f TN Fa antiserum 
blocks ovulation. Although the un-ruptured follicles, nonetheless, underwent luteinization. a fully 
formed CL with accompanying vasculature was not observed (Gottsch et al.. 2000). These data 
suggest that MMP-2. under the regulation o f TNFa. may be critical for CL formation and 
angiogenesis.
We previously reported that MMP-2 is localized to large luteal cells and endothelial cells 
in the bovine CL (Zhang and Tsang, 2001). In the present study, we investigated the regulation o f 
MMP-2 expression in these two cell types by TN Fa and/or IFNy. In bovine luteal cells. TNFa 
stimulated MMP-2 expression in a dose and time dependent manner. Similarly, TN Fa also 
stimulates MMP-2 expression in porcine large luteal cells (Pitzel et al.. 2000). The CL produces 
TNFa. Macrophages are the major sources o f TN Fa in the porcine CL (Zhao et al., 1998), while 
large luteal cells also secrete TNFa at a significantly higher level than endothelial and small 
luteal cells (Zhao et al.. 1998). In both porcine and bovine CL, the large luteal cells are positive 
for TNFa receptor type I (TNFR I) mRNA expression (Richards and Almond, 1994; Sakumoto et
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al.. 2000a). Considering these data, we postulate that MMP-2 production may be regulated by 
TN Fa in a paracrine and/or autocrine manner.
O f interest the present study demonstrated that only the highest dose o f TN Fa (100 
ng/ml) stimulated pro-MMP-2 activation, even though the level o f pro-MMP-2 increased with 
increasing concentration o f TNFa. This indicated that TN Fa may have multiple cellular signal 
transduction pathways to regulate MMP-2 expression and activity. On the one hand, TNFa may 
work through transcriptional activators, such as p53 and/or NFicB, to stimulate MMP-2 gene 
expression (Marti et al.. 1993: Bian and Sun. 1997). which results in the increase o f pro-MMP-2. 
On the other hand. TNFa may modulate activation o f MMP-2 via a  nongenomic pathway. For 
instance, efficient activation of MMP-2 is accomplished on the cell membrane by assembling a 
trimeric complex comprising MT1-MMP. TIMP-2. and pro-MMP-2 (Cao et al.. 1998; Butler et 
al.. 1998). In the bovine CL. we reported the coordinate expression o f MT1-MMP and TIMP-2 
w ith MMP-2 activity (Zhang and Tsang, 2001: Zhang et al.. 2002). Since this activation is 
performed on the cell membrane, it can be greatly affected by factors that modulate membrane 
trafficking, including fluidity, stability, and other biophysical features (Lehti et al.. 2002). Indeed. 
ConA stimulates pro-MMP-2 activation by shifting endogenous MT1-MMP from the intracellular 
compartment to the cell surface (Jiang et al.. 2001). Also, binding o f TN Fa to its membrane 
receptor (TNFR I) induces activation o f sphingomyelinases, which hydrolyze N-acylsphingosin- 
1-phosphorylcholine. a phospholipid preferentially found in the plasma membrane o f mammalian 
cells, to ceremide (Kronke. 1999). The latter can act as a  second messenger to trigger a variety o f  
cellular functions. Notably, conversion o f  sphingomyelin, a  sphingolipid situated predominantly 
in the outer part o f the cell membrane, to ceremide. a  second messenger, may affect the 
biophysical structure of plasma membranes. In addition, TN Fa also increases PGF;a production 
by activating phospholipase A2 enzymes, which liberate arachidonic acid (ACA) from membrane 
phospholipids for the synthesis o f  eicosanoids (Townson and Pate, 1996; Sakumoto et al., 2000b)
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Therefore, one of the cellular functions of TNFa might be through
sphingomyelinase/sphingomyelin and/or PLA2/ACA pathway(s) to affect the oligomerization of 
MT1-MMP on the cell surface, which then modulates pro-MMP-2 activation (Lehti et al.. 2002). 
In the present study, induction o f pro-MMP-2 activation by 100 ng/ml TN Fa was observed as 
early as 6 hours after treatment, indicating that it is likely acting via a  nongenomic pathway rather 
than being regulated at the transcriptional level. By using inhibitors against different second 
messengers, studies are underway to further pinpoint the detailed cellular signal transduction 
events triggered by TN Fa for MMP-2 expression and activation.
Similar to luteal cells. MMP-2 expression in endothelial cells was also enhanced by 
TNFa treatment. Luteal-derived endothelial cells have greater levels of TNFRI mRNA than luteal 
cells (Sakumoto et al.. 2000a). suggesting that endothelial cells are also a major target of TNFa. 
Indeed, injection o f  the rabbit CL with TNFa induced blood vessel regression, a  process 
characterized by strictures, obstructions, and ragged surfaces on the vessels (Nariai et al.. 1995). 
This is similar to the vessel regression observed during luteolysis in cows (Modlich et al., 19%). 
Therefore, one action o f increased TN Fa during the late luteal phase and in the regressed CL may 
be to stimulate MMP-2 expression and activation in endothelial cells. The increased MMP-2 
activity allows endothelial cells to degrade the surrounding ECM proteins, to detach from the 
underlying basement membrane (Modlich et al.. 1996), and to initiate blood vessel regression.
In contrast to TNFa. IFNy inhibited MMP-2 expression by luteal-derived endothelial 
cells. In addition, co-treatment with TN Fa and IFNy resulted in MMP-2 expression that is similar 
to controls, indicating possible interactions between the second messengers induced by these two 
cytokines. IFNy has anti-proliferative effects on luteal-derived microvascular endothelial cells 
(Fenyves et al.. 1994). IFNy also up-regulates endothelial cell expression o f E-cadherin (Fenyves 
et al.. 1993), a cell adhesion molecule. This is consistent with its ability to increase intercellular 
junctions in an in vitro cell culture system (Ricken et al., 1996). Taken together, IFNy may play
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an important role in vasculature maintenance by down-regulating MMP-2 expression, inhibiting 
endothelial cell proliferation, and reinforcing intercellular junctions between endothelial cells. 
These biological functions o f IFNy on luteal-derived endothelial cells may contribute to its 
luteotrophic effects (Prakash et al.. 1997).
Although the physiological roles o f IFNy and TNFa on luteal physiology are very 
complex, they have been postulated to play important roles in luteolysis (Pate, 1994). IFNy 
mRNA levels decline in late diestrus and early luteolysis (Petroff et al.. 1999), although its 
receptor in the CL remains to be elucidated. TNFa mRNA levels in the CL do not vary 
throughout the estrous cycle (Petroff et al.. 1999; Sakumoto et al.. 2000a). However, the TNFa 
protein significantly increases from the mid to late stage (Shaw and Britt. 1995: Sakumoto et al.. 
2000a). Although the concentration o f TN Fa receptors (TNFR I) is significantly lower in the late 
stage than in others, high affinity binding sites for TNFa are detected in the regressed CL 
(Sakumoto et al.. 2000a). Collectively, decreased IFNy expression, increased TN Fa level, and 
appearance o f  high affinity TNFa receptor may act in concert to increase MMP-2 expression and 
activation, which we have observed in the regressing bovine CL (Zhang et al.. unpublished 
observation).
In summary, the present study demonstrated the stimulatory effects o f TNFa on MMP-2 
expression and activation in luteal cells and luteal-derived endothelial cells. In contrast, IFNy 
attenuated MMP-2 expression in endothelial cells. The regulatory effects o f these cytokines on 
MMP expression may contribute to their roles in modulating CL physiology, i.e., angiogenesis, 
vascular maintenance, and luteolysis.
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Figure 5-1. Zymographic analysis o f medium conditioned by bovine luteal cells treated with 
different concentrations o f TNFa for 12 hours. A) In this representative zymogram, Perfect 
Protein™ Marker (Novagen, Madison, WI) molecular weight standards are listed on the left and 
shown in lane 2 (M). In lane 1, HT stands for the conditioned medium o f HT1080 cells. In lane 3, 
C denotes the control culture medium from luteal cells in the absence o f  treatment. In lanes 4-6, 
the concentrations o f  TNFa are indicated on the top. B) Densitometric analysis o f pro-MMP-2. 
Dissimilar letters denote significance at p<0.05.
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Dose dependent responses o f MMP-2 expression in luteal cells to TNFa
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Figure 5-2. Immunoreactive MMP-2 in luteal cells treated with different concentrations o f  TNFa. 
A) Representative Western blot o f latent and active MMP-2. Molecular masses o f Prestained 
protein standards (Bio-Rad Laboratories, Hercules, CA) are listed on the left. In lane 1, HT is the 
conditioned medium o f  HT1080 ceils. In lane 2, C represents the control group. Lanes 3-5 are 
samples from luteal cells treated with 1,10, or 100 ng/ml o f TN Fa for 12 hours. The latent and 
active MMP-2 bands are indicated on the right. B) Densitometric analysis o f  latent (O ) and active 
MMP-2 among different groups. Dissimilar letters denote significance at p<0.05.
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Figure 5-3. Time dependent responses o f MMP-2 expression in bovine luteal cells treated with 
TNFa (100 ng/ml). A) Representative zymogram of luteal cells incubated in the absence (-) and 
presence (+) o f TNFa. Perfect Protein™ Marker (Novagen, Madison, WI) molecular weight 
standards are indicated on the left and shown in lane 1 (M). In lane 10, conditioned medium from 
HT1080 cells (HT) were loaded. Samples incubated for 6-, 12-, 24-, or 48-hours were loaded in 
lanes 2-9. Arrows indicate pro- and active MMP-2. B) Densitometric analysis o f latent MMP-2. 
Dissimilar letters denote significance (p<0.05) among different incubation times following TNFa 
treatment. Asterisks represent significant difference (p<0.05) between respective control and 
TNFa treatment groups at each time point.
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Time dependent responses of MMP-2 expression in luteal cells to TNFa
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Figure 5-4. Time course responses o f latent and active MMP-2 in bovine luteal cells treated with 
TNFa. A) Representative Western blot of conditioned medium from luteal cells in the absence (-) 
and presence (+) of TNFa. Molecular masses o f  Prestained protein standards (Bio-Rad 
Laboratories, Hercules, CA) are indicated on the left. In lane I, FIT represents the conditioned 
medium o f HT1080 cells. Samples incubated for 6-, 12-, 24-, or 48-hour were loaded in lanes 2-9. 
Latent and active MMP-2 bands are indicated by arrows on the right. B) Statistical analysis of 
active and latent MMP-2 levels. Dissimilar letters denote significance (p<0.05) among different 
incubation times following TNFa treatment. Asterisks represent significant difference (p<0.05) 
between respective control and TNFa treatment groups at each time point.
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Regulation of MMP-2 expression in luteal-derived endothelial cells by cytokines






















Figure 5-5. MMP-2 expression in luteal-derived endothelial cells in response to TN Fa and IFNy, 
alone and in combination. A) Representative zymogram o f conditioned medium o f luteal-derived 
endothelial cells. Molecular masses o f Perfect Protein™ Markers (Novagen, Madison, WI) are 
indicated on the left and shown in lane 1 (M). In lane 2, HT represents HT1080 conditioned 
medium. In lanes 3-6, control and cytokine treatments, TN Fa (lOOng/ml) and IFNy (200IU/mI), 
alone or in combination, are shown. B) Densitometric analysis o f MMP-2 levels. Dissimilar 
letters denote significance at p<0.05.
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SUMMARY AND CONCLUSIONS
In the present studies, we cloned the full length cDNAs of the bovine matrix 
metalloproteinase-2 (MMP-2) and membrane type 1 metalloproteinase (MT1-MMP) genes. 
Multiple alignment analysis indicated that the predicted proteins for these two molecules have a 
high level o f sequence identity with their homologs from other mammalian species, suggesting 
that they have been conserved through evolution. Although the transcript levels o f both molecules 
were unchanged in three ages o f bovine corpus luteum (CL) obtained over the estrous cycle, their 
protein levels varied. While latent MT1-MMP was higher (p<0.05) in the early CL than the other 
two stages, the active MT1-MMP was significantly increased from the early stage to the mid and 
late cycle CL. In spite of the fact that the level o f pro-MMP-2 remained constant in all ages o f CL 
evaluated, the level o f active MMP-2 in the mid and late stages was significantly higher than that 
in the early CL. In addition, MT1-MMP and MMP-2 were localized to endothelial and large 
luteal cells. Furthermore. MT1-MMP expression was also detected in the fibroblast-like cells o f 
the late cycle CL. Thus, the correlation between active MTI-MMP and active MMP-2 throughout 
the estrous cycle and their co-localization in the same cellular compartments suggests that M TI- 
MMP may serve as the in vivo activator for pro-MMP-2.
Recent studies report that the activation process o f pro-MMP-2 by MTI-MMP is 
regulated by an endogenous tissue inhibitor o f metalloproteinases 2 (TIMP-2). This inhibitor 
bridges these two MMPs by binding MTI-MMP on the cell surface via its N-terminus and pro- 
MMP-2 at its C-terminal domain. This assembled trimeric complex presents pro-MMP-2 to an 
adjacent, active MTI-MMP, which cleaves the N-terminal pro-peptide domain o f pro-MMP-2, 
initiating its activation. In order to determine whether TIMP-2 is coordinately expressed with 
MTI-MMP and MMP-2. we investigated the temporal and spatial expression o f TIMP-1 and 
TIMP-2 in the bovine CL. TIMP-1 mRNA and protein were expressed at higher levels in the
- 141 -
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
early and mid stages than the late cycle CL. However. TIMP-2 mRNA and protein expression 
was low in early CL, but significantly increased in the mid and late stages, corresponding to the 
changes observed for active MTI-MMP and MMP-2 proteins. Furthermore, TIMP-2 was also 
localized in endothelial and large luteal cells in bovine CL, while TIMP-1 was localized in large 
luteal cells, and in vascular smooth muscle cells in the early and late stage CL. These data 
indicated that the MTl-MMP/TlMP-2/pro-MMP-2 system might be available for pro-MMP-2 
activation in the bovine CL. In addition, the localization o f TIMP-1 in the vascular smooth 
muscle cell compartment suggested that it might have a  role in luteal angiogenesis and vascular 
maintenance.
Besides its distinct activation mechanism. MMP-2 also possesses a different promoter 
organization from other MMPs. The last part o f our experiments was to initiate studies on the 
regulation o f MMP-2 in luteal and endothelial cells by using in vitro cell culture systems. TNFa 
stimulated MMP-2 expression and activation in luteal cells in a time and dose dependent manner. 
Although TN Fa increased MMP-2 expression in luteal-derived endothelial cells. IFNy inhibited 
its expression. In the presence o f both cytokines. IFNy attenuated the stimulatory effects of 
TNFa. reducing MMP-2 expression to control levels.
Collectively, the in vivo data suggest that the MTI -MMP/TIMP-2/pro-MMP-2 system 
might be available in the CL for pro-MMP-2 activation. The localization o f these three molecules 
in the same cellular compartments further support their coordinated actions during turnover o f the 
CL extracellular matrix, such as during enlargement of large luteal cells and luteal angiogenesis. 
Furthermore, localization of TIMP-1 in vascular smooth muscle cells suggests that it is another 
player participating in the regulation o f angiogenesis and vascular maintenance. Lastly, the in 
vitro study using luteal and endothelial cells indicated that the cytokines, TN Fa and IFNy, might 
serve as local regulators o f MMP-2 expression and activation.
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The data provided by the present study on the expression, activation, and regulation of 
MMP-2 will enable us to conduct future experiments to continue elucidating the roles of this and 
other MMP enzymes in angiogenesis and the physiology o f  the corpus luteum.
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The Institutional Animal Care and Use Committee (IACUC) has reviewed and approved your request for a time 
extension for this protocol. Approval is granted until the ‘Next Review Date' indicated above. You will be asked to 
submit a  project report with regard to the involvement of animals before that date. If your project is still active, you 
may apply for extension of IACUC approval through this office.
The appropriate use and care of animals in your project is an ongoing process for which you hold primary 
responsibility. Changes in your protocol must be submitted to the IACUC for review and approval prior to their 
implementation. If you have questions or concerns about your project or this approval, please feel free to contact 
the Regulatory Compliance Office at 862-2003 or 862-3536.
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accompanies this approval; please copy and distribute to ail listed project staff who have not completed this form 
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